prednisone has been researched along with Multiple Myeloma in 916 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R)." | 9.34 | Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. ( Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2020) |
| "n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma." | 9.34 | Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. ( Aquino, S; Baldini, L; Ballanti, S; Boccadoro, M; Bringhen, S; Cellini, C; D'Agostino, M; De Rosa, L; Falco, P; Gazzera, G; Gentile, M; Grasso, M; Hájek, R; Larocca, A; Marasca, R; Palumbo, A; Paris, L; Pavone, V; Pescosta, N; Petrucci, MT; Pezzatti, S; Poggiu, M; Rota-Scalabrini, D; Santoro, A; Spada, S; Tosi, P, 2020) |
| "The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the three-drug combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM)." | 9.34 | First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. ( Dingeldein, G; Goldschmidt, H; Habermehl, C; Knauf, W; Kunz, C; Moehler, T; Raab, MS; Schlag, R; Terzer, T; Walter, S; Welslau, M, 2020) |
| "Bortezomib, melphalan, and prednisone (VMP) is the standard of care for transplant-ineligible newly diagnosed multiple myeloma." | 9.34 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. ( Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J, 2020) |
| "The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.34 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. ( Cavo, M; Dimopoulos, MA; Fernandez, M; Garcia, A; He, J; Heeg, B; Hungria, V; Lam, A; Machnicki, G; Martínez-Baños, DM; Mateos, MV, 2020) |
| "Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM)." | 9.34 | First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. ( Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R, 2020) |
| "The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (BIPN) development was studied." | 9.24 | Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ( Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation." | 9.22 | Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. ( Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2016) |
| "This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM)." | 9.22 | A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. ( Aghemo, E; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Carella, AM; Conticello, C; De Paoli, L; De Rosa, L; Derudas, D; Falcone, AP; Genuardi, M; Guglielmelli, T; Larocca, A; Liberati, AM; Montefusco, V; Morabito, F; Musolino, C; Nozzoli, C; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Petrucci, MT; Ponticelli, E; Sonneveld, P; Spada, S; Villani, O; Vincelli, ID, 2016) |
| "The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic strategies for these patients." | 9.22 | Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. ( Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S, 2016) |
| "This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma." | 9.20 | Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015) |
| "This analysis, using data from the bortezomib-melphalan-prednisone (VMP) arm of the Phase III VISTA study, investigated whether increased cumulative bortezomib dose could improve overall survival (OS) in transplant-ineligible patients with previously untreated multiple myeloma." | 9.20 | Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. ( Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H, 2015) |
| "This phase 1/2 dose-escalation study investigated the combination of carfilzomib with melphalan and prednisone (CMP) in patients aged >65 years with newly diagnosed multiple myeloma (MM)." | 9.20 | Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C, 2015) |
| "This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with untreated multiple myeloma (MM)." | 9.20 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. ( Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 9.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "In the MM-015 trial, melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan-prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years." | 9.19 | Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. ( Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J, 2014) |
| "Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation." | 9.19 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014) |
| "Because interleukin-6 (IL-6) is considered important in the proliferation of early multiple myeloma (MM), we hypothesized that the addition of the anti-IL-6 monoclonal antibody siltuximab to the bortezomib-melphalan-prednisone (VMP) regimen would improve outcomes in transplant-ineligible patients with newly diagnosed MM." | 9.19 | Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. ( Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H, 2014) |
| "We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective." | 9.19 | Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. ( Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A, 2014) |
| "In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP) significantly increases the response rate and event-free survival compared with MP alone." | 9.17 | Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. ( Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A, 2013) |
| "We conducted a phase II trial that evaluated the tolerability and efficacy of combining lenalidomide with melphalan in previously untreated patients with multiple myeloma who were not candidates for autologous stem cell transplantation." | 9.17 | Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. ( Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ, 2013) |
| "This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years of follow-up and to explore the risk of second primary malignancies." | 9.17 | Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H, 2013) |
| " Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy." | 9.17 | Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. ( Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J, 2013) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 9.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma." | 9.16 | Continuous lenalidomide treatment for newly diagnosed multiple myeloma. ( Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M, 2012) |
| "This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone." | 9.15 | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. ( Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL, 2011) |
| "A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau." | 9.15 | Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. ( Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N, 2011) |
| "Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials." | 9.15 | Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. ( Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S, 2011) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 9.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| "We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP)." | 9.15 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011) |
| "This Eastern Cooperative Oncology Group trial evaluated 268 previously untreated patients with active multiple myeloma randomized to vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or VBMCP plus HiCy and recombinant IFN." | 9.14 | The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology ( Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF, 2009) |
| "Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects." | 9.14 | Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009) |
| "Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma." | 9.14 | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. ( Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM, 2009) |
| "PURPOSE Thalidomide-dexamethasone (THAL-DEX) is standard induction therapy for multiple myeloma (MM)." | 9.14 | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). ( Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA, 2009) |
| "The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT)." | 9.14 | "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. ( Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM, 2010) |
| "PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility." | 9.14 | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. ( Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H, 2009) |
| " This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen." | 9.14 | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. ( Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010) |
| "The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies." | 9.14 | Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. ( Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 9.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP)." | 9.14 | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. ( Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F, 2010) |
| "A randomized phase III trial compared standard MP with MP-T (thalidomide 200 mg/d) in newly diagnosed patients with multiple myeloma older than age 65 years." | 9.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points." | 9.14 | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. ( Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H, 2010) |
| "The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma." | 9.14 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D, 2010) |
| "The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), and we sought to improve its efficacy by adding bortezomib, a proteasome inhibitor with proven antimyeloma activity." | 9.13 | Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. ( Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W, 2008) |
| "The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone." | 9.13 | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2008) |
| "Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM)." | 9.12 | Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr ( Deng, J; Gong, Y; Liu, X; Wu, X; Ye, W; Zheng, X, 2021) |
| "Dexamethasone alone increases life expectancy in patients with relapsed multiple myeloma (MM); however, no large randomized study has compared dexamethasone and dexamethasone-based regimens with standard melphalan-prednisone in newly diagnosed MM patients ineligible for high-dose therapy." | 9.12 | Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. ( Anglaret, B; Attal, M; Azaïs, I; Bataille, R; Blanc, M; Casassus, P; Collet, P; Dorvaux, V; Doyen, C; Eghbali, H; Eschard, JP; Facon, T; Ferrant, A; Grosbois, B; Harousseau, JL; Hulin, C; Jaubert, J; Lepeu, G; Maisonneuve, H; Maloisel, F; Mary, JY; Monconduit, M; Orfeuvre, H; Pégourie, B; Renaud, M; Rossi, JF; Sadoun, A; Thielemans, B; Thyss, A; Troncy, J; Vekemans, MC; Voillat, L; Wetterwald, M; Yakoub-Agha, I, 2006) |
| "This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated patients with multiple Myeloma (MM)." | 9.12 | Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a ( Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G, 2006) |
| "Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126)." | 9.12 | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E, 2006) |
| "Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP)." | 9.12 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. ( Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H, 2006) |
| "Melphalan & Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high-dose therapy." | 9.12 | Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. ( Alegre, A; Bárez, A; García-Laraña, J; García-Sanz, R; Hernández, JM; Mateos, MV; Prósper, F; San Miguel, JF; Sureda, A, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 9.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| "The effectiveness of melphalan plus dexamethasone (M-Dex) with melphalan plus prednisone (MP) as induction therapy and dexamethasone with observation as maintenance therapy was compared in 585 older patients with multiple myeloma." | 9.12 | A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. ( Barr, R; Belch, A; Ding, K; Djurfeldt, M; Dolan, SP; Gill, K; Grewal, KS; Kovacs, MJ; Meyer, RM; Robinson, S; Rubin, SH; Rudinskas, L; Shepherd, LE; Shustik, C; Sicheri, DA; Vickars, L; Walde, D; Wilson, J; Wilson, K, 2007) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 9.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| "Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)." | 9.12 | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. ( Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I, 2007) |
| "To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/ MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed." | 9.11 | Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301. ( Chou, T; Deura, K; Hirano, M; Hotta, T; Itoh, K; Kawano, K; Konda, S; Matsuda, S; Mikuni, C; Mizorogi, F; Nagoshi, H; Ohno, T; Sai, T; Sano, M; Shimoyama, M; Suzuki, T; Takenaka, T; Tomonaga, M; Tsushita, K; Utsunomiya, A; Yamada, T, 2004) |
| "Melphalan-prednisone (MP) has been the gold standard treatment for more than 30 years in elderly multiple myeloma (MM) patients." | 9.11 | Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. ( Bladé, J; Carbonell, F; Fernandez-Calvo, J; García-Sanz, R; Gardella, S; Golvano, E; Hernández, JM; Mateo, G; San Miguel, JF; Soler, JA; Trujillo, J, 2004) |
| "We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma." | 9.11 | Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. ( Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D, 2004) |
| "We report on a randomised trial that aimed to compare the efficacy of continued daily prednisolone treatment during the entire induction phase, with prednisolone given for 2 weeks of each cycle in combination with VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)-interferon-alpha 2b (IFN-alpha 2b) treatment in 299 previously untreated elderly patients (median age: 67 years) with multiple myeloma." | 9.11 | Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. ( Adam, Z; Drach, J; Gisslinger, H; Greil, R; Hinke, A; Klener, P; Kuhn, I; Linkesch, W; Ludwig, H; Maniatis, A; Morant, R; Schuster, J; Spicka, I; Tarkovács, G, 2005) |
| "Eighty-nine previously untreated patients with multiple myeloma and prognostic factors indicating a good prognosis were randomized to either oral melphalan plus prednisone (MP) in combination with recombinant interferon-alpha (rIFN-alpha) or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with rIFN-alpha." | 9.09 | Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud ( Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K, 2001) |
| "We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by interferon maintenance relative to conventional treatment with melphalan and prednisone, in patients less than 60 yr of age with multiple myeloma." | 9.09 | Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. ( Gulbrandsen, N; Hjorth, M; Lenhoff, S; Nord, E; Westin, J; Wisløff, F, 2001) |
| "To evaluate the addition of low-dose interferon-alpha 2b to standard melphalan-prednisone therapy in patients with multiple myeloma." | 9.08 | Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. ( , 1996) |
| "In a Nordic multi-centre trial, 583 previously untreated multiple myeloma patients were randomized to receive melphalan-prednisone or melphalan-prednisone+ interferon alpha-2b at a dose of 5 million units subcutaneously, 3 d/week." | 9.08 | Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. ( Hjorth, M; Kaasa, S; Westin, J; Wisløff, F, 1996) |
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 9.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "We evaluated the vincristine, doxorubicin, and dexamethasone (VAD) regimen alone or with chemosensitizers for remission induction and interferon (IFN) versus IFN plus prednisone (IFN/P) for remission maintenance in previously untreated multiple myeloma." | 9.08 | Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. ( Balcerzak, SP; Crowley, JJ; Rivkin, SE; Roach, RW; Salmon, SE; Samlowski, W; Taylor, SA, 1998) |
| "263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone." | 9.08 | VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). ( Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M, 1998) |
| "A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma." | 9.07 | Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994) |
| "This clinical trial was designed to compare the effectiveness of the standard melphalan and prednisone regimen to that of melphalan, prednisone, and interferon in patients with untreated multiple myeloma." | 9.07 | A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. ( Bernhardt, B; Canellos, G; Cooper, MR; Dear, K; Duggan, D; Ellerton, J; Faragher, D; McIntyre, OR; Ozer, H; Schiffer, C, 1993) |
| "From October 1983 until December 1988, 50 patients with asymptomatic multiple myeloma stage I were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) therapy started at the time of diagnosis with deferred therapy where MP was started at the time of disease progression." | 9.07 | Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1993) |
| "Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha-interferon (MP/IFN) (n = 164)." | 9.07 | Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. ( Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Osterborg, A, 1993) |
| "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM)." | 9.07 | Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. ( Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A, 1993) |
| "In a phase II study, 58 patients with resistant multiple myeloma (MM) were treated with a combination chemotherapy (NOP-bolus regimen) consisting of mitoxantrone (16 mg/m2 for the first 25 patients and 12 mg/m2 for the subsequent 33), vincristine (2 mg), both as bolus injections on day 1 and prednisone (250 mg/d on d 1-4 and 17-20)." | 9.07 | Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). ( Gimsing, P; Hedenus, M; Hippe, E; Palva, I; Talstad, I; Turesson, I; Westin, J; Wisløff, F, 1992) |
| "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM)." | 9.07 | Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. ( Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M, 1991) |
| "A vincristine, melphalan, cyclophosphamide, and prednisone (VMCP) multi-drug regimen was used in 85 previously untreated patients with multiple myeloma (MM) (symptomatic Durie Stages II and III) until they became refractory." | 9.07 | No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. ( Baldini, L; Cesana, BM; Chiorboli, O; Cro, L; Fumagalli, S; Maiolo, AT; Polli, EE; Radaelli, F; Segala, M, 1991) |
| "From October 1983 until December 1986, 164 patients with multiple myeloma stage II-III were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) with multidrug chemotherapy (MDC)." | 9.06 | Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1990) |
| "Eighty-one previously untreated patients with multiple myeloma stage II entered a randomized trial comparing oral melphalan (0." | 9.06 | Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Johansson, B; Osterborg, A, 1990) |
| "Twenty-one patients with multiple myeloma were treated with idarubicin 45 mg/m2 orally day 1 and prednisone 60 mg/m2 day 1-4 every three weeks." | 9.06 | A phase II study of idarubicin and prednisone in multiple myeloma. ( Alberts, AS; Falkson, G; Rapoport, BL; Uys, A, 1990) |
| "The influence of interferon-induced fever on oral melphalan pharmacokinetics has been studied in 10 myeloma patients in a randomized crossover design." | 9.06 | Oral melphalan pharmacokinetics: influence of interferon-induced fever. ( Ehrsson, H; Eksborg, S; Mellstedt, H; Osterborg, A; Wallin, I, 1990) |
| "86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44)." | 9.06 | Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A, 1989) |
| "A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)." | 9.06 | Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988) |
| "In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse." | 9.06 | A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. ( Belch, A; Bergsagel, D; Klimo, P; Shelley, W; White, D; Willan, A; Wilson, K, 1988) |
| "In a randomised multicentre trial a combination of methylprednisolone, vincristine, CCNU, cyclophosphamide and melphalan (MOCCA) was compared with intermittent melphalan and prednisone (MP) as primary treatment in multiple myeloma." | 9.06 | Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Apajalahti, J; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Palva, IP, 1987) |
| "Seventy-five patients with previously untreated multiple myeloma were randomly treated with the association of Peptichemio, Vincristine and prednisone (PTC-VCR-P) or of melphalan and P (MPH-P) for first induction therapy." | 9.06 | Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. ( Ascari, E; Cassano, E; Danova, M; Merlini, G; Montecucco, C; Riccardi, A; Ucci, G, 1986) |
| "For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial." | 9.05 | The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. ( Deraedt, W; Dimopoulos, MA; Goldschmidt, H; Hashim, M; He, J; Heeg, B; Hu, P; Lam, A; Mateos, MV; San-Miguel, J; Sonneveld, P, 2020) |
| "Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients)." | 9.05 | Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. ( Ahre, A; Björkholm, M; Brenning, G; Engstedt, L; Gahrton, G; Hällen, J; Holm, G; Johansson, B; Johansson, SG; Karnström, L; Killander, A; Lerner, R; Lockner, D; Lönnqvist, B; Mellstedt, H; Simonsson, B; Stalfelt, AM; Ternstedt, B; Wadman, B, 1983) |
| "In a randomized study with 234 previously untreated patients with multiple myeloma, 129 were treated with melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks) and 105 with melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (MPCCV, 0." | 9.05 | A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. ( Curuchet, M; Dragosky, M; Garay, G; Huberman, AB; Lein, JM; Palmer, L; Pavlovsky, S; Quiroga-Micheo, E; Saslavsky, J; Tezanos Pinto, M, 1984) |
| "Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively." | 9.05 | Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. ( Becherini, JO; Cavagnaro, F; Jait, C; Lein, JM; Micheo, EQ; Musso, A; Pavlovsky, S; Pileggi, JE; Pizzolato, M; Suárez, A, 1980) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 9.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 9.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper." | 9.04 | Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma. ( Silberman, H; Solomon, A; Tornyos, K, 1977) |
| "Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus prednisone (CBP) (42 patients)." | 9.04 | Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. ( Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR, 1979) |
| "A study was designed to evaluate the effectiveness of prednisone therapy in poor-risk patients with multiple myeloma." | 9.04 | The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. ( Cornwell, GG; Cuttner, J; Falkson, G; Glidewell, O; Harley, JB; Holland, JF; Kyle, RA; Martz, G; Silver, RT; Sonntag, RW; Spurr, C; Wasserman, LR; Wiernik, PM, 1975) |
| " Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence." | 8.93 | Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. ( Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC, 2016) |
| "The availability of novel drugs with different and innovative mechanisms of action such as proteasome inhibitors such as bortezomib and immunomdulatory agents as thalidomide and lenalidomide have changed the landscape of the treatment of patients with newly diagnosed multiple myeloma, allowing the development of several new therapeutic regimens both for transplant-eligible and -ineligible patients." | 8.91 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. ( Cejalvo, MJ; de la Rubia, J, 2015) |
| "Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation." | 8.91 | Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. ( McCormack, PL, 2015) |
| "Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence." | 8.87 | Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. ( Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V, 2011) |
| "The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear." | 8.87 | Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. ( Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P, 2011) |
| "To compare combination chemotherapy (CCT) versus melphalan plus prednisone (MP) as treatment for multiple myeloma." | 8.80 | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. ( , 1998) |
| "Bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) remain the standard treatments for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 8.31 | Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study. ( Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA, 2023) |
| "The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China." | 8.02 | Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. ( Li, S; Liu, Q; Luo, X; Peng, L; Peng, Y; Tan, C; Wan, X; Yi, L; Zeng, X, 2021) |
| "This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible." | 8.02 | Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. ( Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M, 2021) |
| "In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved progression-free survival (PFS) and overall survival (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients." | 8.02 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. ( Bladé, J; Campbell, P; Cavo, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iida, S; Iosava, G; Knop, S; Kudva, A; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Pei, H; Pour, L; Qi, M; San-Miguel, J; Suzuki, K; Ukropec, J; Van Rampelbergh, R; Yoon, SS, 2021) |
| "To explore the expression of Blimp1, ATF4 and CHOP in bone marrow mononuclear cells from patients with multiple myeloma as well as the effect of aspirin on their expression." | 7.96 | [Expression of Blimp1、ATF4 and CHOP in Multiple Myeloma Cells and Effect of Aspirin on Their Expression]. ( Geng, J; Li, J; Liu, HC; Liu, JW; Pei, L; Ren, ZZ; Xiong, C, 2020) |
| "The public subsidy in Australia of bortezomib (Velcade) for untreated non-transplant multiple myeloma patients was based on the VISTA trial." | 7.96 | Bortezomib use and outcomes for the treatment of multiple myeloma. ( Hollingworth, S; Loke, C; McPherson, I; Mollee, P; Mutsando, H; Tomlinson, R; Walpole, E; Weston, H; Wong, P; Yue, M, 2020) |
| "Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy." | 7.91 | Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. ( Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES, 2019) |
| "Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM)." | 7.85 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. ( Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS, 2017) |
| "To investigate the safety and efficacy of the combination regimen vincristine, cyclophosphamide, melphalan or mitoxantrone and prednisone (VCMP) plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma (MM)." | 7.85 | Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. ( Guo, C; He, P; Sun, C; Wang, X; Zhang, M, 2017) |
| "To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U." | 7.83 | Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. ( Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W, 2016) |
| "Cyclophosphamide, bortezomib, and prednisone (CyBorP) is a highly effective, well-tolerated regimen in relapsed/refractory multiple myeloma." | 7.83 | Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. ( Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Prica, A; Reece, DE; Tiedemann, R; Trieu, Y; Trudel, S, 2016) |
| "We performed single nucleotide polymorphism (SNP) array analysis of 35 newly diagnosed symptomatic multiple myeloma (MM) patients who received bortezomib-melphalan-prednisone (VMP) to identify collaborating genetic events that could predict the outcome of treatment." | 7.81 | Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK, 2015) |
| "To observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM) with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP)." | 7.81 | [Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure]. ( Chen, X; Guo, L; Hou, J; Li, L; Ling, C; Shi, H; Wei, W; Zhou, F, 2015) |
| "The combination of melphalan and prednisone (MP) has been the standard treatment of multiple myeloma (MM)." | 7.80 | Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. ( Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 7.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM)." | 7.80 | Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. ( Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N, 2014) |
| "Bortezomib is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination in patients with multiple myeloma (MM)." | 7.80 | Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. ( Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T, 2014) |
| "We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients." | 7.79 | The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. ( Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N, 2013) |
| "We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide." | 7.79 | 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. ( Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M, 2013) |
| "Bortezomib (Btz) has emerged as a standard of care in the treatment of patients with multiple myeloma (MM), but Btz-induced peripheral neuropathy (PNP) has a particularly negative impact on patients' quality of life." | 7.79 | Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. ( Drach, J; Drach-Schauer, B; Eder, S; Lamm, W, 2013) |
| "Bortezomib (Velcade) is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination with other cytostatic agents in multiple myeloma (MM)." | 7.79 | Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. ( Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T, 2013) |
| "A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)." | 7.78 | Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 7.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "The purpose of this study was to evaluate the efficacy and tolerability of continuous low-dose cyclophosphamide and prednisone (CP) as a salvage therapy for multiple myeloma (MM)." | 7.76 | Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. ( Guo, L; Hou, J; Lin, C; Shi, H; Zhou, F, 2010) |
| "Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant." | 7.76 | Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. ( Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 7.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 7.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| "A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy." | 7.74 | Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008) |
| "To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)." | 7.73 | Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. ( Chen, CI; Jaksic, W; Mikhael, J; Pond, GR; Reece, DE; Stewart, AK; Trieu, Y; Trudel, S, 2005) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 7.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported." | 7.72 | Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003) |
| "Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent." | 7.71 | Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 7.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Prednisone is an active drug in the treatment of multiple myeloma." | 7.69 | Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study. ( Beckford, J; Bonnet, JD; Chilton, D; Gupta, V; Pierce, HI; Salmon, SE; Stock-Novack, D; Thompson, EB, 1994) |
| "In the submitted study the authors summarize experience with the treatment of resistant forms of multiple myeloma by a combination of Mitoxantrone, Vincristine and Prednisone (NOP regime)." | 7.68 | [Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)]. ( Bacovský, J; Faltýnek, L; Indrák, K; Papajík, T; Scudla, V, 1993) |
| "An investigation was made of 17 patients with multiple myeloma using the method of alkaline filter elution for the detection of DNA damage and the determination of sister chromatid exchange (SCE) frequency in peripheral lymphocytes during a course of chemotherapy with melphalan and prednisone." | 7.68 | Investigations of the frequency of DNA strand breakage and cross-linking and of sister chromatid exchange frequency in the lymphocytes of patients with multiple myeloma undergoing cytostatic therapy with melphalan and prednisone. ( Bach, I; Hoster, M; Norpoth, K; Popp, W; Schmieding, W; Schürfeld, C; Vahrenholz, C, 1992) |
| "An analysis of survival by response category was performed on 76 patients with stage II and III multiple myeloma, who were treated with oral melphalan and prednisone." | 7.68 | Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. ( Falda, M; Levis, A; Marmont, F; Resegotti, L, 1991) |
| "Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma." | 7.67 | [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. ( Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD, 1984) |
| "High doses of melphalan (HDM) and dexamethasone were administered to 43 patients with advanced multiple myeloma, 36 of whom were refractory to both standard melphalan-prednisone and vincristine-adriamycin-dexamethasone (VAD)." | 7.67 | Prognostic factors with high-dose melphalan for refractory multiple myeloma. ( Alexanian, R; Barlogie, B; Cabanillas, F; Cheson, B; Dicke, K; Dixon, D; Smallwood, L, 1988) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 7.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein." | 7.67 | Dose intensity analysis of melphalan and prednisone in multiple myeloma. ( Belch, A; Brox, L; Hanson, J; Palmer, M, 1988) |
| "A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period." | 7.67 | Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). ( Bladé, J; Cervantes, F; Feliu, E; Grañena, A; Marín, P; Montserrat, E; Nomdedeu, B; Rozman, C, 1986) |
| "A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine." | 7.67 | Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. ( Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD, 1985) |
| "In 12 of 18 patients with multiple myeloma refractory to treatment with the combination of vincristine, melphalan, cyclophosphamide, and prednisone, favorable results were obtained by replacing vincristine in this combination with vindesine." | 7.67 | Vindesine in refractory multiple myeloma. ( Monasch, E; Pegels, HG; van der Lelie, H; von dem Borne, AE, 1986) |
| "Twenty-one patients with plasma cell tumors received vindesine (VDS) at the dose of 3 mg/m2 i." | 7.67 | Vindesine in plasma cell tumors. ( Casara, D; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Frizzarin, M; Paccagnella, A; Salvagno, L, 1985) |
| "Twenty-nine patients with multiple myeloma, 16 untreated and 13 relapsing after treatment with melphalan and/or cyclophosphamide, were treated with Peptichemio (PTC), vincristine (VCR) and prednisone (PRD)." | 7.67 | Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. ( Ascari, E; Merlini, G; Montecucco, CM; Pavesi, F; Riccardi, A; Riccardi, PG, 1985) |
| "The results of a combination chemotherapy trial (melphalan, CCNU, vincristine, cyclophosphamide) involving 28 patients with stage III (n = 21) or stage II (n = 7) multiple myeloma suggest a high response rate, with a mean 71% malignant cell destruction in 78." | 7.66 | [Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases]. ( Bierling, P; Brun, B; Cordonnier, C; Dreyfus, B; Farcet, JP; Feuilhade, F; Kuentz, M; Man, NG; Reyes, F; Rochant, H; Vernant, JP, 1983) |
| "Hexamethylmelamine (280 mg/m2) daily for 21 days every 28 days was given, with prednisone 75 mg on days 1-7, to patients with multiple myeloma failing to respond to, or relapsing from, previous therapy." | 7.66 | Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma. ( Bartolucci, AA; Cohen, HJ, 1982) |
| "A case of myelodysplasia (refractory anaemia with excessive blasts) arising 7 years after a 3 year period of intermittent monthly treatment cycles with melphalan for multiple myelomas is reported." | 7.66 | [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case]. ( Boccafogli, A; Scolozzi, R, 1983) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 7.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "A current southeastern cancer study group protocol for the treatment of multiple myeloma involves induction with BCNU, cyclophosphamide, and prednisone (BCP) and maintenance with either melphalan and prednisone (MP), prednisone, Adriamycin, imuran, and vincristine (PAIV), or delayed treatment of relapsed cases following induction." | 7.66 | Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. ( Cohen, HJ; Durant, JR; Ghanta, VK; Hiramoto, RN; Silberman, HR, 1981) |
| "Fourteen patients with multiple myeloma resistant to melphalan plus prednisone were treated with BCNU 50 mg/m2 plus cyclophosphamide 200 mg/m2 on day 1, adriamycin 20 mg/m2 on day 2 and prednisone 60 mg orally, daily for days 1 through 5." | 7.66 | Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma. ( Klahr, C; Presant, CA, 1978) |
| "Four basic coagulation tests, the prothrombin time, thrombin time, partial thromboplastin time, and prothrombin consumption time, were used, with relatively simple modifications, to demonstrate the presence of two circulating anticoagulants in the blood of a patient with IgG myeloma and a severe bleeding tendency." | 7.65 | Antithrombin and antithromboplastin activity accompanying IgG myeloma. Report of a case with a severe bleeding tendency. ( Conn, RB; Harbaugh, ME; Hill, EM, 1975) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 6.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Plerixafor-treated subjects collected 7." | 6.80 | Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. ( Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK, 2015) |
| "Patients with relapsed/refractory (R/R) multiple myeloma (MM) complicated by severe heart failure typically do not tolerate conventional chemotherapy." | 6.79 | Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. ( Guo, L; Hou, J; Li, L; Ling, C; Shi, H; Wei, W; Zhou, F, 2014) |
| "Pomalidomide was given at 1 to 2." | 6.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 6.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| " Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ." | 6.75 | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 6.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "In the absence of a cure for multiple myeloma (MM) with standard-dose therapy, any strategy that can be expected to increase tumor reduction and to extend survival duration is likely to be of clinical relevance." | 6.70 | Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. ( Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2002) |
| "Multiple myeloma is an incurable disease and after several lines of chemotherapy, patients enter a phase in which no standard treatment options are available." | 6.70 | Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. ( Bloem, AC; de Weerdt, O; Hagenbeek, A; Lokhorst, HM; van de Donk, NW; Veth, G, 2001) |
| "The role of maintenance therapy in multiple myeloma is controversial." | 6.70 | Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. ( Barlogie, B; Berenson, JR; Briggs, AD; Crowley, JJ; Grogan, TM; Mills, GM; Salmon, SE; Zangmeister, J, 2002) |
| "The main form of cytotoxic treatment for multiple myeloma (MM) is conventional dose chemotherapy at present." | 6.69 | Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group. ( Araki, K; Fukuda, H; Hanada, S; Hirano, M; Ichimaru, M; Inaba, S; Konishi, H; Mikuni, C; Miura, A; Niimi, M; Ohno, Y; Sai, T; Shimamoto, Y; Shimoyama, M; Shirakawa, S; Tajima, K; Takenaka, T; Toki, H, 1999) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | 6.68 | A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | 6.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | 6.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group. ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "Thrombocytopenia was the most frequent form of toxicity." | 6.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects." | 6.55 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. ( Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL, 2017) |
| "In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.41 | Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. ( Campbell, P; Cavo, M; Cook, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fastenau, J; Fujisaki, T; Garg, M; Gries, KS; Grosicki, S; Jakubowiak, A; Knop, S; Kudva, A; Liberati, AM; Losava, G; Lucio, P; Mateos, MV; Nagy, Z; Pour, L; San-Miguel, J; Shelekhova, T; Suzuki, K; Usenko, G; Wang, J; Wroblewski, S; Yoon, SS, 2021) |
| "Serious renal failure represents a severe complication of multiple myeloma (MM), with an estimated 25-50 % of patients being affected." | 5.39 | Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. ( Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L, 2013) |
| "The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens." | 5.39 | The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan ( Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST, 2013) |
| "Newly diagnosed multiple myeloma is not included in this study." | 5.38 | Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. ( Aziz, A; Baqui, MN; Begum, M; Debnath, RC; Dipta, TF; Habib, MA; Kabir, AL; Rahman, F; Rahman, MJ, 2012) |
| "The outcome of patients with multiple myeloma (MM) aged over 75 years remains poor, and the best therapeutic approach has still to be defined." | 5.36 | Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. ( Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G, 2010) |
| " The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R)." | 5.34 | Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. ( Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2020) |
| "n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma." | 5.34 | Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. ( Aquino, S; Baldini, L; Ballanti, S; Boccadoro, M; Bringhen, S; Cellini, C; D'Agostino, M; De Rosa, L; Falco, P; Gazzera, G; Gentile, M; Grasso, M; Hájek, R; Larocca, A; Marasca, R; Palumbo, A; Paris, L; Pavone, V; Pescosta, N; Petrucci, MT; Pezzatti, S; Poggiu, M; Rota-Scalabrini, D; Santoro, A; Spada, S; Tosi, P, 2020) |
| "The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the three-drug combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM)." | 5.34 | First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. ( Dingeldein, G; Goldschmidt, H; Habermehl, C; Knauf, W; Kunz, C; Moehler, T; Raab, MS; Schlag, R; Terzer, T; Walter, S; Welslau, M, 2020) |
| "Bortezomib, melphalan, and prednisone (VMP) is the standard of care for transplant-ineligible newly diagnosed multiple myeloma." | 5.34 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. ( Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J, 2020) |
| "The phase 3 FIRST trial demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) with an immune-stimulatory agent, lenalidomide, in combination with low-dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.34 | Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. ( Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D, 2020) |
| "The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.34 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. ( Cavo, M; Dimopoulos, MA; Fernandez, M; Garcia, A; He, J; Heeg, B; Hungria, V; Lam, A; Machnicki, G; Martínez-Baños, DM; Mateos, MV, 2020) |
| "Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM)." | 5.34 | First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. ( Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R, 2020) |
| "Bortezomib (Velcade) is a proteasome inhibitor, which is used as a novel anticancer drug in the treatment of multiple myeloma." | 5.33 | Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. ( Heule, F; Lam, K; Sonneveld, P; Wu, KL, 2006) |
| "The management of elderly patients with multiple myeloma is a relevant problem because it concerns a great number of patients." | 5.31 | Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease. ( Cavalieri, E; Falcucci, P; La Verde, G; Mandelli, F; Matera, R; Petrucci, MT; Pulsoni, A; Tosti, ME; Villivà, N, 2002) |
| "Lamivudine is a nucleoside analogue that can directly suppress HBV replication." | 5.31 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. ( Motta, M; Pelizzari, A; Puoti, M; Rossi, G, 2001) |
| "The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation." | 5.27 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. ( Campbell, P; Carson, R; Cavo, M; Chiu, C; Cook, M; Crepaldi, A; Crist, W; Deraedt, W; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iosava, G; Jakubowiak, A; Kaplan, P; Knop, S; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Nguyen, H; Pour, L; Qi, M; San-Miguel, J; Shelekhova, T; Suzuki, K; Wang, J; Yoon, SS, 2018) |
| "The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT." | 5.24 | Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. ( Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM, 2017) |
| "The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (BIPN) development was studied." | 5.24 | Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ( Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) are 2 standards of care for elderly untreated multiple myeloma (MM) patients." | 5.22 | Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. ( Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI, 2016) |
| "The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation." | 5.22 | Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. ( Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S, 2016) |
| "This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM)." | 5.22 | A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. ( Aghemo, E; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Carella, AM; Conticello, C; De Paoli, L; De Rosa, L; Derudas, D; Falcone, AP; Genuardi, M; Guglielmelli, T; Larocca, A; Liberati, AM; Montefusco, V; Morabito, F; Musolino, C; Nozzoli, C; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Petrucci, MT; Ponticelli, E; Sonneveld, P; Spada, S; Villani, O; Vincelli, ID, 2016) |
| "The prognosis of multiple myeloma (MM) patients who become refractory to lenalidomide and bortezomib is very poor, indicating the need for new therapeutic strategies for these patients." | 5.22 | Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. ( Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S, 2016) |
| "This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma." | 5.20 | Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015) |
| "This analysis, using data from the bortezomib-melphalan-prednisone (VMP) arm of the Phase III VISTA study, investigated whether increased cumulative bortezomib dose could improve overall survival (OS) in transplant-ineligible patients with previously untreated multiple myeloma." | 5.20 | Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. ( Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H, 2015) |
| "This phase 1/2 dose-escalation study investigated the combination of carfilzomib with melphalan and prednisone (CMP) in patients aged >65 years with newly diagnosed multiple myeloma (MM)." | 5.20 | Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C, 2015) |
| "This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with untreated multiple myeloma (MM)." | 5.20 | Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. ( Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 5.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "In the MM-015 trial, melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R) significantly prolonged progression-free survival versus melphalan-prednisone (MP) in newly diagnosed patients with multiple myeloma aged ≥ 65 years." | 5.19 | Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. ( Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J, 2014) |
| "Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation." | 5.19 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014) |
| "Because interleukin-6 (IL-6) is considered important in the proliferation of early multiple myeloma (MM), we hypothesized that the addition of the anti-IL-6 monoclonal antibody siltuximab to the bortezomib-melphalan-prednisone (VMP) regimen would improve outcomes in transplant-ineligible patients with newly diagnosed MM." | 5.19 | Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. ( Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H, 2014) |
| "We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective." | 5.19 | Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. ( Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A, 2014) |
| "This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed multiple myeloma." | 5.19 | Autologous transplantation and maintenance therapy in multiple myeloma. ( Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E, 2014) |
| "As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation." | 5.19 | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. ( Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ, 2014) |
| "In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP) significantly increases the response rate and event-free survival compared with MP alone." | 5.17 | Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study. ( Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A, 2013) |
| "We conducted a phase II trial that evaluated the tolerability and efficacy of combining lenalidomide with melphalan in previously untreated patients with multiple myeloma who were not candidates for autologous stem cell transplantation." | 5.17 | Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. ( Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ, 2013) |
| "This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years of follow-up and to explore the risk of second primary malignancies." | 5.17 | Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H, 2013) |
| " Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy." | 5.17 | Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. ( Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J, 2013) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 5.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma." | 5.16 | Continuous lenalidomide treatment for newly diagnosed multiple myeloma. ( Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M, 2012) |
| "To investigate effects of low-dose cyclophosphamide and prednisone (CP) metronomic chemotherapy on microvessel density of bone marrow, serum vascular endothelial growth factor (VEGF) and platelet derived growth factor BB (PDGF-BB)in multiple myeloma (MM) patients." | 5.16 | [Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients]. ( Guo, LP; Hou, J; Li, L; Lin, CH; Shi, HT; Wei, W; Zhang, YZ; Zhou, F, 2012) |
| "This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone." | 5.15 | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. ( Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL, 2011) |
| "A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau." | 5.15 | Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. ( Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N, 2011) |
| "Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials." | 5.15 | Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. ( Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S, 2011) |
| "Several trials comparing the efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in elderly patients with multiple myeloma (MM) have been reported, with inconsistent results." | 5.15 | A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. ( Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A, 2011) |
| "We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP)." | 5.15 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011) |
| "This Eastern Cooperative Oncology Group trial evaluated 268 previously untreated patients with active multiple myeloma randomized to vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or VBMCP plus HiCy and recombinant IFN." | 5.14 | The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology ( Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF, 2009) |
| "Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects." | 5.14 | Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. ( Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB, 2009) |
| "Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma." | 5.14 | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. ( Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM, 2009) |
| "PURPOSE Thalidomide-dexamethasone (THAL-DEX) is standard induction therapy for multiple myeloma (MM)." | 5.14 | Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). ( Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA, 2009) |
| "The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT)." | 5.14 | "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. ( Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM, 2010) |
| "PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility." | 5.14 | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. ( Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H, 2009) |
| " This phase I/II study was conducted to identify the most appropriate dose of defibrotide in combination with melphalan, prednisone and thalidomide in patients with relapsed and relapsed/refractory multiple myeloma, and to determine its safety and tolerability as part of this regimen." | 5.14 | Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. ( Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010) |
| "The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up, and evaluate the impact of subsequent therapies." | 5.14 | Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. ( Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 5.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP)." | 5.14 | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. ( Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F, 2010) |
| "A randomized phase III trial compared standard MP with MP-T (thalidomide 200 mg/d) in newly diagnosed patients with multiple myeloma older than age 65 years." | 5.14 | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010) |
| "The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points." | 5.14 | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. ( Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H, 2010) |
| "Between March, 2006, and October, 2008, 260 patients with untreated multiple myeloma, 65 years and older, from 63 Spanish centres, were randomly assigned to receive six cycles of VMP (n=130) or bortezomib plus thalidomide and prednisone (VTP; n=130) as induction therapy, consisting of one cycle of bortezomib twice per week for 6 weeks (1·3 mg/m² on days 1, 4, 8, 11, 22, 25, 29, and 32), plus either melphalan (9 mg/m² on days 1-4) or daily thalidomide (100 mg), and prednisone (60 mg/m² on days 1-4)." | 5.14 | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom ( Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB, 2010) |
| "The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma." | 5.14 | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D, 2010) |
| "The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), and we sought to improve its efficacy by adding bortezomib, a proteasome inhibitor with proven antimyeloma activity." | 5.13 | Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. ( Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W, 2008) |
| "The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone." | 5.13 | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2008) |
| "Recent studies have demonstrated that novel therapeutic combinations are challenging melphalan and prednisone (MP) as the standard of care in elderly patients with multiple myeloma." | 5.13 | Update on recent developments for patients with newly diagnosed multiple myeloma. ( Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A, 2008) |
| "Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM)." | 5.12 | Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr ( Deng, J; Gong, Y; Liu, X; Wu, X; Ye, W; Zheng, X, 2021) |
| "Dexamethasone alone increases life expectancy in patients with relapsed multiple myeloma (MM); however, no large randomized study has compared dexamethasone and dexamethasone-based regimens with standard melphalan-prednisone in newly diagnosed MM patients ineligible for high-dose therapy." | 5.12 | Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. ( Anglaret, B; Attal, M; Azaïs, I; Bataille, R; Blanc, M; Casassus, P; Collet, P; Dorvaux, V; Doyen, C; Eghbali, H; Eschard, JP; Facon, T; Ferrant, A; Grosbois, B; Harousseau, JL; Hulin, C; Jaubert, J; Lepeu, G; Maisonneuve, H; Maloisel, F; Mary, JY; Monconduit, M; Orfeuvre, H; Pégourie, B; Renaud, M; Rossi, JF; Sadoun, A; Thielemans, B; Thyss, A; Troncy, J; Vekemans, MC; Voillat, L; Wetterwald, M; Yakoub-Agha, I, 2006) |
| "This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated patients with multiple Myeloma (MM)." | 5.12 | Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a ( Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G, 2006) |
| "Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126)." | 5.12 | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E, 2006) |
| "Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP)." | 5.12 | Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. ( Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H, 2006) |
| "Melphalan & Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high-dose therapy." | 5.12 | Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. ( Alegre, A; Bárez, A; García-Laraña, J; García-Sanz, R; Hernández, JM; Mateos, MV; Prósper, F; San Miguel, JF; Sureda, A, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 5.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| "The effectiveness of melphalan plus dexamethasone (M-Dex) with melphalan plus prednisone (MP) as induction therapy and dexamethasone with observation as maintenance therapy was compared in 585 older patients with multiple myeloma." | 5.12 | A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. ( Barr, R; Belch, A; Ding, K; Djurfeldt, M; Dolan, SP; Gill, K; Grewal, KS; Kovacs, MJ; Meyer, RM; Robinson, S; Rubin, SH; Rudinskas, L; Shepherd, LE; Shustik, C; Sicheri, DA; Vickars, L; Walde, D; Wilson, J; Wilson, K, 2007) |
| " Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients." | 5.12 | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. ( Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB, 2007) |
| "Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)." | 5.12 | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. ( Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I, 2007) |
| "To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/ MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed." | 5.11 | Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301. ( Chou, T; Deura, K; Hirano, M; Hotta, T; Itoh, K; Kawano, K; Konda, S; Matsuda, S; Mikuni, C; Mizorogi, F; Nagoshi, H; Ohno, T; Sai, T; Sano, M; Shimoyama, M; Suzuki, T; Takenaka, T; Tomonaga, M; Tsushita, K; Utsunomiya, A; Yamada, T, 2004) |
| "Melphalan-prednisone (MP) has been the gold standard treatment for more than 30 years in elderly multiple myeloma (MM) patients." | 5.11 | Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. ( Bladé, J; Carbonell, F; Fernandez-Calvo, J; García-Sanz, R; Gardella, S; Golvano, E; Hernández, JM; Mateo, G; San Miguel, JF; Soler, JA; Trujillo, J, 2004) |
| "We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma." | 5.11 | Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. ( Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D, 2004) |
| "We report on a randomised trial that aimed to compare the efficacy of continued daily prednisolone treatment during the entire induction phase, with prednisolone given for 2 weeks of each cycle in combination with VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)-interferon-alpha 2b (IFN-alpha 2b) treatment in 299 previously untreated elderly patients (median age: 67 years) with multiple myeloma." | 5.11 | Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. ( Adam, Z; Drach, J; Gisslinger, H; Greil, R; Hinke, A; Klener, P; Kuhn, I; Linkesch, W; Ludwig, H; Maniatis, A; Morant, R; Schuster, J; Spicka, I; Tarkovács, G, 2005) |
| "The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF." | 5.09 | Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells. ( Ballester, O; Berenson, JR; DiPersio, J; Jacobs, C; Krieger, MS; Kuhn, D; Noga, SJ; Scherzo, E; Schiller, G; Sing, A; Stewart, K; Stiff, P; Tarantolo, S; White, JM, 1999) |
| "We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM)." | 5.09 | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. ( Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Delfini, C; Di Stasi, M; Giordano, M; Mora, O; Nicoletti, G; Piccinini, L; Riccardi, A; Rinaldi, E; Spanedda, R; Tinelli, C; Valentini, D, 2000) |
| "Eighty-nine previously untreated patients with multiple myeloma and prognostic factors indicating a good prognosis were randomized to either oral melphalan plus prednisone (MP) in combination with recombinant interferon-alpha (rIFN-alpha) or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with rIFN-alpha." | 5.09 | Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud ( Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K, 2001) |
| "We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by interferon maintenance relative to conventional treatment with melphalan and prednisone, in patients less than 60 yr of age with multiple myeloma." | 5.09 | Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. ( Gulbrandsen, N; Hjorth, M; Lenhoff, S; Nord, E; Westin, J; Wisløff, F, 2001) |
| "Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years." | 5.09 | Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. ( Alcalá, A; Besalduch, J; Besses, C; Bladé, J; Brunet, S; Carbonell, F; Carnero, M; Conde, E; Escudero, ML; Estapé, J; Esteve, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Conde, J; Gardella, S; Hernández-Martín, J; Maldonado, J; Martí, JM; Montserrat, E; Moro, MJ; Ortega, F; Ribera, JM; Rozman, C; San Miguel, JF; Trujillo, J, 2001) |
| "To determine whether interferon maintenance therapy improves overall survival and response duration in patients with multiple myeloma who have responded to induction therapy with melphalan and prednisone." | 5.08 | Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. ( Barr, R; Belch, A; Bergsagel, D; Browman, GP; O'Reilly, S; Rubin, S; Shustik, C; Sicheri, D; Walker, I; Wilson, KS, 1995) |
| "To evaluate the addition of low-dose interferon-alpha 2b to standard melphalan-prednisone therapy in patients with multiple myeloma." | 5.08 | Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. ( , 1996) |
| "In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b." | 5.08 | Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma. ( Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Di Stasi, M; Mora, O; Petrini, M; Piccinini, L; Piva, N; Riccardi, A; Rinaldi, E; Trotti, G; Ucci, G, 1996) |
| "When a randomized trial (NMSG 4/90) comparing treatment with melphalan/prednisone to melphalan/ prednisone + interferon alpha-2b in newly diagnosed multiple myeloma was initiated in 1990, a quality-of-life assessment was integrated into the study." | 5.08 | Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. ( Eika, S; Hippe, E; Hjorth, M; Holmberg, E; Kaasa, S; Palva, I; Westin, J; Wisløff, F, 1996) |
| "In a Nordic multi-centre trial, 583 previously untreated multiple myeloma patients were randomized to receive melphalan-prednisone or melphalan-prednisone+ interferon alpha-2b at a dose of 5 million units subcutaneously, 3 d/week." | 5.08 | Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. ( Hjorth, M; Kaasa, S; Westin, J; Wisløff, F, 1996) |
| " From January 1985 to December 1989, 487 patients with multiple myeloma (MM) were randomized to receive melphalan and prednisone (MP) versus alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, BCNU, adriamycin, and prednisone (VBAP)." | 5.08 | Treatment of multiple myeloma in elderly people: long-term results in 178 patients. ( Alcalá, A; Besses, C; Bladé, J; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Muñoz, M; Rozman, C; San Miguel, J, 1996) |
| "To compare VMCP, a multidrug combination chemotherapy comprising vincristine (VCR), melphalan (MPH), cyclophosphamide (CPM) and prednisolone (PSL), with MMPP comprising MPH, ranimustine (MCNU), procarbazine, and PSL as induction, to elucidate the value of alternating combination chemotherapy, and to search for an appropriate maintenance therapy in multiple myeloma." | 5.08 | A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma. ( Hirabayashi, N; Hotta, T; Ichikawa, A; Kamiya, O; Kato, R; Kato, Y; Kawashima, K; Kobayashi, M; Mizuno, H; Nagura, E; Naito, K; Nishiwaki, H; Nitta, M; Saito, H; Shibata, T; Shimizu, K; Takeyama, H; Tanaka, M; Utsumi, M, 1997) |
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 5.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "Measurement of health-related quality of life was integrated into a randomized trial (NMSG 4/90) comparing melphalan/prednisone to melphalan/prednisone + interferon alpha-2b in newly diagnosed multiple myeloma." | 5.08 | Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. ( Hjorth, M; Wisløff, F, 1997) |
| "We evaluated the vincristine, doxorubicin, and dexamethasone (VAD) regimen alone or with chemosensitizers for remission induction and interferon (IFN) versus IFN plus prednisone (IFN/P) for remission maintenance in previously untreated multiple myeloma." | 5.08 | Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. ( Balcerzak, SP; Crowley, JJ; Rivkin, SE; Roach, RW; Salmon, SE; Samlowski, W; Taylor, SA, 1998) |
| "263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone." | 5.08 | VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). ( Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M, 1998) |
| "This prospective study was undertaken to evaluate the efficacy of combination chemotherapy with alternating cycles of vincristine, doxorubicin, and dexamethasone (VAD) and prednisone, vindesine, carmustine, and cyclophosphamide (PECC) in poor-risk multiple myeloma (MM)." | 5.07 | VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. ( Benboubker, L; Colombat, P; Combe, M; Delain, M; Goupille, P; Lamagnère, JP; Linassier, C; Luthier, F; Petitdidier, C; Reisenleiter, M, 1994) |
| "A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma." | 5.07 | Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994) |
| "This clinical trial was designed to compare the effectiveness of the standard melphalan and prednisone regimen to that of melphalan, prednisone, and interferon in patients with untreated multiple myeloma." | 5.07 | A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. ( Bernhardt, B; Canellos, G; Cooper, MR; Dear, K; Duggan, D; Ellerton, J; Faragher, D; McIntyre, OR; Ozer, H; Schiffer, C, 1993) |
| "From October 1983 until December 1988, 50 patients with asymptomatic multiple myeloma stage I were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) therapy started at the time of diagnosis with deferred therapy where MP was started at the time of disease progression." | 5.07 | Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1993) |
| "Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha-interferon (MP/IFN) (n = 164)." | 5.07 | Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. ( Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Osterborg, A, 1993) |
| "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM)." | 5.07 | Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. ( Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A, 1993) |
| "In a phase II study, 58 patients with resistant multiple myeloma (MM) were treated with a combination chemotherapy (NOP-bolus regimen) consisting of mitoxantrone (16 mg/m2 for the first 25 patients and 12 mg/m2 for the subsequent 33), vincristine (2 mg), both as bolus injections on day 1 and prednisone (250 mg/d on d 1-4 and 17-20)." | 5.07 | Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). ( Gimsing, P; Hedenus, M; Hippe, E; Palva, I; Talstad, I; Turesson, I; Westin, J; Wisløff, F, 1992) |
| "From September 1975 to December 1986, 115 consecutive previously untreated patients with multiple myeloma (MM) were treated with combination chemotherapy consisting of BCNU, cyclophosphamide, melphalan, vincristine, and prednisone (M-2)." | 5.07 | Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. ( Baggio, G; Bolzonella, S; Casara, D; Chiarion-Sileni, V; De Besi, P; Favaretto, A; Frizzarin, M; Paccagnella, A; Salvagno, L; Soesan, M, 1991) |
| "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM)." | 5.07 | Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. ( Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M, 1991) |
| "A vincristine, melphalan, cyclophosphamide, and prednisone (VMCP) multi-drug regimen was used in 85 previously untreated patients with multiple myeloma (MM) (symptomatic Durie Stages II and III) until they became refractory." | 5.07 | No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. ( Baldini, L; Cesana, BM; Chiorboli, O; Cro, L; Fumagalli, S; Maiolo, AT; Polli, EE; Radaelli, F; Segala, M, 1991) |
| "From October 1983 until December 1986, 164 patients with multiple myeloma stage II-III were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) with multidrug chemotherapy (MDC)." | 5.06 | Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1990) |
| "Eighty-one previously untreated patients with multiple myeloma stage II entered a randomized trial comparing oral melphalan (0." | 5.06 | Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Johansson, B; Osterborg, A, 1990) |
| "Twenty-one patients with multiple myeloma were treated with idarubicin 45 mg/m2 orally day 1 and prednisone 60 mg/m2 day 1-4 every three weeks." | 5.06 | A phase II study of idarubicin and prednisone in multiple myeloma. ( Alberts, AS; Falkson, G; Rapoport, BL; Uys, A, 1990) |
| "The influence of interferon-induced fever on oral melphalan pharmacokinetics has been studied in 10 myeloma patients in a randomized crossover design." | 5.06 | Oral melphalan pharmacokinetics: influence of interferon-induced fever. ( Ehrsson, H; Eksborg, S; Mellstedt, H; Osterborg, A; Wallin, I, 1990) |
| "Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-alpha-2C (rIFN-alpha-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone." | 5.06 | Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. ( Baldini, L; Cortelezzi, A; Fritz, E; Kührer, I; Ludwig, H; Polli, E; Scheithauer, W, 1989) |
| "86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44)." | 5.06 | Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A, 1989) |
| "A randomized study comparing melphalan/prednisone (M/P) therapy with MP + natural alpha-IFN in untreated patients with multiple myeloma stages II and III started April 1, 1986." | 5.06 | Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS. ( Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Johansson, B; Mellstedt, H; Osterborg, A, 1989) |
| "A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)." | 5.06 | Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988) |
| "In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse." | 5.06 | A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. ( Belch, A; Bergsagel, D; Klimo, P; Shelley, W; White, D; Willan, A; Wilson, K, 1988) |
| "Four hundred forty previously untreated patients with active multiple myeloma were entered into a randomized trial (Southwest Oncology Group [SWOG] study 7927/28) comparing vincristine, melphalan, Cytoxan (Mead Johnson & Company, Evansville, Ind), and prednisone (VMCP) alternating with vincristine, BCNU, Adriamycin (Adria Laboratories, Columbus, Ohio) and prednisone (VBAP) with or without levamisole with vincristine, Cytoxan, and prednisone (VCP) with or without levamisole for induction therapy." | 5.06 | Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. ( Bonnet, J; Carter, S; Costanzi, JJ; Dabich, L; Dixon, DO; Durie, BG; Files, JC; Rivkin, S; Salmon, SE; Stephens, R, 1986) |
| "Forty-two previously untreated patients with multiple myeloma were entered in a prospective, randomised trial comparing recombinant interferon alfa-2C monotherapy with VMCP (vincristin, melphalan, cyclophosphamide and prednisolone)." | 5.06 | Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. ( Cortelezzi, A; Fillet, G; Flener, R; Kuzmits, R; Ludwig, H; Peetermans, M; Polli, E; Scheithauer, W; Van Camp, BG, 1986) |
| "67 previously untreated patients with multiple myeloma were entered on a randomized clinical trial to determine whether the use of combination chemotherapy including vincristine, carmustine, alkylating agents, and prednisone was more effective than conventional therapy with melphalan and prednisone." | 5.06 | Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy. ( Bjark, P; Bondevik, A; Bull, O; Dehli, O; Kildahl-Andersen, O; Kvambe, V; Lamvik, J; Nordahl, E; Ytrehus, K, 1986) |
| "In a randomised multicentre trial a combination of methylprednisolone, vincristine, CCNU, cyclophosphamide and melphalan (MOCCA) was compared with intermittent melphalan and prednisone (MP) as primary treatment in multiple myeloma." | 5.06 | Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Apajalahti, J; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Palva, IP, 1987) |
| "Seventy-five patients with previously untreated multiple myeloma were randomly treated with the association of Peptichemio, Vincristine and prednisone (PTC-VCR-P) or of melphalan and P (MPH-P) for first induction therapy." | 5.06 | Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. ( Ascari, E; Cassano, E; Danova, M; Merlini, G; Montecucco, C; Riccardi, A; Ucci, G, 1986) |
| "For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial." | 5.05 | The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. ( Deraedt, W; Dimopoulos, MA; Goldschmidt, H; Hashim, M; He, J; Heeg, B; Hu, P; Lam, A; Mateos, MV; San-Miguel, J; Sonneveld, P, 2020) |
| "Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients)." | 5.05 | Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. ( Ahre, A; Björkholm, M; Brenning, G; Engstedt, L; Gahrton, G; Hällen, J; Holm, G; Johansson, B; Johansson, SG; Karnström, L; Killander, A; Lerner, R; Lockner, D; Lönnqvist, B; Mellstedt, H; Simonsson, B; Stalfelt, AM; Ternstedt, B; Wadman, B, 1983) |
| "In a randomized study with 234 previously untreated patients with multiple myeloma, 129 were treated with melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks) and 105 with melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (MPCCV, 0." | 5.05 | A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. ( Curuchet, M; Dragosky, M; Garay, G; Huberman, AB; Lein, JM; Palmer, L; Pavlovsky, S; Quiroga-Micheo, E; Saslavsky, J; Tezanos Pinto, M, 1984) |
| "Thirty-five previously untreated patients with multiple myeloma were treated with a 60-week course of alternating, potentially non-cross-resistant chemotherapy combinations (melphalan and prednisone; vincristine, cyclophosphamide, doxorubicin, and prednisone; and carmustine, melphalan, and prednisone), alternating every 15 weeks in an attempt to prevent the development of drug resistance." | 5.05 | Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. ( Bunn, PA; Carney, DN; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Morstyn, G; Schechter, GP, 1984) |
| "Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively." | 5.05 | Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. ( Becherini, JO; Cavagnaro, F; Jait, C; Lein, JM; Micheo, EQ; Musso, A; Pavlovsky, S; Pileggi, JE; Pizzolato, M; Suárez, A, 1980) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 5.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine (BCNU), cyclophosphamide, and prednisone (BCP) to melphalan (Alkeran) and prednisone (AP)." | 5.05 | Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. ( Abramson, N; Bennett, JM; Horton, J; Lurie, P; Mietlowski, WL; Schilling, A, 1982) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 5.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-two evaluable good risk patients with multiple myeloma received a 70-day tapering course of prednisone beginning at a dose of 1." | 5.05 | Response rate and survival in myeloma patients receiving prednisone alone. ( Cornwell, GG; Kyle, RA; Leone, L; McIntyre, OR; Pajak, TF, 1985) |
| "Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper." | 5.04 | Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma. ( Silberman, H; Solomon, A; Tornyos, K, 1977) |
| "Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) against a regimen employing oral melphalan (MP)." | 5.04 | Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. ( Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF, 1979) |
| "Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus prednisone (CBP) (42 patients)." | 5.04 | Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. ( Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR, 1979) |
| "A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma." | 5.04 | Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976) |
| "The effects of various regimens of melphalan combination chemotherapy were evaluated in 508 patients with multiple myeloma." | 5.04 | Remission maintenance therapy for multiple myeloma. ( , 1975) |
| "A randomized study compared the response of patients with multiple myeloma to chlorambucil, melphalan, and azathioprine." | 5.04 | Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine. ( , 1975) |
| "The effect of certain disease parameters on remission and survial time was evaluated in 482 patients with multiple myeloma treated with intermittent courses of melphalan-prednisone combinations." | 5.04 | Prognostic factors in multiple myeloma. ( Alexanian, R; Balcerzak, S; Bonnet, JD; Gehan, EA; Haut, A; Hewlett, JS; Monto, RW, 1975) |
| "A study was designed to evaluate the effectiveness of prednisone therapy in poor-risk patients with multiple myeloma." | 5.04 | The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. ( Cornwell, GG; Cuttner, J; Falkson, G; Glidewell, O; Harley, JB; Holland, JF; Kyle, RA; Martz, G; Silver, RT; Sonntag, RW; Spurr, C; Wasserman, LR; Wiernik, PM, 1975) |
| " Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence." | 4.93 | Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. ( Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC, 2016) |
| "The availability of novel drugs with different and innovative mechanisms of action such as proteasome inhibitors such as bortezomib and immunomdulatory agents as thalidomide and lenalidomide have changed the landscape of the treatment of patients with newly diagnosed multiple myeloma, allowing the development of several new therapeutic regimens both for transplant-eligible and -ineligible patients." | 4.91 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. ( Cejalvo, MJ; de la Rubia, J, 2015) |
| "Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation." | 4.91 | Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. ( McCormack, PL, 2015) |
| "Multiple myeloma (MM) is an ancient disease, but until the alkylating agent melphalan was found to have anti-myeloma properties in the 1950s there was virtually no effective therapy." | 4.89 | Evolving therapeutic paradigms for multiple myeloma: back to the future. ( Cherry, BM; Korde, N; Kwok, M; Landgren, O; Roschewski, M, 2013) |
| "Many advances were made in the treatment of multiple myeloma since the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib." | 4.89 | Part II: role of maintenance therapy in transplant-ineligible patients. ( Mina, R; Palumbo, A, 2013) |
| "Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence." | 4.87 | Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. ( Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V, 2011) |
| "The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear." | 4.87 | Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. ( Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P, 2011) |
| "The management of multiple myeloma has benefited substantially from the introduction of three new drugs, namely, the proteasome inhibitor bortezomib and the immunomodulators thalidomide and lenalidomide." | 4.86 | New treatments for myeloma. ( Azaïs, I; Brault, R; Debiais, F, 2010) |
| "Until recently, standard treatment of multiple myeloma (MM) in elderly patients who were not candidates for autologous stem cell transplantation was with the combination of melphalan plus prednisone (MP)." | 4.86 | Multiple myeloma in the elderly: when to treat, when to go to transplant. ( Harousseau, JL, 2010) |
| "Until 2007, frontline chemotherapy with melphalan and prednisone (MP) was considered as the standard of care in the treatment of elderly patients with multiple myeloma (MM)." | 4.84 | Frontline treatment of multiple myeloma in elderly patients. ( Facon, T; Hulin, C; Moreau, P, 2008) |
| "Melphalan was the first described treatment for patients with multiple myeloma in the 1960s and is still being used in clinical practice." | 4.81 | Treatment of myeloma: recent developments. ( Huijgens, PC; Zweegman, S, 2002) |
| "To compare combination chemotherapy (CCT) versus melphalan plus prednisone (MP) as treatment for multiple myeloma." | 4.80 | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. ( , 1998) |
| "Standard chemotherapy with melphalan-prednisone or a combination of alkylating agents has not extended the overall survival of patients with multiple myeloma during the last 30 years and strictly defined complete remissions (CR) are exceedingly rare." | 4.79 | Hematopoietic stem cell transplants for multiple myeloma. ( Barlogie, B; Bracy, D; Desikan, KR; Jagannath, S; Siegel, D; Tricot, G; Vesole, DH, 1996) |
| "The association of melphalan and prednisone, introduced in the sixties, allowed a dramatic improvement in the prognosis of multiple myeloma." | 4.79 | [Therapy of multiple myeloma]. ( La Verde, G; Mandelli, F; Petrucci, MT; Pulsoni, A, 1997) |
| "Melphalan and prednisolone (MP) have been the standard therapy for multiple myeloma for more than 25 years." | 4.79 | [Progress in the treatment of multiple myeloma]. ( Mizoguchi, H; Wada, M, 1997) |
| "L-PAM and prednisone (MP) has been challenged, almost from the start, by combination chemotherapy (CT) with its strong theoretic backing, as the standard chemotherapy for multiple myeloma." | 4.78 | Standard chemotherapy for myelomatosis: an area of great controversy. ( Boccadoro, M; Pileri, A, 1992) |
| "A case of fatal pulmonary fibrosis and atypical epithelial proliferation (AEP) in a patient with multiple myeloma treated with melphalan is presented." | 4.75 | Pulmonary histopathologic changes associated with melphalan therapy. ( Dickman, PS; Feldman, PS; Taetle, R, 1978) |
| "Bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) remain the standard treatments for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 4.31 | Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study. ( Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA, 2023) |
| " After bone marrow aspiration, associated IgG multiple myeloma was detected, so chemotherapy with VMP (bortezomib, melphalan and prednisone) was started." | 4.12 | Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital. ( Egea Valenzuela, J; Leal Rubio, JD; Mesa López, MJ; Muñoz Tornero, M; Salazar Nicolás, A, 2022) |
| "The ALCYONE trial found that daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) can significantly improve progression-free survival (PFS) and overall survival (OS) for patients with transplant-ineligible, newly diagnosed multiple myeloma (MM) in China." | 4.02 | Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. ( Li, S; Liu, Q; Luo, X; Peng, L; Peng, Y; Tan, C; Wan, X; Yi, L; Zeng, X, 2021) |
| "This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible." | 4.02 | Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. ( Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M, 2021) |
| "In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved progression-free survival (PFS) and overall survival (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients." | 4.02 | Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. ( Bladé, J; Campbell, P; Cavo, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iida, S; Iosava, G; Knop, S; Kudva, A; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Pei, H; Pour, L; Qi, M; San-Miguel, J; Suzuki, K; Ukropec, J; Van Rampelbergh, R; Yoon, SS, 2021) |
| "To explore the expression of Blimp1, ATF4 and CHOP in bone marrow mononuclear cells from patients with multiple myeloma as well as the effect of aspirin on their expression." | 3.96 | [Expression of Blimp1、ATF4 and CHOP in Multiple Myeloma Cells and Effect of Aspirin on Their Expression]. ( Geng, J; Li, J; Liu, HC; Liu, JW; Pei, L; Ren, ZZ; Xiong, C, 2020) |
| "The public subsidy in Australia of bortezomib (Velcade) for untreated non-transplant multiple myeloma patients was based on the VISTA trial." | 3.96 | Bortezomib use and outcomes for the treatment of multiple myeloma. ( Hollingworth, S; Loke, C; McPherson, I; Mollee, P; Mutsando, H; Tomlinson, R; Walpole, E; Weston, H; Wong, P; Yue, M, 2020) |
| "Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy." | 3.91 | Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. ( Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES, 2019) |
| "Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM)." | 3.85 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. ( Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS, 2017) |
| "To investigate the safety and efficacy of the combination regimen vincristine, cyclophosphamide, melphalan or mitoxantrone and prednisone (VCMP) plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma (MM)." | 3.85 | Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. ( Guo, C; He, P; Sun, C; Wang, X; Zhang, M, 2017) |
| "To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U." | 3.83 | Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. ( Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W, 2016) |
| "Cyclophosphamide, bortezomib, and prednisone (CyBorP) is a highly effective, well-tolerated regimen in relapsed/refractory multiple myeloma." | 3.83 | Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. ( Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Prica, A; Reece, DE; Tiedemann, R; Trieu, Y; Trudel, S, 2016) |
| " We report a rare case of bilateral steroid-induced osteonecrosis of the proximal femora and humeri nine months after a short course of intravenous methylprednisolone for treatment of multiple myeloma." | 3.83 | Bilateral Osteonecrosis of the Femoral and Humeral Heads after Short Term Corticosteroid Therapy. A Case Study. ( Ed AlTayeb Mussa, M; Eh Samir Ansara, S; El Gamal, TA; El-Bakoury, A; Er Ahmed Sweed, T; Hawkins, A, 2016) |
| "We performed single nucleotide polymorphism (SNP) array analysis of 35 newly diagnosed symptomatic multiple myeloma (MM) patients who received bortezomib-melphalan-prednisone (VMP) to identify collaborating genetic events that could predict the outcome of treatment." | 3.81 | Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK, 2015) |
| "To observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM) with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP)." | 3.81 | [Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure]. ( Chen, X; Guo, L; Hou, J; Li, L; Ling, C; Shi, H; Wei, W; Zhou, F, 2015) |
| "The combination of melphalan and prednisone (MP) has been the standard treatment of multiple myeloma (MM)." | 3.80 | Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. ( Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K, 2014) |
| "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM)." | 3.80 | Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. ( Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S, 2014) |
| "Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM)." | 3.80 | Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. ( Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N, 2014) |
| "Bortezomib is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination in patients with multiple myeloma (MM)." | 3.80 | Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. ( Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T, 2014) |
| "We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients." | 3.79 | The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. ( Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N, 2013) |
| "We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide." | 3.79 | 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. ( Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M, 2013) |
| "Bortezomib (Btz) has emerged as a standard of care in the treatment of patients with multiple myeloma (MM), but Btz-induced peripheral neuropathy (PNP) has a particularly negative impact on patients' quality of life." | 3.79 | Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. ( Drach, J; Drach-Schauer, B; Eder, S; Lamm, W, 2013) |
| "The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen." | 3.79 | The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. ( Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E, 2013) |
| "Bortezomib (Velcade) is a proteasome inhibitor that has shown important clinical efficacy either as a single agent or in combination with other cytostatic agents in multiple myeloma (MM)." | 3.79 | Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. ( Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T, 2013) |
| "A total of 18 patients with newly diagnosed/untreated MM and renal insufficiency (GFR < 35 ml/min) were treated with bendamustine, prednisone, and bortezomib (BPV)." | 3.78 | Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. ( Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T, 2012) |
| "The introduction of novel agents (thalidomide, bortezomib and lenalidomide) in the frontline therapy of multiple myeloma has markedly improved the outcome both in younger patients who are candidates for high-dose therapy plus autologous stem-cell transplantation (HDT/ASCT) and in elderly patients." | 3.78 | How to select among available options for the treatment of multiple myeloma. ( Harousseau, JL, 2012) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 3.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "The traditional concept of treatment of patients aged over 65 years with multiple myeloma is historical combination of melphalan and prednisone (MP)." | 3.77 | [New concept of the treatment in elderly patients with multiple myeloma]. ( Bila, J; Gotić, M; Mihaljević, B, 2011) |
| "The purpose of this study was to evaluate the efficacy and tolerability of continuous low-dose cyclophosphamide and prednisone (CP) as a salvage therapy for multiple myeloma (MM)." | 3.76 | Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. ( Guo, L; Hou, J; Lin, C; Shi, H; Zhou, F, 2010) |
| "Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant." | 3.76 | Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. ( Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010) |
| " There was little evidence that either form of treatment was superior in prolonging survival, for in one study the patients treated with a drug combination lived significantly longer than those treated with MP, while in another the reverse was true, and there was no difference in the survival of the two groups in the remaining 11 studies." | 3.76 | Melphalan/prednisone versus drug combinations for plasma cell myeloma. ( Bergsagel, DE, 1989) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 3.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| "The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism." | 3.75 | Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009) |
| " A diagnosis of erythrophagocytic multiple myeloma was made and treatment with prednisone and melphalan was begun." | 3.74 | Erythrophagocytic multiple myeloma in a cat. ( Almy, F; Chary, P; Northrup, N; Webb, J, 2008) |
| " For acute myelogenous leukemia, cytarabine with anthracycline agent is believed to be the standard treatment in first remission induction therapy." | 3.74 | [The standard treatments for patients with hematological malignancies in Japan]. ( Ishizawa, K, 2007) |
| "A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy." | 3.74 | Thromboembolic events with lenalidomide-based therapy for multiple myeloma. ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008) |
| "The feasibility and efficacy of the combination of melphalan, prednisone, and thalidomide (MPT) have been valuated in 49 newly diagnosed patients with multiple myeloma." | 3.73 | Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. ( Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A, 2005) |
| "To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)." | 3.73 | Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. ( Chen, CI; Jaksic, W; Mikhael, J; Pond, GR; Reece, DE; Stewart, AK; Trieu, Y; Trudel, S, 2005) |
| "We report on six cases of skin lesions induced by bortezomib in patients treated for relapsed multiple myeloma." | 3.73 | Skin lesions induced by bortezomib. ( Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A, 2005) |
| "If our results are confirmed, mechanistic studies examining how prior use of insulin, prednisone, and, perhaps, gout medication might promote increased occurrence of multiple myeloma and how antilipid statins, estrogen replacement therapy, and certain medical conditions might protect against multiple myeloma may provide insights to the as yet unknown etiology of multiple myeloma." | 3.73 | Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. ( Baris, D; Inskip, P; Landgren, O; Zahm, SH; Zhang, Y; Zheng, T, 2006) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 3.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported." | 3.72 | Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003) |
| "To evaluate the impact of an additive therapy with an oral enzyme (OE) preparation given for more than 6 months additionally to standard combination chemotherapy (vincristine/melphalan/cyclophosphamide/prednisone (VMCP)- or methylprednisolone/ vincristine/CCNU/cyclophosphamide/melphalan (MOCCA)-regimen) in the primary treatment of patients with multiple myeloma stages I-III." | 3.71 | Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. ( Bock, PR; Chabronová, I; Dedík, L; Gazová, S; Hanisch, J; Holomanova, D; Hrubisko, M; Mistrík, M; Sakalová, A; Schiess, W, 2001) |
| "Since the introduction of the simple cyclic oral treatment with melphalan and prednisone in the late 1960s, there has been no substantial improvement in the therapy of multiple myeloma." | 3.71 | [High dose therapy with autologous stem cell support--finally a progress in myelomatosis]. ( Brinch, L; Dahl, IM; Ernst, P; Gruber, FX; Hammerstrøm, J; Nesthus, I; Tangen, JM; Waage, A; Wisløff, F, 2001) |
| "Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent." | 3.71 | Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 3.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "A newly designed combination chemotherapy for multiple myeloma, MMCP [ranimustine (MCNU), melphalan (MPH), cyclophosphamide (CPM) and prednisolone (PSL)], was analyzed and compared with the results of our previous randomized trial of VMCP [vincristine, MPH, CPM and PSL] and MMPP [MCNU, MPH, procarbazine and PSL]." | 3.71 | Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma. ( Ichikawa, A; Kamiya, O; Kawashima, K; Kobayashi, M; Mizuno, H; Nagura, E; Nitta, M; Saito, H; Shimizu, K; Takeyama, H; Wakita, A; Yamao, H, 2002) |
| "This study was undertaken to assess the significance of lung-resistance related protein (LRP) expression in plasma cells from untreated multiple myeloma (MM) patients and to determine whether LRP was associated with a poor response and survival in patients treated with different dose regimens of melphalan." | 3.70 | Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. ( Belien, JA; Bloem, AC; de Leeuw, C; Dekker, AW; Izquierdo, MA; Lokhorst, HM; Raaijmakers, HG; Scheper, RJ; Sonneveld, P, 1998) |
| "In a randomized trial conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), interferon alpha-2b (IFN) maintenance therapy (2 mU/m2 subcutaneously three times per week) after successful induction with melphalan and prednisone was found to prolong time to progression in patients with multiple myeloma." | 3.70 | Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. ( Browman, G; Cole, B; James, K; Johnston, D; Li, T; Pater, J; Sugano, D; Zee, B, 1998) |
| "Prednisone is an active drug in the treatment of multiple myeloma." | 3.69 | Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study. ( Beckford, J; Bonnet, JD; Chilton, D; Gupta, V; Pierce, HI; Salmon, SE; Stock-Novack, D; Thompson, EB, 1994) |
| "A case of acute nonlymphocytic leukemia (ANLL) occurring 2 years after the diagnosis of multiple myeloma (MM) that had been treated by only one course of melphalan/prednisone chemotherapy is reported." | 3.69 | Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia. ( Hossfeld, DK; Junge, I; Seeger, D; Weh, HJ, 1996) |
| "In the submitted study the authors summarize experience with the treatment of resistant forms of multiple myeloma by a combination of Mitoxantrone, Vincristine and Prednisone (NOP regime)." | 3.68 | [Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)]. ( Bacovský, J; Faltýnek, L; Indrák, K; Papajík, T; Scudla, V, 1993) |
| "In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months." | 3.68 | [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B]. ( Gola, A; Kotlarek-Haus, S; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wołowiec, D, 1993) |
| " Initially the bone marrow and serum protein dischanges were identical to multiple myeloma, therefore she was treated with melphalan-prednisolone regimen for one year." | 3.68 | [Smoldering myeloma]. ( Dolgos, J; Patakfalvi, A, 1993) |
| "An investigation was made of 17 patients with multiple myeloma using the method of alkaline filter elution for the detection of DNA damage and the determination of sister chromatid exchange (SCE) frequency in peripheral lymphocytes during a course of chemotherapy with melphalan and prednisone." | 3.68 | Investigations of the frequency of DNA strand breakage and cross-linking and of sister chromatid exchange frequency in the lymphocytes of patients with multiple myeloma undergoing cytostatic therapy with melphalan and prednisone. ( Bach, I; Hoster, M; Norpoth, K; Popp, W; Schmieding, W; Schürfeld, C; Vahrenholz, C, 1992) |
| "An analysis of survival by response category was performed on 76 patients with stage II and III multiple myeloma, who were treated with oral melphalan and prednisone." | 3.68 | Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone. ( Falda, M; Levis, A; Marmont, F; Resegotti, L, 1991) |
| "In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5." | 3.68 | [Erythropoietin in multiple myeloma]. ( Baumgartner, G; Fortelny, A; Pecherstorfer, M; Schmoranzer, F; Vesely, M, 1990) |
| "Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma." | 3.67 | [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. ( Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD, 1984) |
| "37 consecutive, previously untreated patients with advanced multiple myeloma (16 patients Stage II, 21 patients Stage III) were treated with a five drug regimen consisting of carmustine, melphalan, vincristine, cyclophosphamide and prednisolone (M-2-protocol) in a prospective manner." | 3.67 | Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma. ( Bauer, K; Bettelheim, P; Gössinger, H; Hinterberger, W; Korninger, K; Lechner, K; Neumann, E; Niessner, H; Pabinger-Fasching, I, 1984) |
| "High doses of melphalan (HDM) and dexamethasone were administered to 43 patients with advanced multiple myeloma, 36 of whom were refractory to both standard melphalan-prednisone and vincristine-adriamycin-dexamethasone (VAD)." | 3.67 | Prognostic factors with high-dose melphalan for refractory multiple myeloma. ( Alexanian, R; Barlogie, B; Cabanillas, F; Cheson, B; Dicke, K; Dixon, D; Smallwood, L, 1988) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 3.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein." | 3.67 | Dose intensity analysis of melphalan and prednisone in multiple myeloma. ( Belch, A; Brox, L; Hanson, J; Palmer, M, 1988) |
| "One hundred seventy-three patients with multiple myeloma were treated from the time of diagnosis with standard oral melphalan and prednisone at 28-day intervals until they became refractory to treatment." | 3.67 | Are the current criteria for response useful in the management of multiple myeloma? ( Belch, A; Brox, L; Koch, M; Palmer, M; Pollock, E, 1987) |
| "99 patients with multiple myeloma were treated over a period of 6 1/2 years; 62 of these were initially treated with vincristine, carmustine, cyclophosphamide, melphalan and prednisone: M 2-Protocol." | 3.67 | [Results with the use of the M-2 protocol in plasmacytoma]. ( Ho, AD; Hunstein, W; Keilholz, U; Theml, H; Wittkamp, S, 1986) |
| "A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period." | 3.67 | Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). ( Bladé, J; Cervantes, F; Feliu, E; Grañena, A; Marín, P; Montserrat, E; Nomdedeu, B; Rozman, C, 1986) |
| "A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine." | 3.67 | Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. ( Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD, 1985) |
| "In 12 of 18 patients with multiple myeloma refractory to treatment with the combination of vincristine, melphalan, cyclophosphamide, and prednisone, favorable results were obtained by replacing vincristine in this combination with vindesine." | 3.67 | Vindesine in refractory multiple myeloma. ( Monasch, E; Pegels, HG; van der Lelie, H; von dem Borne, AE, 1986) |
| "Twenty-one patients with plasma cell tumors received vindesine (VDS) at the dose of 3 mg/m2 i." | 3.67 | Vindesine in plasma cell tumors. ( Casara, D; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Frizzarin, M; Paccagnella, A; Salvagno, L, 1985) |
| "Twenty-nine patients with multiple myeloma, 16 untreated and 13 relapsing after treatment with melphalan and/or cyclophosphamide, were treated with Peptichemio (PTC), vincristine (VCR) and prednisone (PRD)." | 3.67 | Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. ( Ascari, E; Merlini, G; Montecucco, CM; Pavesi, F; Riccardi, A; Riccardi, PG, 1985) |
| "The results of a combination chemotherapy trial (melphalan, CCNU, vincristine, cyclophosphamide) involving 28 patients with stage III (n = 21) or stage II (n = 7) multiple myeloma suggest a high response rate, with a mean 71% malignant cell destruction in 78." | 3.66 | [Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases]. ( Bierling, P; Brun, B; Cordonnier, C; Dreyfus, B; Farcet, JP; Feuilhade, F; Kuentz, M; Man, NG; Reyes, F; Rochant, H; Vernant, JP, 1983) |
| "62 patients with multiple myeloma were primarily treated with the combination vincristin + melphalan + cyclophosphamide + prednisolone (VMCP)." | 3.66 | [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. ( Anger, G; Wutke, K, 1983) |
| "Hexamethylmelamine (280 mg/m2) daily for 21 days every 28 days was given, with prednisone 75 mg on days 1-7, to patients with multiple myeloma failing to respond to, or relapsing from, previous therapy." | 3.66 | Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma. ( Bartolucci, AA; Cohen, HJ, 1982) |
| "A case of myelodysplasia (refractory anaemia with excessive blasts) arising 7 years after a 3 year period of intermittent monthly treatment cycles with melphalan for multiple myelomas is reported." | 3.66 | [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case]. ( Boccafogli, A; Scolozzi, R, 1983) |
| "In order to ascertain whether multiple myeloma patients resistant to one alkylating agent would respond to a second one, high-dose intermittent cyclophosphamide was administered to 12 patients showing resistance to melphalan and prednisone." | 3.66 | Cross-resistance to alkylating agents in multiple myeloma. ( Bladé, J; Estapé, J; Feliú, E; Millá, A; Montserrat, E; Rozman, C, 1983) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 3.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "A current southeastern cancer study group protocol for the treatment of multiple myeloma involves induction with BCNU, cyclophosphamide, and prednisone (BCP) and maintenance with either melphalan and prednisone (MP), prednisone, Adriamycin, imuran, and vincristine (PAIV), or delayed treatment of relapsed cases following induction." | 3.66 | Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. ( Cohen, HJ; Durant, JR; Ghanta, VK; Hiramoto, RN; Silberman, HR, 1981) |
| "In order to study the response of patients with multiple myeloma of the bones (MM) to various anti-cancer drugs (Melphalan M, Cyclophosphamide Cy, Nitrosourea NU, Vincristine V, Adriamycine A and Prednisone P), 70 MM received the following treatment : 1) Induction therapy : a) M and P or b) M and Cy and P ; 2) Levelling with partial or complete response : V Cy P (in case a) or V M Cy P (in case b) ; 3) Relapse : A and NU." | 3.66 | [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years]. ( Bataille, R; Blotman, F; Bussière, JL; Ciurana, AJ; Lopitaux, R; Morlock, G; Rampon, S; Rosenberg, F; Sany, J; Serre, H; Simon, L, 1980) |
| "A patient with multiple myeloma had pancytopenia after treatment with melphalan and prednisone and died of an interstitial pneumonia." | 3.66 | Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case. ( Olsen, TS; von Eyben, F, 1978) |
| "The frequency of solid tumors was evaluated in 628 consecutive patients with multiple myeloma who had been treated with various melphalan-prednisone combinations." | 3.66 | Solid tumors in multiple myeloma. ( Alexanian, R; Stegman, R, 1979) |
| "Twenty-eight patients with multiple myeloma responding to prior melphalan-prednisone combinations, but without additional chemotherapy, were followed until relapse." | 3.66 | Unmaintained remissions in multiple myeloma. ( Alexanian, R; Gehan, E; Haut, A; Saiki, J; Weick, J, 1978) |
| "Fourteen patients with multiple myeloma resistant to melphalan plus prednisone were treated with BCNU 50 mg/m2 plus cyclophosphamide 200 mg/m2 on day 1, adriamycin 20 mg/m2 on day 2 and prednisone 60 mg orally, daily for days 1 through 5." | 3.66 | Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma. ( Klahr, C; Presant, CA, 1978) |
| "Serial changes in tumor mass were evaluated in 61 patients with multiple myeloma who had received intermittent courses of melphalan-prednisone until death." | 3.65 | Tumor growth patterns in multiple myeloma. ( Alexanian, R; Brown, BW; Drewinko, B; Hokanson, JA; Thompson, JR, 1977) |
| "Rapidly fatal acute myelomonocytic leukemia developed in five patients with multiple myeloma who were treated with melphalan for 28 to 54 months." | 3.65 | Multiple myeloma and acute leukemia associated with alkylating agents. ( Bayrd, ED; Kyle, RA; Pierre, RV, 1975) |
| "Four basic coagulation tests, the prothrombin time, thrombin time, partial thromboplastin time, and prothrombin consumption time, were used, with relatively simple modifications, to demonstrate the presence of two circulating anticoagulants in the blood of a patient with IgG myeloma and a severe bleeding tendency." | 3.65 | Antithrombin and antithromboplastin activity accompanying IgG myeloma. Report of a case with a severe bleeding tendency. ( Conn, RB; Harbaugh, ME; Hill, EM, 1975) |
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | 2.94 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 2.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM)." | 2.82 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. ( Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB, 2016) |
| "The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients." | 2.82 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. ( Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB, 2016) |
| "Plerixafor-treated subjects collected 7." | 2.80 | Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. ( Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK, 2015) |
| "Patients with relapsed/refractory (R/R) multiple myeloma (MM) complicated by severe heart failure typically do not tolerate conventional chemotherapy." | 2.79 | Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. ( Guo, L; Hou, J; Li, L; Ling, C; Shi, H; Wei, W; Zhou, F, 2014) |
| "In 36 multiple myeloma (MM) patients, we measured serial changes in iFLC and M-protein after start of treatment." | 2.79 | Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. ( Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT, 2014) |
| "Pomalidomide was given at 1 to 2." | 2.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were randomized to receive 8 cycles of M (9 mg/m(2) /d) and P (60 mg/m(2) /d) for 4d every 6 wk (n=62) or MP and thalidomide (100 mg/d) continuously (n=60)." | 2.76 | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. ( Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L, 2011) |
| " Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ." | 2.75 | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 2.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "Multiple myeloma is incurable with standard chemotherapy." | 2.70 | Bendamustine in the treatment of multiple myeloma: results and future perspectives. ( Niederwieser, D; Pönisch, W, 2002) |
| "In the absence of a cure for multiple myeloma (MM) with standard-dose therapy, any strategy that can be expected to increase tumor reduction and to extend survival duration is likely to be of clinical relevance." | 2.70 | Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. ( Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E, 2002) |
| "Multiple myeloma is an incurable disease and after several lines of chemotherapy, patients enter a phase in which no standard treatment options are available." | 2.70 | Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. ( Bloem, AC; de Weerdt, O; Hagenbeek, A; Lokhorst, HM; van de Donk, NW; Veth, G, 2001) |
| "The role of maintenance therapy in multiple myeloma is controversial." | 2.70 | Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. ( Barlogie, B; Berenson, JR; Briggs, AD; Crowley, JJ; Grogan, TM; Mills, GM; Salmon, SE; Zangmeister, J, 2002) |
| "The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker." | 2.69 | Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. ( Benike, CJ; Blume, KG; Engleman, EG; Levy, R; Liso, A; Okada, CY; Reichardt, VL; Stockerl-Goldstein, KE, 1999) |
| "Melphalan-prednisone was used for initial therapy in 87%." | 2.69 | Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). ( Hjorth, M; Holmberg, E; Rödjer, S; Turesson, I; Westin, J; Wislöff, F, 1999) |
| "Severe infections were seen as often with VBMCP as with VBMCP + rIFN(alpha2) (13% vs." | 2.69 | The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. ( Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B, 1999) |
| "The main form of cytotoxic treatment for multiple myeloma (MM) is conventional dose chemotherapy at present." | 2.69 | Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group. ( Araki, K; Fukuda, H; Hanada, S; Hirano, M; Ichimaru, M; Inaba, S; Konishi, H; Mikuni, C; Miura, A; Niimi, M; Ohno, Y; Sai, T; Shimamoto, Y; Shimoyama, M; Shirakawa, S; Tajima, K; Takenaka, T; Toki, H, 1999) |
| "Interferon (IFN) treatment trials in multiple myeloma have yielded discordant results regarding response rates, maintenance duration, and survival times." | 2.68 | Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. ( Cohen, AM; Eckhardt, S; Günczler, P; Huber, H; Ludwig, H; Morant, R; Nachbaur, D; Polliack, A; Seewann, HL; Senn, HJ, 1995) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | 2.68 | A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease." | 2.68 | Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. ( Crowley, J; Modiano, MR; Salmon, SE; Villar-Werstler, P, 1996) |
| "To analyze the outcome of patients with multiple myeloma (MM) who were potential candidates for early high-dose therapy (HDT) intensification followed by autotransplantation from a series treated with conventional chemotherapy." | 2.68 | Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. ( Alcalá, A; Bladé, J; Conde, E; Conzález-Brito, G; Escudero, ML; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Pascual, A; Rozman, C; San Miguel, JF; Trujillo, J, 1996) |
| "Fifty-eight patients with previously untreated multiple myeloma were entered." | 2.68 | Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. ( Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A, 1996) |
| "In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis." | 2.68 | Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. ( Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B, 1996) |
| "Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids." | 2.67 | Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. ( Barlogie, B; Crowley, JJ; Finley, P; Grogan, TM; Pugh, RP; Salmon, SE, 1994) |
| " 15% of previously untreated myeloma patients achieve a clinical response to IFN alpha alone with a possible dose-response relationship." | 2.67 | Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. ( Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Juliusson, G; Mellstedt, H; Osterborg, A, 1991) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | 2.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | 2.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group. ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "Almost all patients with multiple myeloma still relapse or become refractory in 2 to 3 years." | 2.66 | The use of interferon in the treatment of multiple myeloma. ( Costanzi, JJ; Pollard, RB, 1987) |
| "Thrombocytopenia was the most frequent form of toxicity." | 2.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "Acute leukemia has developed in 14 patients." | 2.65 | The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. ( Bailey, AJ; Bergsagel, DE; Langley, GR; MacDonald, RN; Miller, AB; White, DF, 1979) |
| "Decision making for patients with multiple myeloma (MM) not transplant eligible (NTE) is complicated by a lack of head-to-head comparisons of standards of care, the increase in the choice of treatment modalities, and the promising results that are rapidly evolving from studies with novel regimens." | 2.61 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. ( Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S, 2019) |
| "Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects." | 2.55 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. ( Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL, 2017) |
| "Despite many recent advances in the treatment of multiple myeloma, the course of the disease is characterized by a repeating pattern of periods of remission and relapse as patients cycle through the available treatment options." | 2.52 | Maintenance therapy for multiple myeloma in the era of novel agents. ( Facon, T, 2015) |
| "The treatment of multiple myeloma is evolving rapidly." | 2.48 | Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? ( Rajkumar, SV, 2012) |
| "To summarize the results of treatment of multiple myeloma in the era of novel agents." | 2.44 | Advances in therapy of multiple myeloma. ( Bladé, J; Rosiñol, L, 2008) |
| "For the management of multiple myeloma, high-dose chemotherapy, mainly melphalan with autologous stem cell transplantation, has become the standard treatment even for elderly patients less than 65 years of age." | 2.44 | [Hematological malignancies]. ( Usui, N, 2007) |
| "Although no cure exists for multiple myeloma, current treatments, such as oral melphalan and prednisone, can slow disease progression and prolong overall survival." | 2.44 | Clinical updates and nursing considerations for patients with multiple myeloma. ( Faiman, B, 2007) |
| "There is no evidence that early treatment of multiple myeloma is advantageous." | 2.43 | Treatment of multiple myeloma: an emphasis on new developments. ( Kyle, RA; Vincent Rajkumar, S, 2006) |
| "Thalidomide has been found to be effective for relapsed or refractory myeloma and, more recently, also as induction therapy." | 2.42 | Pharmacotherapy of multiple myeloma: an economic perspective. ( Messori, A; Santarlasci, B; Trippoli, S, 2003) |
| " Particularly in patients aged over 80 years, to avoid side effects it is essential to adjust dosage and route of administration of chemotherapy." | 2.42 | [Malignant lymphoma, multiple myeloma and myeloproliferative diseases in the elderly]. ( Umeda, M, 2004) |
| "Multiple myeloma is still an incurable disease." | 2.41 | Autologous and allogeneic stem cell transplantation in multiple myeloma. ( Egerer, G; Goldschmidt, H; Ho, AD, 2000) |
| "Treatment of Multiple Myeloma in the Elderly: Consensus of the Cooperative Group of Geriatric Oncology of the DGHO and DGG Multiple myeloma is an illness of old age." | 2.41 | [Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics]. ( Bokemeyer, C; Genvresse, I; Späth-Schwalbe, E; Wedding, U, 2001) |
| "Treatment with melphalan and prednisone results in an objective response in 50%-60% of patients." | 2.41 | Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. ( Kyle, RA, 2001) |
| "However, multiple myeloma also can occur rarely in association with sarcoidosis." | 2.41 | Multiple myeloma in association with sarcoidosis. ( Mann, KP; Medeiros, LJ; Sen, F, 2002) |
| "The diagnosis of multiple myeloma (MM) is often difficult; most patients present with asymptomatic gammopathy." | 2.40 | Diagnosis, prognosis, and standard treatment of multiple myeloma. ( Boccadoro, M; Pileri, A, 1997) |
| "Following recent data on multiple myeloma (MM) in the literature, a possible model of myeloma development, involving different cytokine signals, is advanced, and the prognostic significance of two principle staging systems is evaluated." | 2.40 | Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: Multiple myeloma and Waldenström's macroglobulinemia. ( Di Leonardo, G; Di Simone, S; Furia, N; Pasqualoni, E; Quaglino, D, 1998) |
| "This is a general overview on the treatment of multiple myeloma (MM) with particular emphasis on controversial aspects." | 2.40 | Therapeutic strategies and controversies in the treatment of multiple myeloma. ( Bladé, J, 1999) |
| "Although multiple myeloma remains incurable, several drug therapies are valuable in the management of patients suffering from this condition." | 2.40 | Maintenance therapy and supportive care for patients with multiple myeloma. ( Kyle, RA, 1999) |
| "The crucial first step in management of multiple myeloma is to be certain regarding the diagnosis." | 2.39 | [Diagnosis and therapy of multiple myeloma: current aspects]. ( Betticher, DC; Cerny, T; Fey, MF, 1995) |
| "Finally, new insights in the biology of multiple myeloma have been provided by studies of molecular biology and flow cytometry." | 2.38 | [Recent biological and therapeutic advances in multiple myeloma]. ( Avvisati, G; Cantonetti, M; Coppetelli, U; La Verde, G; Papa, G; Petrucci, T; Stasi, R; Tribalto, M, 1992) |
| "Multiple myeloma is one of the most common hematological malignancies worldwide." | 1.91 | Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population. ( Balcerczak, E; Jeleń, A; Michalska, K; Pietrzak, J; Saed, L; Żebrowska-Nawrocka, M, 2023) |
| "Her medical history is remarkable for multiple myeloma, with successful bone marrow transplantation and recurrent disease as secondary plasma cell leukemia, managed with a biologic agent." | 1.72 | [BILATERAL OCULAR PLASMACYTOMA PRESENTING AS ACUTE ANTERIOR UVEITIS]. ( Hayman, L; Kramer, M; Reich, E; Sharon, Y, 2022) |
| "Then lenalidomide was performed as a maintenance therapy." | 1.56 | Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report. ( Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y, 2020) |
| "Extrapolations based on 30-month pivotal multiple myeloma trial data were compared with 75-month data from the same trial." | 1.51 | Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions. ( Hashim, M; Heeg, B; Ouwens, M; Postma, M; Soikkeli, F, 2019) |
| "Accessibility to innovative multiple myeloma therapies is limited in sub-Saharan Africa." | 1.46 | [Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016]. ( Dieng, F; Diouf, C; Djiba, B; Fall, S; Ndao, AC; Ndiaye, FSD, 2017) |
| "To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM." | 1.43 | [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. ( Liu, HB; Wang, W, 2016) |
| "High-risk cytogenetic abnormalities were not associated with the diffuse/variegated MRI pattern (p = 0." | 1.42 | Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. ( Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK, 2015) |
| "The third plasmacytoma was accompanied by progressive cervical pain and swallow dysfunction." | 1.42 | Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report. ( Schols, SE; Tick, LL, 2015) |
| "Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules." | 1.40 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. ( Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H, 2014) |
| "Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields." | 1.39 | [Current technologies in radiotherapy for non-Hodgkin lymphomas]. ( Vinogradova, IuN, 2013) |
| "Serious renal failure represents a severe complication of multiple myeloma (MM), with an estimated 25-50 % of patients being affected." | 1.39 | Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. ( Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L, 2013) |
| "The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens." | 1.39 | The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan ( Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST, 2013) |
| "Newly diagnosed multiple myeloma is not included in this study." | 1.38 | Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma. ( Aziz, A; Baqui, MN; Begum, M; Debnath, RC; Dipta, TF; Habib, MA; Kabir, AL; Rahman, F; Rahman, MJ, 2012) |
| "Since in vitro developed drug-resistant multiple myeloma sublines do not have similar microenvironment of tumor cells, correlation of ECM proteins with drug resistance requires further analysis." | 1.38 | Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. ( Gündüz, U; Mutlu, P; Ural, AU, 2012) |
| "In all, 22 multiple myeloma patients were treated with EPOCH-F before RI-alloHSCT." | 1.37 | EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT. ( Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM, 2011) |
| "The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide." | 1.37 | History of multiple myeloma. ( Kyle, RA; Steensma, DP, 2011) |
| "A 58-year-old Caucasian woman with multiple myeloma developed subacute vision loss bilaterally and was found to have plasma cells in her cerebrospinal fluid." | 1.37 | Central nervous system myelomatosis with optic neuropathy and intramedullary spinal cord compression responding to radiation therapy. ( Alsharif, M; Jenrette, JM; Riley, JM; Russo, JK; Shipp, A, 2011) |
| "IgG multiple myeloma and IgG monoclonal gammopathies are very rare in patients with pyoderma gangrenosum." | 1.37 | Pustular pyoderma gangrenosum. ( Chu, J; Leger, M; Meehan, S; Newlove, T; Stein, J, 2011) |
| "The outcome of patients with multiple myeloma (MM) aged over 75 years remains poor, and the best therapeutic approach has still to be defined." | 1.36 | Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. ( Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G, 2010) |
| "Pyogenic infection was the major cause of TRM after VAD (9 in 11, 81." | 1.36 | High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen. ( Chao, TC; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Liu, JH; Teng, CJ; Teng, HW; Wang, WS; Yang, MH; Yang, YH; Yen, CC, 2010) |
| "Bone lesions in multiple myeloma (MM) are screened with radiological skeletal survey (RSS) due to its widespread availability." | 1.35 | Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. ( Durie, BG; Engelhardt, M; Frydrychowicz, A; Kleber, M; Pache, G; Schmitt-Gräff, A; Wäsch, R, 2009) |
| "The chromosome abnormalities were found in 3 of those cases." | 1.34 | [Four cases of therapy-related leukemia in multiple myeloma]. ( Fujimoto, Y; Ishihara, S; Izumi, H; Kaneko, K; Kato, M; Kuraishi, Y; Nagase, D; Natori, K; Umeda, M, 2007) |
| "Treatment regimens for multiple myeloma are evolving because of advances in both pharmacotherapy and transplantation strategies." | 1.33 | Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. ( Anderson, KC; Palumbo, A, 2005) |
| "Conventional therapy for type III hyperlipoproteinemia was attempted but ineffective." | 1.33 | Type III hyperlipoproteinemia with xanthomas and multiple myeloma. ( Alberta, L; Bostom, A; Burnside, NJ; Robinson-Bostom, L, 2005) |
| "Long-term complete remission in IgD multiple myeloma (MM) is rare." | 1.33 | Long-term complete remission in IgD-myeloma. ( Bemelmans, RH; Schaar, CG; van Leeuwen, L; van Toorn, DW, 2006) |
| " There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors." | 1.33 | Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. ( Belkacémi, Y; Bolla, M; Castelain, B; Knobel, D; Landmann, C; Oner, FD; Ozsahin, M; Poortmans, P; Tsang, RW; Zouhair, A, 2006) |
| "Bortezomib (Velcade) is a proteasome inhibitor, which is used as a novel anticancer drug in the treatment of multiple myeloma." | 1.33 | Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. ( Heule, F; Lam, K; Sonneveld, P; Wu, KL, 2006) |
| " After a few dosage increases, ending with a weekly warfarin dose of 21 mg, the patient's INR values remained in the therapeutic range." | 1.33 | Effects of prednisone on the International Normalized Ratio. ( Chock, A; Faulkner, MA; Skrabal, MZ; Stading, JA, 2006) |
| "Multiple myeloma is a low malignant, non-Hodgkin's lymphoma, which is characterised by infiltration of the bone marrow by clonal prolifaration of atypical plasma cells." | 1.33 | [Pulmonary and pleural manifestations of multiple myeloma]. ( Florschütz, A; Kachel, R; Knolle, J; Schelle, M; Schreiber, C; Schreiber, J, 2006) |
| "A case of systemic lupus erythematosus (SLE) complicated by multiple myeloma is presented." | 1.32 | Multiple myeloma associated with systemic lupus erythematosus. ( Kaklamanis, P; Konstantopoulos, K; Mantzourani, M; Vaiopoulos, G, 2003) |
| "Immunoglobulin D (IgD) multiple myeloma is rare, accounting for less than 2% of all patients with multiple myeloma." | 1.32 | [Pleural effusion as a first sign of Ig D lambda multiple myeloma]. ( Bastard, JP; Capeau, J; Diop, ME; Fellahi, S; Francois, T; Maachi, M, 2003) |
| "Although exceptional, multiple myeloma must be borne in mind in the presence of diffuse bone sclerosis." | 1.32 | Multiple myeloma presenting with widespread osteosclerotic lesions. ( Cotten, A; Duquesnoy, B; Flipo, RM; Gaxatte, C; Guillerm, G; Leroy, X; Mulleman, D, 2004) |
| "Twenthy-tree out of 65 patients had monoclonal gammapathy of undetermined significance (MGUS) and 42 suffered from multiple myeloma (MM)." | 1.32 | Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias. ( Alvino, S; Del Monte, G; Greco, C; Lopez, M; Venturo, I, 2003) |
| "Neovascularisation and bone resorption are related to myeloma disease activity." | 1.32 | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. ( Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP, 2004) |
| "Multiple myeloma was diagnosed at an advanced stage in the three cases." | 1.32 | [Multiple myeloma and HIV infection: report of 3 cases]. ( Elira Dokekias, A; Malanda, F; Moutschen, M; Moyikoua, A; Purhuence, MF, 2004) |
| "The management of elderly patients with multiple myeloma is a relevant problem because it concerns a great number of patients." | 1.31 | Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease. ( Cavalieri, E; Falcucci, P; La Verde, G; Mandelli, F; Matera, R; Petrucci, MT; Pulsoni, A; Tosti, ME; Villivà, N, 2002) |
| "While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare." | 1.31 | Myelomatous effusion with poor response to chemotherapy. ( Hong, DS; Kim, YM; Lee, DW; Lee, KK; Oh, HS; Park, HS; Park, JS; Park, SK; Won, JH, 2000) |
| "Patients with monoclonal gammopathy of undetermined significance/smoldering MM had intermediate values." | 1.31 | Expression of BAX in plasma cell dyscrasias. ( Krajewska, M; Krajewski, S; Lichtenstein, A; Reed, JC; Renner, S; Weisz, J, 2000) |
| "Lamivudine is a nucleoside analogue that can directly suppress HBV replication." | 1.31 | Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. ( Motta, M; Pelizzari, A; Puoti, M; Rossi, G, 2001) |
| "Proptosis and 6th nerve palsy is very uncommon presentation." | 1.31 | Multiple myeloma presenting as proptosis and sixth nerve palsy. ( Multani, LS; Neki, NS; Sharma, N; Sharma, RK, 2001) |
| "Multiple myeloma was the cause of death in four patients; one patient died of systemic amyloidosis." | 1.30 | Primary systemic amyloidosis with delayed progression to multiple myeloma. ( Gertz, MA; Kyle, RA; Rajkumar, SV, 1998) |
| "Multiclonal gammopathies associated with multiple myeloma may result either from a neoplastic transformation of a cell clone undergoing immunoglobulin class switching or from independent transforming events yielding proliferation of unrelated plasma cell clones." | 1.30 | IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. ( Bragantini, G; Bresciani, P; Chuba, J; Ghiso, J; Pavlovsky, S; Pizzolato, M; Rostagno, A; Vidal, R, 1998) |
| "POEMS syndrome is a rare synopsis of different multisystemic disorders (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin lesions) associated with plasma cell dyscrasia." | 1.30 | POEMS syndrome, steroid-dependent diabetes mellitus, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia. ( Albitar, S; Bourgeon, B; Genin, R; Jacquesson, M; Ribera, A; Riviere, JP; Serveaux, JP; Serveaux, MO, 1998) |
| "One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved." | 1.30 | Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. ( Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE, 1999) |
| "We diagnosed multiple myeloma in both." | 1.30 | [Multiple myeloma nephropathy as a cause of renal failure--diagnostic difficulties and prospects for treatment]. ( Nartowicz, E; Polak, G; Tomczak-Watras, W, 1998) |
| "The association of leukemia and multiple myeloma is well described usually as a complication of chemotherapy but also in the absence of chemotherapy or at diagnosis." | 1.30 | Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages. ( Dunkley, S; Gibson, J; Iland, H; Joshua, D; Li, C, 1999) |
| "We report two patients who developed visual hallucinations during treatment with vincristine." | 1.29 | Visual hallucinations following treatment with vincristine. ( Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK, 1994) |
| "Treatment with aspirin and prednisone in one patient." | 1.29 | Anterior ischemic optic neuropathy secondary to interferon alfa. ( Purvin, VA, 1995) |
| "Multiple myeloma was first diagnosed." | 1.29 | Coexisting kappa light chain multiple myeloma and primary hyperparathyroidism. ( Acquaviva, PC; Bille, F; Henry, JF; Toussirot, E, 1994) |
| "We report a case of IgG lambda multiple myeloma with inaugural cutaneous xanthomatosis." | 1.29 | [Remission under treatment of cutaneous xanthomatosis disclosing myeloma: apropos of a case with a three-year course]. ( Courtois, H; Daragon, A; Gancel, A; Lévesque, H; Mabilais, P, 1993) |
| "There are only 3." | 1.29 | [Recent therapy for refractory myeloma]. ( Togawa, A, 1993) |
| "Other 16 patients with low bone mineral density have received also calcitonin (100 units subcutaneous daily) with vitamin D3 and calcium carbonate." | 1.29 | [Effect of calcitonin treatment on bone mineralization in patients with multiple myeloma]. ( Kuratowska, Z; Niesiobedzka-Krezel, J; Ostrowski, G; Ostrowski, K; Paluszewska, M; Paprocka, E; Przedlacki, J; Swieboda, A; Walter, Z, 1995) |
| "Cytostatic treatment of multiple myeloma in combination with repetitive i." | 1.29 | Reversible metastatic pulmonary calcification in a patient with multiple myeloma. ( Frickhofen, N; Friedrich, JM; Hoffmeister, A; Mattfeldt, T; Merkle, E; Prümmer, O; Weber, CK, 1996) |
| "Curative therapy for multiple myeloma continues to be an elusive goal." | 1.28 | Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma. ( Artim, R; Davidson, H; Gandara, D; George, C; MacKenzie, MR; Meyers, F; Ray, G; Schiff, S; Shields, J; Wold, H, 1992) |
| "A case of non-secretory multiple myeloma presenting as primary plasma cell leukaemia in a 65 year old woman is presented." | 1.28 | Non-secretory multiple myeloma presenting as primary plasma cell leukaemia. ( Hernando, JC; Pais, JR; Pascual, J; Pérez Vaquero, MA; Sureda, A, 1992) |
| "Thus DNA aneuploidy is considered rare in benign monoclonal gammopathy." | 1.28 | Flow cytometric DNA analysis and clinical correlations in multiple myeloma. ( Pelliniemi, TT; Tienhaara, A, 1992) |
| "The development of multiple myeloma has not been reported previously during a course of malignant lymphoma." | 1.28 | [Multiple myeloma in a patient in remission from malignant lymphoma]. ( Aotuka, N; Asai, T; Hashimoto, S; Hirasawa, A; Itoh, K; Kawano, E; Morio, S; Nakamura, H; Oh, H; Yoshida, S, 1992) |
| "The authors describe 4 cases of multiple myeloma that developed one or more extraskeletal localizations." | 1.28 | [Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases]. ( Bucalossi, A; Cantore, M; Leoncini, L; Smerieri, F, 1991) |
| "These findings indicate that his multiple myeloma had undergone a leukemic change associated with acute myelogenous leukemia." | 1.28 | [A myeloma (IgG-kappa) terminating in acute myelogenous leukemia]. ( Fujii, H; Horishi, M; Kitagawa, Y; Kuzuyama, Y; Miyoshi, M; Suyama, Y; Taniwaki, M; Urata, Y; Yashige, H, 1990) |
| "A 66-year-old man with kappa-light chain multiple myeloma had adult Fanconi syndrome." | 1.28 | Adult Fanconi syndrome secondary to kappa-light chain myeloma: improvement of tubular functions after treatment for myeloma. ( Ando, R; Hamaguchi, H; Kanemitsu, H; Marumo, F; Matsuda, O; Miyake, S; Takemura, T; Uchida, S; Yokota, T, 1990) |
| "Multiple myeloma was diagnosed in a 65-year-old woman in 1974 who thereafter received five-drug M2 chemotherapy." | 1.28 | Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy. ( Factor, SM; Reed, LJ; van Hoeven, KH, 1990) |
| "Current management of spinal cord compression due to multiple myeloma usually involves irradiation with or without decompressive surgery." | 1.28 | Spinal cord compression in myelomatosis: response to chemotherapy alone. ( Blumsohn, A; Sinoff, CL, 1989) |
| "Of 10 patients with non-Hodgkin's lymphoma 2 achieved complete remission and 5 a partial response." | 1.27 | Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone. ( Gomez, GA; Han, T; Henderson, ES; Ozer, H, 1984) |
| "Three patients with plasma cell leukemia are reported." | 1.27 | Plasma cell leukemia: a report on three patients. ( Cochi, S; De Laurenzi, A; Ferraro, P; Pacilli, L, 1983) |
| "Multiple myeloma is a disease characterized by the proliferation of malignant plasma cells, the over-production of a monoclonal immunoglobulin (paraprotein) and the subsequent depression of the other normal immunoglobulins." | 1.27 | Long-term survival of a patient with multiple myeloma--a cure? A case report. ( Dutcher, JP; Wiernik, PH, 1984) |
| "Pretreatment spermidine concentrations did not distinguish those who responded to treatment nor did they differ in patients and controls." | 1.27 | Plasma spermidine concentrations as early indication of response to therapy in human myeloma. ( Halie, MR; Houwen, B; Jurjens, H; Marrink, J; Nieweg, HO; Van Dobbenburgh, OA, 1983) |
| "The prognosis of malignant lymphomas has been transformed since the introduction of this drug in the chemotherapeutic protocols: the level of complete remission increased from 25% with CVP protocols to 50% with CHOP-types protocols, and to more than 70% with intensive chemotherapy protocols (m-BACOD, LNH-80)." | 1.27 | [Contribution of anthracyclines in treatment of lymphoproliferative disorders]. ( Coiffier, B, 1987) |
| "Eight of ten patients with acute renal failure (ARF) obtained recovery of renal function, and in five of them serum creatinine concentration returned to normal." | 1.27 | Management of myeloma kidney: an anti-light-chain approach. ( Mecca, G; Mingardi, G; Misiani, R; Tiraboschi, G, 1987) |
| "There was no evidence of multiple myeloma." | 1.27 | IgD multiple myeloma: a cure at 21 years. ( Kyle, RA, 1988) |
| "Treatment with melphalan, cyclophosphamide, and prednisone was associated with long-term survival (median, 540 days)." | 1.27 | Prognostic factors for multiple myeloma in the dog. ( Hurvitz, AI; Leifer, CE; MacEwen, EG; Matus, RE, 1986) |
| "Twenty previously treated patients with multiple myeloma were treated with rDNA human alpha-2 interferon (INTRON A) in a phase II trial." | 1.27 | Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase. ( Bonnem, E; Boyd, MA; Case, DC; Dorsk, BM; Hiebel, J; Paul, SD; Shepp, MA; Sonneborn, HL, 1986) |
| "Optimal therapy in patients with multiple myeloma relies on methods which indicate stability or progression of disease." | 1.27 | Monitoring myeloma: light chain isotype suppression. A new parameter. ( Joshua, DE; Kronenberg, H; Wearne, A, 1985) |
| "Neither had evidence of recurrent breast cancer." | 1.27 | Multiple myeloma masquerading as metastatic breast cancer. ( Garrett, TJ; Savage, D, 1986) |
| "A patient with multiple myeloma is described who developed severe intrahepatic cholestasis secondary to hepatic deposition of amyloid." | 1.27 | Obstructive jaundice from hepatic amyloidosis in a patient with multiple myeloma. ( Calomeni, JA; Smith, JR, 1985) |
| "Sixteen patients with multiple myeloma refractory to alkylating agents were treated with vincristine 0." | 1.27 | Salvage treatment for patient with multiple myeloma refractory to alkylating agents. ( Gomez, GA; Han, T; Henderson, ES; Ozer, H, 1985) |
| " The defect causing the periodicity was probably related to the reduced number of neutrophils in the marrow maturation storage pool, which in turn may be related to a reduced and/or defective granulocytic stem cell pool size consequent to the long-term administration of cytotoxic drugs and/or infiltration of the marrow by myeloma cells." | 1.26 | Cyclic oscillation of blood neutrophils in a patient with multiple myeloma. ( Chanana, AD; Chandra, P; Chikkappa, G; Cronkite, EP; Thompson, KH, 1980) |
| "One of them showed blood picture of plasma cell leukemia." | 1.26 | Concomitant association of pyroglobulinemia and cryoglobulinemia in 2 patients in multiple myeloma. ( Hatake, K; Saito, K, 1982) |
| "A 76-year-old man with plasma cell leukemia was treated with L-phenylalanine mustard and prednisone (CLGB 7461)." | 1.26 | Plasma cell leukemia: response to conventional myeloma therapy. ( Gailani, S; Henderson, ES; Seon, BK, 1977) |
| "Of 476 patients with multiple myeloma treated during a 9-year period, 11 developed acute myelogenous leukemia or sideroblastic anemia." | 1.26 | Acute leukemia in multiple myeloma. ( Alexanian, R; Gonzalez, F; Trujillo, JM, 1977) |
| "The meningeal metastasis was treated by surgery and irradiation with orbital penetration; the lymph nodes were irradiated, and COPP polychemotherapy was given to treat the rest of the metastatic localizations." | 1.26 | [Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)]. ( Caballero, O; Martínez, J; Marty, ML; Mayans, J; Sanz, MA, 1979) |
| "Osteosclerotic multiple myeloma is very rare." | 1.26 | [2 cases of multiple myeloma with osteosclerosis]. ( Felder, M; Keiser, G; Wirth, W, 1979) |
| "Criteria for the diagnosis of multiple myeloma and differential diagnostic considerations are presented." | 1.26 | [Prognosis and therapy of multiple myeloma]. ( Sonntag, RW, 1978) |
| "Described is a patient with multiple myeloma who, during long-term treatment with alkylating agents, developed cutaneous Kaposi's sarcoma." | 1.26 | Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma. ( Kapadia, SB; Krause, JR, 1977) |
| " The long-term administration of fluoride, supplemented by calcium and androgen, induced radiologically apparent bone fluorosis, but strengthening of lytic bone was not observed." | 1.25 | Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen. ( Finkel, HE; Schilling, A, 1975) |
| " Because of rapid progression of the amyloidosis and further infections, cytotoxic drug therapy was stopped, corticosteroid dosage was decreased, and supplementary immunoglobulin therapy was instituted." | 1.25 | Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy. ( Dawkins, RL; Zilko, PJ, 1975) |
| "Patients with IgG multiple myeloma underwent serial studies of tumor cell kinetics including (1) estimation of the total body myeloma cell number (TBMC), (2) measurement of the myeloma cell tritiated thymidine labeling index (LI), and (3) calculation of the total number of myeloma cells undergoing DNA synthesis." | 1.25 | Expansion of the growth fraction in multiple myeloma with alkylating agents. ( Salmon, SE, 1975) |
| "Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino-terminal, variant half (VL) or to the carboxyl-terminal, constant half (CL) of the Bence Jones protein." | 1.25 | Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy. ( Capra, JD; McLaughlin, CL; Solomon, A, 1975) |
| "A review of 869 cases of multiple myeloma seen at the Mayo Clinic from 1960 through 1971 revealed that 98% of patients were 40 years of age or older and that 61% of them were males." | 1.25 | Multiple myeloma: review of 869 cases. ( Kyle, RA, 1975) |
| "Two cases of acute renal failure complicating multiple myeloma are reported." | 1.25 | Acute renal failure in multiple myeloma. ( Booth, LJ; Minielly, JA; Smith, EK, 1974) |
| "Twenty-three patients with multiple myeloma were studied." | 1.25 | Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases. ( Basch, CM; Rosenbaum, EH, 1969) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 352 (38.43) | 18.7374 |
| 1990's | 196 (21.40) | 18.2507 |
| 2000's | 161 (17.58) | 29.6817 |
| 2010's | 174 (19.00) | 24.3611 |
| 2020's | 33 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, W | 1 |
| Wu, X | 1 |
| Liu, X | 1 |
| Zheng, X | 1 |
| Deng, J | 1 |
| Gong, Y | 1 |
| Pérez-Persona, E | 2 |
| Oiartzabal-Ormategui, I | 1 |
| Herraez, S | 1 |
| Menchaca, C | 1 |
| Cuevas-Palomares, L | 1 |
| Santamaría-López, A | 1 |
| Díez-Angulo, R | 1 |
| Robles-Castro, D | 1 |
| de Miguel-Sánchez, C | 1 |
| Gabilondo-Jalón, M | 1 |
| Pisón-Herrero, C | 1 |
| Unamunzaga-Cilaurren, A | 1 |
| Vega González-Viñaspre, A | 1 |
| Salcedo-Cuesta, L | 1 |
| Mendizabal-Abad, A | 1 |
| Guinea de Castro, JM | 1 |
| Mesa López, MJ | 1 |
| Salazar Nicolás, A | 1 |
| Leal Rubio, JD | 1 |
| Muñoz Tornero, M | 1 |
| Egea Valenzuela, J | 1 |
| Zhi, Y | 1 |
| Bao, S | 1 |
| Mao, J | 1 |
| Chai, G | 1 |
| Zhu, J | 1 |
| Liu, C | 1 |
| Chen, X | 2 |
| Sharon, Y | 1 |
| Reich, E | 1 |
| Hayman, L | 1 |
| Kramer, M | 1 |
| Suzuki, T | 4 |
| Maruyama, D | 3 |
| Machida, R | 3 |
| Kataoka, T | 3 |
| Fukushima, N | 3 |
| Takayama, N | 3 |
| Ohba, R | 3 |
| Omachi, K | 3 |
| Imaizumi, Y | 3 |
| Tokunaga, M | 3 |
| Katsuya, H | 3 |
| Yoshida, I | 3 |
| Sunami, K | 3 |
| Kurosawa, M | 3 |
| Kubota, N | 3 |
| Morimoto, H | 3 |
| Kobayashi, M | 7 |
| Yamamoto, K | 3 |
| Kameoka, Y | 4 |
| Kagami, Y | 3 |
| Tabayashi, T | 3 |
| Maruta, M | 3 |
| Kobayashi, T | 5 |
| Iida, S | 6 |
| Nagai, H | 3 |
| Michalska, K | 2 |
| Balcerczak, E | 2 |
| Jeleń, A | 2 |
| Saed, L | 2 |
| Pietrzak, J | 2 |
| Żebrowska-Nawrocka, M | 2 |
| Lee, JY | 1 |
| Park, SS | 1 |
| Jeon, YW | 1 |
| Shin, SH | 1 |
| Yahng, SA | 1 |
| Min, CK | 8 |
| Facon, T | 25 |
| Dimopoulos, MA | 27 |
| Meuleman, N | 1 |
| Belch, A | 12 |
| Mohty, M | 1 |
| Chen, WM | 2 |
| Kim, K | 4 |
| Zamagni, E | 4 |
| Rodriguez-Otero, P | 2 |
| Renwick, W | 1 |
| Rose, C | 1 |
| Tempescul, A | 1 |
| Boyle, E | 1 |
| Manier, S | 1 |
| Attal, M | 11 |
| Moreau, P | 11 |
| Macro, M | 4 |
| Leleu, X | 3 |
| Lorraine Chretien, M | 1 |
| Ludwig, H | 11 |
| Guo, S | 3 |
| Sturniolo, M | 1 |
| Tinel, A | 1 |
| Silvia Monzini, M | 1 |
| Costa, B | 1 |
| Houck, V | 3 |
| Hulin, C | 13 |
| Yves Mary, J | 1 |
| Soikkeli, F | 1 |
| Hashim, M | 2 |
| Ouwens, M | 1 |
| Postma, M | 1 |
| Heeg, B | 4 |
| Nielsen, LK | 1 |
| Stege, C | 1 |
| Lissenberg-Witte, B | 1 |
| van der Holt, B | 2 |
| Mellqvist, UH | 4 |
| Salomo, M | 2 |
| Bos, G | 1 |
| Levin, MD | 3 |
| Visser-Wisselaar, H | 2 |
| Hansson, M | 2 |
| van der Velden, A | 1 |
| Deenik, W | 2 |
| Coenen, J | 1 |
| Hinge, M | 1 |
| Klein, S | 1 |
| Tanis, B | 1 |
| Szatkowski, D | 1 |
| Brouwer, R | 1 |
| Westerman, M | 2 |
| Leys, R | 1 |
| Sinnige, H | 2 |
| Haukås, E | 3 |
| van der Hem, K | 1 |
| Durian, M | 1 |
| Gimsing, P | 8 |
| van de Donk, N | 1 |
| Sonneveld, P | 12 |
| Waage, A | 9 |
| Abildgaard, N | 6 |
| Zweegman, S | 8 |
| Bringhen, S | 26 |
| D'Agostino, M | 1 |
| Paris, L | 2 |
| Ballanti, S | 3 |
| Pescosta, N | 4 |
| Spada, S | 4 |
| Pezzatti, S | 3 |
| Grasso, M | 8 |
| Rota-Scalabrini, D | 2 |
| De Rosa, L | 4 |
| Pavone, V | 1 |
| Gazzera, G | 1 |
| Aquino, S | 1 |
| Poggiu, M | 1 |
| Santoro, A | 2 |
| Gentile, M | 4 |
| Baldini, L | 7 |
| Petrucci, MT | 30 |
| Tosi, P | 2 |
| Marasca, R | 3 |
| Cellini, C | 2 |
| Palumbo, A | 52 |
| Falco, P | 14 |
| Hájek, R | 11 |
| Boccadoro, M | 43 |
| Larocca, A | 17 |
| Cavo, M | 21 |
| Mateos, MV | 29 |
| van Beekhuizen, S | 1 |
| Gebregergish, SB | 1 |
| Nair, S | 1 |
| Pisini, M | 1 |
| Lam, A | 4 |
| Slavcev, M | 1 |
| San-Miguel, J | 8 |
| Goldschmidt, H | 6 |
| Deraedt, W | 8 |
| Hu, P | 1 |
| He, J | 3 |
| Bhutani, M | 1 |
| Usmani, SZ | 2 |
| Killock, D | 1 |
| Lee, HS | 2 |
| Kim, SJ | 2 |
| Lee, JJ | 5 |
| Kim, I | 3 |
| Kim, JS | 2 |
| Eom, HS | 2 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Shin, HJ | 3 |
| Mun, YC | 2 |
| Kim, MK | 2 |
| Lim, SN | 2 |
| Choi, CW | 3 |
| Kang, HJ | 1 |
| Yoon, SS | 8 |
| Vaxman, I | 1 |
| Gertz, M | 1 |
| Liu, HC | 1 |
| Xiong, C | 1 |
| Geng, J | 1 |
| Liu, JW | 1 |
| Ren, ZZ | 1 |
| Li, J | 1 |
| Pei, L | 1 |
| Knauf, W | 2 |
| Dingeldein, G | 1 |
| Schlag, R | 8 |
| Welslau, M | 1 |
| Moehler, T | 2 |
| Terzer, T | 1 |
| Walter, S | 1 |
| Habermehl, C | 1 |
| Kunz, C | 1 |
| Raab, MS | 1 |
| Jakubowiak, A | 3 |
| Kampfenkel, T | 1 |
| Qi, M | 4 |
| Loke, C | 1 |
| Mollee, P | 1 |
| McPherson, I | 1 |
| Walpole, E | 1 |
| Yue, M | 1 |
| Mutsando, H | 1 |
| Wong, P | 1 |
| Weston, H | 1 |
| Tomlinson, R | 1 |
| Hollingworth, S | 1 |
| Bahlis, N | 3 |
| White, D | 7 |
| Cheung, M | 1 |
| Chen, C | 8 |
| Shustik, C | 6 |
| Song, K | 5 |
| Tosikyan, A | 2 |
| Dispenzieri, A | 6 |
| Anderson, K | 3 |
| Brown, D | 1 |
| Robinson, S | 2 |
| Srinivasan, S | 2 |
| Hungria, V | 2 |
| Martínez-Baños, DM | 1 |
| Garcia, A | 2 |
| Machnicki, G | 1 |
| Fernandez, M | 1 |
| Abonour, R | 2 |
| Rifkin, RM | 1 |
| Gasparetto, C | 2 |
| Toomey, K | 1 |
| Durie, BGM | 1 |
| Hardin, JW | 1 |
| Terebelo, HR | 1 |
| Jagannath, S | 4 |
| Narang, M | 1 |
| Ailawadhi, S | 2 |
| Omel, JL | 1 |
| Lee, HC | 1 |
| Kitali, A | 1 |
| Agarwal, A | 1 |
| Wagner, L | 1 |
| Shi, X | 1 |
| Wu, J | 1 |
| Jiang, Q | 1 |
| Zhang, S | 1 |
| Chen, W | 1 |
| Yu, X | 1 |
| Liu, Y | 1 |
| Chen, M | 1 |
| Peng, J | 1 |
| Li, T | 2 |
| Zhu, Y | 1 |
| Xi, X | 1 |
| Chari, A | 1 |
| McCarthy, H | 1 |
| Suzuki, K | 5 |
| Sureda Balari, A | 1 |
| Perrot, A | 1 |
| Magen, H | 1 |
| Maisnar, V | 3 |
| Karlin, L | 2 |
| Pour, L | 8 |
| Parasrampuria, DA | 1 |
| Masterson, T | 1 |
| Kosh, M | 1 |
| Yang, S | 1 |
| Delioukina, M | 1 |
| Carson, R | 2 |
| Touzeau, C | 2 |
| Holzhey, T | 1 |
| Pönisch, W | 7 |
| Wang, SY | 1 |
| Holzvogt, M | 1 |
| Holzvogt, B | 3 |
| Andrea, M | 5 |
| Zehrfeld, T | 5 |
| Hammerschmidt, D | 4 |
| Hoffmann, FA | 5 |
| Becker, C | 5 |
| Schwarzer, A | 6 |
| Schwarz, M | 4 |
| Schönfelder-Fricke, U | 1 |
| Edelmann, T | 5 |
| Braunert, L | 1 |
| Franke, GN | 2 |
| Jentzsch, M | 2 |
| Schwind, S | 2 |
| Bill, M | 1 |
| Grimm, J | 1 |
| Remane, Y | 3 |
| Platzbecker, U | 1 |
| Scholz, M | 1 |
| Zeng, X | 1 |
| Liu, Q | 1 |
| Peng, L | 1 |
| Peng, Y | 1 |
| Yi, L | 1 |
| Luo, X | 1 |
| Li, S | 2 |
| Wan, X | 1 |
| Tan, C | 1 |
| Cejalvo, MJ | 2 |
| Bustamante, G | 1 |
| González, E | 1 |
| Vázquez-Álvarez, J | 1 |
| García, R | 1 |
| Ramírez-Payer, Á | 1 |
| Abella, E | 1 |
| Garzón, S | 1 |
| Jarque, I | 1 |
| González, MS | 1 |
| Sampol, A | 1 |
| Motlló, C | 1 |
| Martí, JM | 4 |
| Alcalá, M | 1 |
| Duro, R | 1 |
| González, Y | 7 |
| Sastre, JL | 1 |
| Sarrà, J | 3 |
| Lostaunau, G | 1 |
| López, R | 1 |
| de la Rubia, J | 7 |
| Knop, S | 3 |
| Doyen, C | 9 |
| Lucio, P | 3 |
| Nagy, Z | 3 |
| Usenko, G | 1 |
| Cook, M | 2 |
| Grosicki, S | 4 |
| Crepaldi, A | 3 |
| Liberati, AM | 12 |
| Campbell, P | 4 |
| Shelekhova, T | 2 |
| Losava, G | 1 |
| Fujisaki, T | 3 |
| Garg, M | 3 |
| Wang, J | 2 |
| Wroblewski, S | 1 |
| Kudva, A | 2 |
| Gries, KS | 1 |
| Fastenau, J | 1 |
| Sandecká, V | 2 |
| Špička, I | 9 |
| Minařík, J | 2 |
| Radocha, J | 2 |
| Jelínek, T | 1 |
| Heindorfer, A | 1 |
| Pavlíček, P | 2 |
| Sýkora, M | 1 |
| Jungová, A | 1 |
| Kessler, P | 1 |
| Wróbel, M | 2 |
| Starostka, D | 2 |
| Ullrychová, J | 1 |
| Stejskal, L | 1 |
| Štork, M | 1 |
| Straub, J | 2 |
| Pika, T | 2 |
| Brožová, L | 1 |
| Ševčíková, S | 1 |
| Iosava, G | 3 |
| Bladé, J | 29 |
| Ukropec, J | 1 |
| Pei, H | 1 |
| Van Rampelbergh, R | 1 |
| Bahlis, NJ | 5 |
| Corso, A | 4 |
| Mugge, LO | 1 |
| Shen, ZX | 2 |
| Desjardins, P | 1 |
| Stoppa, AM | 2 |
| Decaux, O | 2 |
| de Revel, T | 1 |
| Granell, M | 3 |
| Marit, G | 1 |
| Nahi, H | 3 |
| Demuynck, H | 1 |
| Huang, SY | 2 |
| Basu, S | 2 |
| Guthrie, TH | 1 |
| Ervin-Haynes, A | 7 |
| Marek, J | 2 |
| Chen, G | 5 |
| Grammatico, S | 2 |
| Vozella, F | 1 |
| Siniscalchi, A | 4 |
| Kwak, JY | 2 |
| Bae, SB | 1 |
| Kim, KH | 1 |
| Nam, SH | 2 |
| Kim, HJ | 3 |
| Bae, SH | 2 |
| Lee, JH | 5 |
| Park, JS | 2 |
| Jeong, SH | 1 |
| Lee, MH | 1 |
| Kim, YS | 1 |
| Park, KW | 1 |
| Lee, WS | 1 |
| Lee, SM | 2 |
| Lee, JO | 2 |
| Hyun, MS | 1 |
| Jo, DY | 1 |
| Cho, DY | 1 |
| Do, YR | 2 |
| Kim, JA | 1 |
| Park, SK | 2 |
| Kim, H | 1 |
| Yi, HG | 1 |
| Moon, JH | 1 |
| Kim, SH | 1 |
| Joo, YD | 1 |
| Kim, HG | 1 |
| Kim, BS | 2 |
| Park, MR | 1 |
| Song, MK | 2 |
| Kim, SY | 1 |
| Lee, SE | 2 |
| Choi, K | 1 |
| Han, S | 1 |
| Lee, J | 1 |
| Hong, T | 1 |
| Park, GJ | 1 |
| Yim, DS | 1 |
| Offidani, M | 13 |
| Corvatta, L | 3 |
| Pulini, S | 3 |
| Richardson, PG | 12 |
| Holstein, SA | 2 |
| Schlossman, RL | 2 |
| Anderson, KC | 8 |
| McCarthy, PL | 3 |
| Fall, S | 1 |
| Dieng, F | 1 |
| Diouf, C | 1 |
| Djiba, B | 1 |
| Ndao, AC | 1 |
| Ndiaye, FSD | 1 |
| Zojer, N | 3 |
| Kaplan, P | 1 |
| Chiu, C | 1 |
| Crist, W | 1 |
| Nguyen, H | 1 |
| Stirrups, R | 1 |
| Ichikawa, S | 1 |
| Fukuhara, N | 1 |
| Hatta, S | 1 |
| Himuro, M | 1 |
| Nasu, K | 1 |
| Ono, K | 2 |
| Okitsu, Y | 1 |
| Onishi, Y | 1 |
| Ri, M | 1 |
| Ichinohasama, R | 1 |
| Harigae, H | 1 |
| Favier-Archinard, C | 1 |
| Leguelinel-Blache, G | 1 |
| Dubois, F | 1 |
| Le Gall, T | 1 |
| Bourquard, P | 1 |
| Passemard, N | 1 |
| Tora, S | 1 |
| Rey, A | 1 |
| Rossi, M | 1 |
| Chevallier, T | 1 |
| Cousin, C | 1 |
| Favier, M | 1 |
| Lee, SR | 1 |
| Choi, H | 1 |
| Lee, BH | 1 |
| Kang, KW | 1 |
| Yu, ES | 1 |
| Kim, DS | 1 |
| Park, Y | 1 |
| Sung, HJ | 1 |
| Yokoo, M | 1 |
| Kojima, K | 1 |
| Sano, H | 1 |
| Kai, K | 1 |
| Arakawa, F | 1 |
| Ohshima, K | 1 |
| Matsunaga, T | 1 |
| Kimura, S | 1 |
| Blommestein, HM | 1 |
| van Beurden-Tan, CHY | 1 |
| Franken, MG | 1 |
| Uyl-de Groot, CA | 2 |
| Syed, YY | 1 |
| Cho, SH | 1 |
| Jung, KS | 1 |
| Kim, Y | 1 |
| Ge, YL | 1 |
| Liu, CH | 1 |
| Zhang, Q | 1 |
| Wang, YM | 1 |
| Wang, N | 1 |
| Zhang, HF | 1 |
| Chen, QC | 1 |
| Chen, Y | 1 |
| Li, WQ | 1 |
| Zhu, XY | 1 |
| Fu, AS | 1 |
| Mina, R | 5 |
| Ledda, A | 1 |
| Patriarca, F | 10 |
| Evangelista, A | 4 |
| Benevolo, G | 13 |
| Oddolo, D | 1 |
| Innao, V | 1 |
| Cangiolosi, C | 1 |
| Bernardini, A | 1 |
| Musto, P | 19 |
| Amico, V | 1 |
| Fraticelli, V | 1 |
| Giuliani, N | 4 |
| Falcone, AP | 6 |
| Zambello, R | 4 |
| De Paoli, L | 3 |
| Romano, A | 1 |
| Montefusco, V | 7 |
| Kuroda, J | 1 |
| Fuchida, S | 1 |
| Murakami, S | 1 |
| Hatsuse, M | 1 |
| Okano, A | 1 |
| Iwai, T | 1 |
| Tsutsumi, Y | 1 |
| Kamitsuji, Y | 1 |
| Akaogi, T | 1 |
| Kawata-Iida, E | 1 |
| Shimizu, D | 1 |
| Uchiyama, H | 1 |
| Matsumoto, Y | 1 |
| Horiike, S | 1 |
| Nakao, M | 1 |
| Takahashi, R | 1 |
| Kaneko, H | 4 |
| Uoshima, N | 1 |
| Kobayashi, Y | 1 |
| Shimazaki, C | 1 |
| Taniwaki, M | 2 |
| Mangiacavalli, S | 2 |
| Pochintesta, L | 2 |
| Cocito, F | 2 |
| Pompa, A | 2 |
| Bernasconi, P | 1 |
| Cazzola, M | 1 |
| Nitschmann, S | 1 |
| Moatti, M | 1 |
| Zohar, S | 1 |
| Mary, JY | 5 |
| Chevret, S | 3 |
| Gregora, E | 1 |
| Plonkova, H | 1 |
| Jarkovsky, J | 1 |
| Walterova, L | 1 |
| Adamova, D | 1 |
| Melicharova, H | 1 |
| Gumulec, J | 1 |
| Bacovsky, J | 2 |
| Adam, Z | 2 |
| Scudla, V | 2 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 3 |
| Skoetz, N | 1 |
| Rossi, D | 8 |
| Crippa, C | 5 |
| Galli, M | 3 |
| Marcatti, M | 2 |
| La Verde, G | 5 |
| Magarotto, V | 9 |
| Guglielmelli, T | 9 |
| Omedé, P | 9 |
| Santagostino, A | 1 |
| Baldi, I | 1 |
| Carella, AM | 4 |
| Corradini, P | 6 |
| Vinogradova, IuN | 1 |
| Moll, B | 2 |
| Bourgeois, M | 3 |
| Schliwa, T | 3 |
| Heyn, S | 4 |
| Schmalfeld, M | 2 |
| Kreibich, U | 4 |
| Egert, M | 1 |
| Stiegler, R | 1 |
| Krahl, R | 3 |
| Bachmann, A | 2 |
| Lindner, T | 3 |
| Weidhase, L | 1 |
| Petros, S | 2 |
| Fricke, S | 1 |
| Vucinic, V | 3 |
| Al Ali, H | 1 |
| Niederwieser, D | 7 |
| Lamm, W | 1 |
| Drach-Schauer, B | 1 |
| Eder, S | 1 |
| Drach, J | 5 |
| Pascutto, C | 1 |
| Ferretti, VV | 1 |
| Ciampichini, R | 1 |
| Mantovani, LG | 1 |
| Lund, J | 1 |
| Uttervall, K | 1 |
| Liwing, J | 1 |
| Gahrton, G | 8 |
| Alici, E | 1 |
| Aschan, J | 1 |
| Holmberg, E | 5 |
| Lonial, S | 4 |
| Kropff, M | 11 |
| Lewis, P | 2 |
| Millar, S | 1 |
| Zhang, J | 2 |
| Mei, J | 3 |
| Delforge, M | 12 |
| Morabito, F | 9 |
| Wijermans, P | 3 |
| Victoria Mateos, M | 1 |
| Mazzone, C | 2 |
| Gottardi, D | 3 |
| José Lahuerta, J | 1 |
| Schaafsma, M | 3 |
| Oriol, A | 12 |
| Juliusson, G | 5 |
| Cerrato, C | 3 |
| Catalano, L | 4 |
| Isabel Turel, A | 1 |
| Marina Liberati, A | 1 |
| Cavalli, M | 3 |
| Passera, R | 3 |
| Rosso, S | 1 |
| Beksac, M | 5 |
| San Miguel, J | 5 |
| Di Raimondo, F | 7 |
| Levi, A | 3 |
| Vincelli, ID | 2 |
| Franceschini, L | 1 |
| Nozzoli, C | 7 |
| Gaidano, G | 4 |
| Ria, R | 7 |
| Zhou, F | 4 |
| Ling, C | 2 |
| Guo, L | 3 |
| Wei, W | 3 |
| Li, L | 3 |
| Shi, H | 5 |
| Hou, J | 4 |
| Zelis, N | 1 |
| Devos, T | 1 |
| Dierickx, D | 1 |
| Janssens, A | 1 |
| Raddoux, J | 1 |
| Verhoef, G | 1 |
| Lahuerta, JJ | 11 |
| García-Sanz, R | 11 |
| Esseltine, DL | 10 |
| van de Velde, H | 14 |
| Desai, A | 1 |
| Londhe, A | 1 |
| San Miguel, JF | 23 |
| Hansen, CT | 1 |
| Pedersen, PT | 1 |
| Nielsen, LC | 1 |
| Shpilberg, O | 8 |
| Maloisel, F | 2 |
| Polo Zarzuela, M | 1 |
| Robak, T | 2 |
| Prasad, SV | 1 |
| Tee Goh, Y | 1 |
| Laubach, J | 1 |
| Spencer, A | 2 |
| Puchalski, T | 1 |
| Reddy, M | 1 |
| Uhlar, C | 1 |
| Qin, X | 1 |
| Xie, H | 1 |
| Orlowski, RZ | 1 |
| Plötze, M | 2 |
| Gutsche, K | 2 |
| Reifenrath, K | 2 |
| Winkelmann, C | 2 |
| Hennig, E | 1 |
| Kaiser, T | 1 |
| Behre, G | 1 |
| Cheng, J | 1 |
| Talamo, G | 1 |
| Malysz, J | 1 |
| Ochmann, M | 1 |
| Lamy, T | 1 |
| Loughran, TP | 1 |
| Kim, MY | 1 |
| Sposto, R | 1 |
| Swaika, A | 1 |
| Asano, H | 1 |
| Alamgir, A | 1 |
| Chanan-Khan, A | 2 |
| Martínez-López, J | 6 |
| Teruel, AI | 5 |
| López de la Guía, A | 2 |
| López, J | 2 |
| Bengoechea, E | 4 |
| Pérez, M | 2 |
| Martínez, R | 5 |
| Palomera, L | 8 |
| de Arriba, F | 8 |
| Hernández, JM | 8 |
| Bello, JL | 3 |
| Bargay, J | 7 |
| Peñalver, FJ | 3 |
| Martín-Mateos, ML | 3 |
| Paiva, B | 5 |
| Montalbán, MA | 2 |
| San-Miguel, JF | 2 |
| Zeng, W | 1 |
| Meng, F | 1 |
| Liu, Z | 1 |
| Mao, X | 1 |
| Luo, L | 1 |
| Zheng, M | 1 |
| Qin, S | 1 |
| Liu, W | 1 |
| Zhou, J | 1 |
| Sun, H | 1 |
| Huang, L | 1 |
| Kim, M | 1 |
| Lee, SH | 1 |
| Kim, J | 1 |
| Kim, YJ | 1 |
| Reece, DE | 5 |
| Masih-Khan, E | 2 |
| Atenafu, EG | 2 |
| Jimenez-Zepeda, VH | 1 |
| Anglin, P | 1 |
| Kukreti, V | 3 |
| Mikhael, JR | 2 |
| Trudel, S | 5 |
| Cavallo, F | 8 |
| Gay, F | 12 |
| Ben Yehuda, D | 2 |
| Caravita, T | 9 |
| Ribakovsky, E | 1 |
| Genuardi, M | 5 |
| Cafro, A | 1 |
| Ciccone, G | 6 |
| Nagler, A | 2 |
| Benboubker, L | 7 |
| Catalano, J | 2 |
| Belch, AR | 4 |
| Pinto, A | 1 |
| Weisel, K | 2 |
| Banos, A | 1 |
| Tiab, M | 2 |
| Cavenagh, J | 1 |
| Geraldes, C | 1 |
| Qiu, L | 2 |
| White, DJ | 2 |
| Binder, D | 1 |
| Fermand, JP | 3 |
| Knight, R | 2 |
| Van Oostendorp, J | 1 |
| Jacques, C | 3 |
| Avet-Loiseau, H | 3 |
| Tsurumi, H | 1 |
| Kovacs, MJ | 5 |
| Davies, GA | 1 |
| Chapman, JA | 3 |
| Voralia, M | 1 |
| Roy, J | 4 |
| Kouroukis, CT | 2 |
| Reece, D | 3 |
| Zhu, L | 2 |
| Meyer, RM | 6 |
| Shepherd, L | 4 |
| Stewart, KA | 1 |
| Abenhardt, W | 1 |
| Aldaoud, A | 1 |
| Nusch, A | 1 |
| Grugel, R | 1 |
| Münz, M | 1 |
| Hartmann, H | 1 |
| Marschner, N | 1 |
| Elliott, J | 1 |
| Dow, E | 1 |
| Niculescu, L | 1 |
| Minuk, L | 1 |
| Eisenmann, JC | 1 |
| Arnulf, B | 2 |
| Canepa, L | 3 |
| Fragasso, A | 2 |
| Leyvraz, S | 1 |
| Langer, C | 2 |
| Ezaydi, Y | 1 |
| Vogl, DT | 1 |
| Giraldo-Castellano, P | 1 |
| Zarnitsky, C | 1 |
| Escoffre-Barbe, M | 1 |
| Lemieux, B | 1 |
| Monzini, MS | 1 |
| Kolb, B | 3 |
| Caillot, D | 1 |
| Roussel, M | 3 |
| Chaleteix, C | 2 |
| Planche, L | 1 |
| Chiffoleau, A | 1 |
| Fortin, J | 1 |
| Roy, V | 2 |
| Stewart, AK | 9 |
| Bergsagel, PL | 2 |
| Laumann, K | 1 |
| Allred, J | 1 |
| Lacy, MQ | 5 |
| Fonseca, R | 2 |
| Reeder, CB | 1 |
| Kumar, S | 3 |
| Rivera, CE | 1 |
| Gertz, MA | 6 |
| Buadi, FK | 2 |
| Hayman, SR | 2 |
| Rajkumar, SV | 9 |
| Kristinsson, SY | 1 |
| Sucak, GT | 1 |
| Lupparelli, G | 1 |
| Fıratlı-Tuğlular, T | 2 |
| Turesson, I | 9 |
| Ishida, T | 1 |
| Chung, JS | 1 |
| Song, IC | 1 |
| Shin, DY | 1 |
| Lee, GW | 1 |
| Lee, IS | 1 |
| Schols, SE | 1 |
| Tick, LL | 1 |
| Rosiñol, L | 5 |
| Puig, N | 4 |
| Martín, J | 3 |
| Echeveste, MA | 3 |
| Ocio, E | 1 |
| Ramírez, G | 1 |
| Payer, A | 1 |
| Iglesias, R | 1 |
| Alegre, A | 5 |
| Chinea, AI | 1 |
| McCormack, PL | 1 |
| Chen, Z | 1 |
| Wang, W | 2 |
| Rich, A | 1 |
| Tang, G | 1 |
| Hu, S | 1 |
| Poenisch, W | 1 |
| Schwarzbach, H | 1 |
| Leiblein, S | 1 |
| Lange, T | 1 |
| AlAli, HK | 1 |
| Jacobus, S | 2 |
| Weiss, M | 1 |
| Callander, NS | 1 |
| Chanan-Khan, AA | 1 |
| Andersen, MN | 1 |
| Andersen, NF | 1 |
| Rødgaard-Hansen, S | 1 |
| Hokland, M | 1 |
| Møller, HJ | 1 |
| Majithia, N | 1 |
| Vincent Rajkumar, S | 3 |
| Dingli, D | 3 |
| Kapoor, P | 2 |
| Hwa, L | 1 |
| Lust, JA | 2 |
| Russell, SJ | 1 |
| Go, RS | 1 |
| Kyle, RA | 31 |
| Kumar, SK | 1 |
| Hardan, I | 1 |
| Donato, F | 1 |
| Yu, Z | 2 |
| Boccadifuoco, L | 1 |
| Vincelli, D | 1 |
| Yang, C | 2 |
| Xiong, F | 1 |
| Dou, J | 1 |
| Xue, J | 1 |
| Zhan, X | 1 |
| Shi, F | 1 |
| Li, M | 1 |
| Wu, S | 1 |
| Luo, S | 1 |
| Zhang, T | 1 |
| Zhang, Y | 2 |
| Ming, J | 1 |
| Gu, N | 1 |
| Jagirdar, N | 1 |
| Harvey, RD | 1 |
| Nooka, A | 2 |
| Flowers, C | 1 |
| Kaufman, J | 1 |
| Lechowicz, MJ | 1 |
| Langston, A | 1 |
| Lipscomb, C | 1 |
| Gaylor, C | 1 |
| Waller, EK | 1 |
| Hernández, MT | 6 |
| Ocio, EM | 3 |
| Gutiérrez, NC | 4 |
| Martín Ramos, ML | 1 |
| Pérez de Oteyza, J | 1 |
| Gironella, M | 3 |
| Encinas, C | 2 |
| Cabrera, C | 2 |
| Cedena, MT | 2 |
| Cavenagh, JD | 1 |
| Yiu, W | 2 |
| Nagarwala, Y | 1 |
| Berger, A | 1 |
| Pelligra, CG | 1 |
| Binder, G | 1 |
| Gibson, CJ | 1 |
| Kokonozaki, M | 1 |
| Tsirakis, G | 1 |
| Devetzoglou, M | 1 |
| Kyriakaki, S | 1 |
| Antonakis, A | 1 |
| Vyzoukaki, R | 1 |
| Pappa, CA | 1 |
| Tzardi, M | 1 |
| Alexandrakis, MG | 2 |
| Oliva, S | 4 |
| Conticello, C | 2 |
| Carella, A | 1 |
| Malfitano, A | 1 |
| Petrò, D | 1 |
| Cheung, MC | 1 |
| Liu, T | 2 |
| Gamberi, B | 1 |
| Derigs, HG | 1 |
| Eom, H | 1 |
| Belhadj, K | 1 |
| Lenain, P | 2 |
| Van der Jagt, R | 1 |
| Rigaudeau, S | 1 |
| Dib, M | 3 |
| Hall, R | 1 |
| Jardel, H | 2 |
| Jaccard, A | 1 |
| Bensinger, W | 1 |
| Schots, R | 5 |
| Leupin, N | 2 |
| Kuhr, K | 1 |
| Wirth, D | 1 |
| Srivastava, K | 1 |
| Lehmacher, W | 1 |
| Hellmich, M | 1 |
| Corchete, LA | 1 |
| Vidriales, MB | 3 |
| Maiso, P | 1 |
| Rodriguez, I | 1 |
| Alignani, D | 1 |
| Burgos, L | 1 |
| Sanchez, ML | 1 |
| Barcena, P | 1 |
| Johnson, SK | 1 |
| Epstein, J | 1 |
| Barlogie, B | 16 |
| Orfao, A | 3 |
| Bos, GM | 1 |
| van der Velden, AW | 1 |
| Gruber, A | 2 |
| Coenen, JL | 1 |
| Plesner, T | 2 |
| Klein, SK | 2 |
| Tanis, BC | 1 |
| Szatkowski, DL | 1 |
| Brouwer, RE | 1 |
| Leys, MR | 1 |
| Sinnige, HA | 2 |
| van der Hem, KG | 1 |
| Durian, MF | 1 |
| Mattijssen, EV | 1 |
| van de Donk, NW | 2 |
| Stevens-Kroef, MJ | 1 |
| Lyu, WW | 1 |
| Zhao, QC | 1 |
| Song, DH | 1 |
| Zhang, JJ | 1 |
| Ding, ZX | 1 |
| Li, BY | 1 |
| Wei, CM | 1 |
| Villani, O | 1 |
| Ponticelli, E | 1 |
| Derudas, D | 2 |
| Aghemo, E | 1 |
| Musolino, C | 2 |
| Ise, M | 1 |
| Matsubayashi, K | 1 |
| Tsujimura, H | 1 |
| Kumagai, K | 1 |
| Arana, P | 1 |
| Cordon, L | 1 |
| Flores-Montero, J | 1 |
| Martín-Ramos, ML | 1 |
| Van Dongen, JJ | 1 |
| Dührsen, U | 1 |
| Lu, J | 2 |
| Rodon, P | 3 |
| Pégourié, B | 4 |
| Garderet, L | 2 |
| Hunter, H | 1 |
| Azais, I | 7 |
| Eek, R | 1 |
| Gisslinger, H | 5 |
| Dakhil, S | 1 |
| Goncalves, C | 1 |
| LeBlanc, R | 1 |
| Romeril, K | 1 |
| Royer, B | 2 |
| Offner, F | 1 |
| Han, M | 1 |
| Murugesan, A | 1 |
| Seftel, MD | 1 |
| Howsen-Jan, K | 1 |
| Stewart, K | 2 |
| Xie, Y | 1 |
| Hay, AE | 1 |
| Djurfeldt, M | 2 |
| Chen, BE | 1 |
| Reiman, T | 3 |
| Liu, HB | 1 |
| Trieu, Y | 2 |
| Prica, A | 1 |
| Tiedemann, R | 1 |
| Nijhof, IS | 1 |
| Franssen, LE | 1 |
| Bos, GMJ | 1 |
| Broijl, A | 1 |
| Koene, HR | 1 |
| Bloem, AC | 3 |
| Beeker, A | 1 |
| Faber, LM | 1 |
| van der Spek, E | 1 |
| Ypma, PF | 1 |
| Raymakers, R | 1 |
| van Spronsen, DJ | 1 |
| Westerweel, PE | 1 |
| Oostvogels, R | 1 |
| van Velzen, J | 1 |
| van Kessel, B | 1 |
| Mutis, T | 1 |
| Lokhorst, HM | 4 |
| van de Donk, NWCJ | 1 |
| Wang, X | 1 |
| He, P | 1 |
| Guo, C | 1 |
| Sun, C | 1 |
| Zhang, M | 1 |
| Teresa Petrucci, M | 1 |
| Uccello, G | 1 |
| Petrungaro, A | 1 |
| Vigna, E | 1 |
| Greco, R | 1 |
| Grazia Recchia, A | 1 |
| Tripepi, G | 1 |
| El Gamal, TA | 1 |
| El-Bakoury, A | 1 |
| Hawkins, A | 1 |
| Ed AlTayeb Mussa, M | 1 |
| Er Ahmed Sweed, T | 1 |
| Eh Samir Ansara, S | 1 |
| Masala, S | 1 |
| Anselmetti, GC | 1 |
| Marcia, S | 1 |
| Massari, F | 1 |
| Manca, A | 1 |
| Simonetti, G | 1 |
| Rodriguez, GP | 1 |
| Mikhael, J | 2 |
| Pantoja, M | 1 |
| Xu, W | 1 |
| Khuageva, NK | 6 |
| Samoilova, OS | 4 |
| Dmoszynska, A | 6 |
| Abdulkadyrov, KM | 4 |
| Jiang, B | 3 |
| Liu, K | 7 |
| Cakana, A | 9 |
| Durie, BG | 6 |
| Webb, J | 1 |
| Chary, P | 1 |
| Northrup, N | 1 |
| Almy, F | 1 |
| Khan, KA | 1 |
| Siddiqui, NS | 1 |
| Junaid, A | 1 |
| Siddiqui, S | 1 |
| Hattori, N | 1 |
| Adachi, D | 1 |
| Nakashima, H | 1 |
| Saito, B | 1 |
| Nakamaki, T | 1 |
| Tomoyasu, S | 1 |
| Islam, A | 1 |
| Ambrus, JL | 1 |
| Conti, AA | 1 |
| Dilaghi, B | 1 |
| Modesti, PA | 1 |
| Tsubokura, M | 1 |
| Kami, M | 1 |
| Komatsu, T | 1 |
| Avvisati, G | 7 |
| Rodríguez-Martín, M | 1 |
| Sáez-Rodríguez, M | 1 |
| García-Bustínduy, M | 1 |
| Martín-Herrera, A | 1 |
| Noda-Cabrera, A | 1 |
| Weisel, KC | 1 |
| Böckeler, M | 1 |
| Bianchi, L | 1 |
| Terracciano, LM | 1 |
| Mayer, F | 1 |
| Kanz, L | 1 |
| Doherty, C | 1 |
| Ulitsky, O | 1 |
| Petronic-Rosic, V | 1 |
| Friedenberg, WR | 1 |
| Slabber, CF | 1 |
| Greipp, PR | 7 |
| Fratoni, S | 1 |
| Santeusanio, G | 1 |
| Del Poeta, G | 1 |
| de Fabritiis, P | 2 |
| Talamo, GP | 1 |
| Ibrahim, S | 1 |
| Claxton, D | 1 |
| Tricot, GJ | 1 |
| Fink, LM | 1 |
| Zangari, M | 2 |
| Berenson, JR | 3 |
| Falcone, A | 3 |
| Gozzetti, A | 2 |
| Luraschi, A | 1 |
| Nozza, A | 1 |
| Knight, RD | 1 |
| Zeldis, JB | 3 |
| Guillerm, G | 3 |
| Salles, B | 1 |
| Eschard, JP | 2 |
| Casassus, P | 4 |
| Mathiot, C | 2 |
| Fontan, J | 1 |
| Lafon, I | 1 |
| Virion, JM | 1 |
| Hussein, MA | 1 |
| Bolejack, V | 1 |
| Zonder, JA | 1 |
| Jakubowiak, AJ | 1 |
| Crowley, JJ | 4 |
| Kleber, M | 2 |
| Ihorst, G | 1 |
| Deschler, B | 1 |
| Jakob, C | 1 |
| Liebisch, P | 1 |
| Koch, B | 1 |
| Sezer, O | 1 |
| Engelhardt, M | 3 |
| Gockerman, JP | 1 |
| Diehl, LF | 1 |
| de Castro, CM | 1 |
| Moore, JO | 1 |
| Long, GD | 1 |
| Horwitz, ME | 1 |
| Keogh, G | 1 |
| Chute, JP | 1 |
| Sullivan, KM | 1 |
| Neuwirth, R | 1 |
| Davis, PH | 1 |
| Sutton, LM | 1 |
| Anderson, RD | 1 |
| Chao, NJ | 1 |
| Rizzieri, D | 1 |
| Machaczka, M | 2 |
| Lerner, R | 2 |
| Klimkowska, M | 2 |
| Hägglund, H | 2 |
| Kastritis, E | 2 |
| Alexeeva, J | 1 |
| Masszi, T | 1 |
| Chiu, W | 1 |
| Pullon, H | 1 |
| Woon, ST | 1 |
| Oei, P | 1 |
| The, R | 1 |
| Ameratunga, R | 1 |
| Brault, R | 1 |
| Debiais, F | 1 |
| Frydrychowicz, A | 1 |
| Pache, G | 1 |
| Schmitt-Gräff, A | 2 |
| Wäsch, R | 1 |
| Rossini, F | 2 |
| Caltagirone, S | 1 |
| Rossi, G | 2 |
| Kotwica, K | 1 |
| Rus, C | 2 |
| Masini, L | 2 |
| Iacobelli, M | 1 |
| Mitsiades, C | 1 |
| Richardson, P | 1 |
| Krzesiński, P | 1 |
| Wierzbowski, R | 1 |
| Gielerak, G | 1 |
| Hałka, J | 1 |
| Matysiak, O | 1 |
| Smurzyński, P | 1 |
| Lin, C | 1 |
| Davies, F | 1 |
| Leal da Costa, F | 1 |
| Garcia Sanz, R | 1 |
| Schey, S | 1 |
| Morgan, G | 1 |
| Vaktnäs, J | 1 |
| Sanpaolo, G | 1 |
| Federico, V | 1 |
| Crugnola, M | 1 |
| Bagratuni, T | 1 |
| Wu, P | 1 |
| Gonzalez de Castro, D | 1 |
| Davenport, EL | 1 |
| Dickens, NJ | 1 |
| Walker, BA | 1 |
| Boyd, K | 1 |
| Johnson, DC | 1 |
| Gregory, W | 1 |
| Morgan, GJ | 1 |
| Davies, FE | 1 |
| Fayers, P | 1 |
| Ahlberg, L | 1 |
| Björkstrand, B | 1 |
| Carlson, K | 4 |
| Dahl, IM | 3 |
| Forsberg, K | 1 |
| Gulbrandsen, N | 4 |
| Hjertner, O | 1 |
| Hjorth, M | 13 |
| Karlsson, T | 1 |
| Knudsen, LM | 2 |
| Nielsen, JL | 2 |
| Linder, O | 1 |
| Nesthus, I | 2 |
| Rolke, J | 1 |
| Strandberg, M | 1 |
| Sørbø, JH | 1 |
| Wisløff, F | 10 |
| Keith Stewart, A | 1 |
| Leoni, P | 3 |
| Gentili, S | 3 |
| Polloni, C | 2 |
| Galieni, P | 2 |
| Catarini, M | 2 |
| Alesiani, F | 2 |
| Mele, A | 1 |
| Brunori, M | 1 |
| Blasi, N | 1 |
| Ferranti, M | 1 |
| Visani, G | 1 |
| Termorshuizen, F | 3 |
| Ammerlaan, R | 1 |
| Wittebol, S | 2 |
| van Marwijk Kooy, M | 2 |
| van der Griend, R | 2 |
| Lokhorst, H | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Harousseau, JL | 10 |
| Kentos, A | 1 |
| Golenkov, A | 1 |
| Komarnicki, M | 1 |
| Jamshed, S | 1 |
| Fowler, DH | 1 |
| Neelapu, SS | 1 |
| Dean, RM | 1 |
| Steinberg, SM | 1 |
| Odom, J | 1 |
| Bryant, K | 1 |
| Hakim, F | 1 |
| Bishop, MR | 1 |
| Johnsen, HE | 2 |
| Klausen, TW | 1 |
| Boegsted, M | 1 |
| Lenhoff, S | 2 |
| Christiansen, I | 1 |
| Gedde-Dahl, T | 1 |
| Lindås, R | 1 |
| Teng, HW | 1 |
| Teng, CJ | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Chiou, TJ | 1 |
| Hsu, HC | 1 |
| Liu, JH | 1 |
| Yen, CC | 1 |
| Hsiao, LT | 1 |
| Yang, MH | 1 |
| Chao, TC | 1 |
| Yang, YH | 1 |
| Gau, JP | 1 |
| Gutiérrez, N | 2 |
| de Paz, R | 1 |
| García-Laraña, J | 6 |
| Martín, A | 1 |
| Mediavilla, JD | 1 |
| Sureda, A | 7 |
| Ribera, JM | 5 |
| Cibeira, MT | 1 |
| Ramos, ML | 1 |
| Miguel, JF | 3 |
| Callea, V | 6 |
| Rizzo, V | 1 |
| Cangialosi, C | 4 |
| Wu, KL | 2 |
| Leonardi, G | 1 |
| Rizzo, M | 1 |
| Haznedar, R | 2 |
| Ozdogu, H | 1 |
| Aydogdu, I | 1 |
| Konuk, N | 1 |
| Sucak, G | 1 |
| Kaygusuz, I | 1 |
| Karakus, S | 1 |
| Kaya, E | 1 |
| Ali, R | 1 |
| Gulbas, Z | 1 |
| Ozet, G | 1 |
| Goker, H | 1 |
| Undar, L | 1 |
| Kumar, A | 1 |
| Hozo, I | 1 |
| Wheatley, K | 1 |
| Djulbegovic, B | 2 |
| Mandrekar, SJ | 1 |
| Mutlu, P | 3 |
| Baran, Y | 1 |
| Ural, AU | 3 |
| Avcu, F | 1 |
| Dirican, B | 1 |
| Beyzadeoglu, M | 1 |
| Gündüz, U | 3 |
| Chou, T | 2 |
| Tobinai, K | 2 |
| Uike, N | 1 |
| Asakawa, T | 1 |
| Saito, I | 1 |
| Fukuda, H | 2 |
| Mizoroki, F | 1 |
| Ando, K | 1 |
| Ueda, R | 1 |
| Tsukasaki, K | 2 |
| Hotta, T | 4 |
| Terpos, E | 2 |
| Magen-Nativ, H | 1 |
| Ricci, DS | 1 |
| Verelst, SG | 1 |
| Schaafsma, MR | 1 |
| Ammerlaan, AH | 1 |
| Wijermans, PW | 2 |
| Steensma, DP | 1 |
| Sacchi, S | 1 |
| Marcheselli, R | 1 |
| Lazzaro, A | 1 |
| Di Renzo, N | 1 |
| Balleari, E | 1 |
| Neri, S | 1 |
| Quarta, G | 1 |
| Ferrara, R | 1 |
| Vigliotti, ML | 1 |
| Polimeno, G | 1 |
| Consoli, U | 1 |
| Zoboli, A | 1 |
| Buda, G | 1 |
| Pastorini, A | 1 |
| Fayers, PM | 2 |
| Riley, JM | 1 |
| Russo, JK | 1 |
| Shipp, A | 1 |
| Alsharif, M | 1 |
| Jenrette, JM | 1 |
| Vincelli, I | 1 |
| Cascavilla, N | 2 |
| Majolino, I | 1 |
| Leger, M | 1 |
| Newlove, T | 1 |
| Chu, J | 1 |
| Meehan, S | 1 |
| Stein, J | 1 |
| Shimoyama, M | 3 |
| Chang, HJ | 1 |
| Lee, JL | 1 |
| Bang, SM | 1 |
| Takahashi, N | 1 |
| Miura, M | 1 |
| Abumiya, M | 1 |
| Sawada, K | 1 |
| Gaballa, MR | 1 |
| Laubach, JP | 1 |
| Redman, K | 1 |
| Noonan, K | 1 |
| Mitsiades, CS | 1 |
| Ghobrial, IM | 1 |
| Munshi, N | 1 |
| Kabir, AL | 1 |
| Rahman, MJ | 1 |
| Begum, M | 1 |
| Dipta, TF | 1 |
| Baqui, MN | 1 |
| Aziz, A | 1 |
| Rahman, F | 1 |
| Debnath, RC | 1 |
| Habib, MA | 1 |
| Caraffa, P | 1 |
| Bila, J | 1 |
| Gotić, M | 1 |
| Mihaljević, B | 1 |
| Dhawan, R | 2 |
| Robinson, D | 1 |
| Meunier, J | 1 |
| Regnault, A | 1 |
| Wagner, I | 2 |
| Wiktor-Jędrzejczak, W | 1 |
| Zodelava, M | 1 |
| Kloczko, J | 1 |
| Radke, J | 1 |
| Herbein, L | 1 |
| Badros, AZ | 1 |
| Grzasko, N | 1 |
| Hus, M | 1 |
| Pluta, A | 1 |
| Jurczyszyn, A | 1 |
| Walter-Croneck, A | 2 |
| Morawska, M | 1 |
| Chocholska, S | 1 |
| Roussou, M | 1 |
| Gkotzamanidou, M | 1 |
| Nikitas, N | 1 |
| Psimenou, E | 1 |
| Mparmparoussi, D | 1 |
| Matsouka, C | 1 |
| Spyropoulou-Vlachou, M | 1 |
| Bertolini, F | 1 |
| Cherry, BM | 1 |
| Korde, N | 1 |
| Kwok, M | 1 |
| Roschewski, M | 1 |
| Landgren, O | 2 |
| Polo, M | 1 |
| Guo, LP | 1 |
| Zhang, YZ | 1 |
| Shi, HT | 1 |
| Lin, CH | 1 |
| Rocci, A | 1 |
| Siez, ML | 1 |
| Molica, S | 1 |
| Freilone, R | 1 |
| Scotti, S | 1 |
| Gentilini, F | 1 |
| Russo, S | 1 |
| Foà, R | 2 |
| Marcellus, DC | 2 |
| Macdonald, DA | 1 |
| Harnett, E | 1 |
| Couban, S | 1 |
| Jäkel, N | 1 |
| Rohrberg, R | 1 |
| Hurtz, HJ | 1 |
| Aßmann, M | 1 |
| Mohren, M | 1 |
| Schönfelder, U | 1 |
| Hensel, G | 1 |
| Löschcke, K | 1 |
| Ali, HA | 1 |
| Nixon, A | 1 |
| Sabry, W | 1 |
| Rubinger, M | 1 |
| Cantin, G | 1 |
| Tompkins, KA | 1 |
| Sussman, J | 1 |
| Brundage, M | 1 |
| Harnett, EL | 1 |
| Garrison, LP | 1 |
| Wang, ST | 1 |
| Huang, H | 1 |
| Ba-Mancini, A | 1 |
| Chen, K | 1 |
| Korves, C | 1 |
| Corzo, D | 1 |
| Duh, MS | 1 |
| Nizeica, V | 1 |
| Collet, P | 2 |
| Marotte, H | 1 |
| Misbahi, R | 1 |
| Milpied, N | 1 |
| Morineau, N | 1 |
| Mahé, B | 1 |
| Vigier, M | 1 |
| Rapp, MJ | 1 |
| Bataille, R | 4 |
| Benni, M | 1 |
| Ronconi, S | 1 |
| Fiacchini, M | 1 |
| Baccarani, M | 3 |
| Tura, S | 5 |
| Pulsoni, A | 3 |
| Villivà, N | 1 |
| Cavalieri, E | 1 |
| Falcucci, P | 1 |
| Matera, R | 1 |
| Tosti, ME | 1 |
| Mandelli, F | 3 |
| Riccardi, A | 9 |
| Mora, O | 3 |
| Tinelli, C | 2 |
| Porta, C | 1 |
| Danova, M | 4 |
| Brugnatelli, S | 5 |
| Grasso, D | 1 |
| Tolcà, B | 1 |
| Spanedda, R | 2 |
| De Paoli, A | 4 |
| Barbarano, L | 4 |
| Cavanna, L | 2 |
| Giordano, M | 4 |
| Delfini, C | 2 |
| Nicoletti, G | 2 |
| Bergonzi, C | 4 |
| Rinaldi, E | 3 |
| Piccinini, L | 4 |
| Ascari, E | 8 |
| Shimokawa, T | 1 |
| Kajiguchi, T | 1 |
| Saito, M | 1 |
| Kojima, Y | 1 |
| Takeyama, H | 4 |
| Boye, J | 1 |
| Elter, T | 1 |
| Messori, A | 1 |
| Trippoli, S | 1 |
| Santarlasci, B | 1 |
| Vaiopoulos, G | 1 |
| Konstantopoulos, K | 1 |
| Mantzourani, M | 1 |
| Kaklamanis, P | 1 |
| O'Brien, BJ | 1 |
| Benger, A | 1 |
| Marcellus, D | 1 |
| Foley, R | 1 |
| Garner, J | 1 |
| Ingram, C | 1 |
| Haines, P | 1 |
| Henderson-O'Connor, N | 1 |
| Meyer, R | 1 |
| Seoane Urgorri, A | 1 |
| Galeras Sadurni, JA | 1 |
| Coll Estrada, S | 1 |
| Solà Lamoglia, R | 1 |
| Bory Ros, F | 1 |
| Maachi, M | 1 |
| Fellahi, S | 1 |
| Diop, ME | 1 |
| Francois, T | 1 |
| Capeau, J | 1 |
| Bastard, JP | 1 |
| Ribersani, M | 1 |
| Palumbo, G | 1 |
| De Felice, L | 1 |
| Rusignuolo, A | 1 |
| Simone, F | 1 |
| Meloni, G | 1 |
| Lautzenhiser, SJ | 1 |
| Walker, MC | 1 |
| Goring, RL | 1 |
| KELLOCK, IA | 1 |
| SCLARE, G | 1 |
| SCAFI, M | 1 |
| BALDASSARRI, R | 1 |
| DI GUGLIELMO, R | 1 |
| WITTEKIND, D | 1 |
| SESSNER, HH | 1 |
| CATTANEO, I | 1 |
| ESPOSITO, S | 1 |
| BAGUENA CANDELA, R | 1 |
| FORTEZA BOVER, G | 1 |
| SKOOG, WA | 2 |
| ADAMS, WS | 2 |
| MACDONALD, NS | 1 |
| PATEL, KM | 1 |
| SINGH, JS | 1 |
| LAZOR, MZ | 1 |
| ROSENBERG, LE | 1 |
| HAUT, A | 8 |
| DENNY, WF | 1 |
| ESPARZA, A | 1 |
| PLATTHY, A | 1 |
| MEISSNER, GF | 1 |
| SCHEERER, PP | 1 |
| SCHWARTZ, DL | 1 |
| PIERRE, RV | 2 |
| BOOTSMA, BK | 1 |
| VERHAEGHE, A | 1 |
| ROBERTD ESHOUGUES, J | 1 |
| LEBEURRE, R | 1 |
| LESAGE, R | 1 |
| BISERTE, G | 1 |
| HAVEZ, R | 1 |
| CARIDROIT, M | 1 |
| FROMMEYER, WB | 1 |
| HAMMACK, WJ | 1 |
| WATKIN, DM | 1 |
| STEINFELD, JL | 1 |
| DRIVSHOLM, A | 4 |
| BENTZEL, CJ | 1 |
| CARBONE, PP | 1 |
| ROSENBERG, L | 1 |
| EVANS, FJ | 1 |
| HILTON, JH | 1 |
| DUMA, RJ | 1 |
| BOYETT, JD | 1 |
| BEETHAM, WP | 1 |
| GALTON, DA | 1 |
| LICHTWITZ, A | 1 |
| HIOCO, D | 1 |
| BORDIER, P | 1 |
| MAZABRAUD, A | 1 |
| MASS, RE | 1 |
| Witzens, M | 1 |
| Neben, K | 1 |
| Fruehauf, S | 1 |
| Hartschuh, W | 1 |
| Ho, AD | 3 |
| Passam, FH | 1 |
| Sfiridaki, K | 1 |
| Moschandrea, J | 1 |
| Pappa, C | 1 |
| Liapi, D | 1 |
| Petreli, E | 1 |
| Roussou, P | 1 |
| Kyriakou, DS | 1 |
| Genty, V | 2 |
| Dine, G | 2 |
| Dufer, J | 2 |
| Kees, M | 1 |
| Dimou, G | 1 |
| Sillaber, C | 1 |
| Ackermann, J | 2 |
| Lechner, K | 2 |
| Nakanishi, H | 1 |
| Chuganji, Y | 1 |
| Uraushihara, K | 1 |
| Yamamoto, T | 1 |
| Araki, A | 1 |
| Sazaki, N | 1 |
| Momoi, M | 1 |
| Kawahara, Y | 1 |
| Mulleman, D | 1 |
| Gaxatte, C | 1 |
| Leroy, X | 1 |
| Cotten, A | 1 |
| Duquesnoy, B | 1 |
| Flipo, RM | 1 |
| Hjermstad, MJ | 1 |
| Takenaka, T | 2 |
| Itoh, K | 2 |
| Utsunomiya, A | 1 |
| Matsuda, S | 1 |
| Sai, T | 2 |
| Sano, M | 2 |
| Konda, S | 1 |
| Ohno, T | 2 |
| Mikuni, C | 2 |
| Deura, K | 1 |
| Yamada, T | 1 |
| Mizorogi, F | 1 |
| Nagoshi, H | 1 |
| Tomonaga, M | 1 |
| Kawano, K | 1 |
| Tsushita, K | 1 |
| Hirano, M | 3 |
| Elhajj, I | 1 |
| Chehal, A | 1 |
| Shamseddine, A | 1 |
| Mourad, YA | 1 |
| Taher, A | 1 |
| Greco, C | 1 |
| Alvino, S | 1 |
| Del Monte, G | 1 |
| Venturo, I | 1 |
| Lopez, M | 1 |
| Schaar, CG | 2 |
| Kluin-Nelemans, JC | 1 |
| le Cessie, S | 1 |
| Franck, PF | 1 |
| te Marvelde, MC | 1 |
| Kyrtsonis, MC | 1 |
| Vassilakopoulos, TP | 1 |
| Siakantaris, MP | 1 |
| Kokoris, SI | 1 |
| Gribabis, DA | 1 |
| Dimopoulou, MN | 1 |
| Angelopoulou, MK | 1 |
| Pangalis, GA | 1 |
| Elira Dokekias, A | 1 |
| Moutschen, M | 1 |
| Purhuence, MF | 1 |
| Malanda, F | 1 |
| Moyikoua, A | 1 |
| Bertola, A | 2 |
| Haran, MZ | 1 |
| Basous, L | 1 |
| Berrebi, A | 1 |
| Golvano, E | 1 |
| Fernandez-Calvo, J | 4 |
| Trujillo, J | 4 |
| Soler, JA | 1 |
| Gardella, S | 4 |
| Carbonell, F | 3 |
| Mateo, G | 3 |
| Chen, CI | 3 |
| Howson-Jan, K | 1 |
| Sadura, A | 1 |
| Ding, K | 2 |
| Umeda, M | 5 |
| Basi, S | 1 |
| Schulman, G | 1 |
| Fogo, AB | 1 |
| Rao, PS | 1 |
| Kuroda, Y | 1 |
| Sakai, A | 1 |
| Okikawa, Y | 1 |
| Munemasa, S | 1 |
| Katayama, Y | 1 |
| Hyodo, H | 1 |
| Imagawa, J | 1 |
| Takimoto, Y | 1 |
| Okita, H | 1 |
| Ohtaki, M | 1 |
| Kimura, A | 1 |
| Díaz-Mediavilla, J | 2 |
| Giraldo, P | 1 |
| Callís, M | 1 |
| Moro, MJ | 8 |
| Barez, A | 2 |
| Soler, A | 2 |
| Font, L | 2 |
| Fontanillas, M | 5 |
| Larson, DR | 1 |
| Plevak, MF | 1 |
| Grande, JP | 1 |
| Nunzi, M | 1 |
| Strobel, ES | 1 |
| Bauchmüller, K | 1 |
| Renaud, M | 2 |
| Sadoun, A | 1 |
| Voillat, L | 2 |
| Dorvaux, V | 2 |
| Lepeu, G | 1 |
| Ferrant, A | 1 |
| Blanc, M | 1 |
| Orfeuvre, H | 1 |
| Rossi, JF | 2 |
| Monconduit, M | 5 |
| Anglaret, B | 2 |
| Yakoub-Agha, I | 2 |
| Wetterwald, M | 2 |
| Eghbali, H | 1 |
| Vekemans, MC | 1 |
| Maisonneuve, H | 3 |
| Troncy, J | 2 |
| Grosbois, B | 5 |
| Thyss, A | 1 |
| Jaubert, J | 2 |
| Thielemans, B | 1 |
| El-Khoury, V | 1 |
| Liautaud-Roger, F | 1 |
| Klener, P | 1 |
| Greil, R | 1 |
| Tarkovács, G | 1 |
| Linkesch, W | 1 |
| Maniatis, A | 3 |
| Morant, R | 2 |
| Kuhn, I | 1 |
| Schuster, J | 2 |
| Hinke, A | 1 |
| Burnside, NJ | 1 |
| Alberta, L | 1 |
| Robinson-Bostom, L | 1 |
| Bostom, A | 1 |
| Nanji, S | 1 |
| Prabhu, A | 1 |
| Beheshti, R | 1 |
| Yi, QL | 1 |
| Sutton, D | 1 |
| Katsahian, S | 1 |
| Divine, M | 2 |
| Leblond, V | 2 |
| Dreyfus, F | 2 |
| Mariette, X | 2 |
| Pertuiset, E | 2 |
| Belanger, C | 2 |
| Janvier, M | 1 |
| Brouet, JC | 2 |
| Ravaud, P | 2 |
| Loos, U | 2 |
| Musch, E | 2 |
| Schulte-Vennburg, M | 1 |
| Ferber, J | 1 |
| Hrycek, A | 1 |
| Gruszka, A | 1 |
| Nicolucci, A | 1 |
| Valentini, M | 1 |
| Belfiglio, M | 1 |
| Delaini, F | 1 |
| Barbui, AM | 1 |
| Giussani, U | 1 |
| Rambaldi, A | 1 |
| Barbui, T | 3 |
| Pond, GR | 1 |
| Jaksic, W | 1 |
| Mitrou, PS | 1 |
| Merkle, K | 1 |
| Herold, M | 1 |
| Assmann, M | 1 |
| Wilhelm, G | 1 |
| Dachselt, K | 1 |
| Richter, P | 1 |
| Schirmer, V | 1 |
| Schulze, A | 1 |
| Subert, R | 1 |
| Harksel, B | 1 |
| Grobe, N | 1 |
| Stelzer, E | 1 |
| Schulze, M | 1 |
| Bittrich, A | 1 |
| Freund, M | 1 |
| Pasold, R | 1 |
| Friedrich, T | 1 |
| Helbig, W | 1 |
| Lazarus, HM | 2 |
| Hurd, DD | 1 |
| McCoy, J | 1 |
| Moore, DF | 1 |
| Dakhil, SR | 1 |
| Lanier, KS | 1 |
| Chapman, RA | 1 |
| Cromer, JN | 1 |
| Salmon, SE | 17 |
| Durie, B | 1 |
| Crowley, JC | 1 |
| Zdenek, A | 1 |
| Krejci, M | 1 |
| Krivanova, A | 1 |
| Vorlicek, J | 1 |
| Bemelmans, RH | 1 |
| van Toorn, DW | 1 |
| van Leeuwen, L | 1 |
| Yutaka, H | 1 |
| Mariko, Y | 1 |
| Shinichiro, O | 1 |
| Kunihiko, M | 1 |
| Yusuke, T | 1 |
| Yasuo, I | 1 |
| Merla, E | 1 |
| Capparella, V | 1 |
| De Stefano, V | 1 |
| Ceccarelli, M | 1 |
| Ambrosini, MT | 3 |
| Avonto, I | 2 |
| Leong, T | 3 |
| Oken, MM | 7 |
| Kay, NE | 4 |
| Van Ness, B | 3 |
| Burton, A | 1 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Fernández, P | 2 |
| Carrera, D | 3 |
| Besalduch, J | 4 |
| García Boyero, R | 1 |
| Palomera Bernal, L | 1 |
| García, PR | 1 |
| Pérez-Calvo, J | 1 |
| Alcalá, A | 6 |
| Casado, LF | 1 |
| Knobel, D | 1 |
| Zouhair, A | 1 |
| Tsang, RW | 1 |
| Poortmans, P | 1 |
| Belkacémi, Y | 1 |
| Bolla, M | 1 |
| Oner, FD | 1 |
| Landmann, C | 1 |
| Castelain, B | 1 |
| Ozsahin, M | 1 |
| Fuertes, M | 2 |
| Terol, MJ | 2 |
| Ribas, P | 2 |
| Prósper, F | 3 |
| Handa, H | 1 |
| Irisawa, H | 1 |
| Komatsumoto, S | 1 |
| Matsushima, T | 1 |
| Tsukamoto, N | 1 |
| Nojima, Y | 1 |
| Murakami, H | 1 |
| Rodeghiero, F | 1 |
| Heule, F | 1 |
| Lam, K | 1 |
| Stading, JA | 1 |
| Chock, A | 1 |
| Faulkner, MA | 1 |
| Skrabal, MZ | 1 |
| Zahm, SH | 1 |
| Inskip, P | 1 |
| Zheng, T | 1 |
| Baris, D | 1 |
| Pregno, P | 1 |
| Schelle, M | 1 |
| Schreiber, C | 1 |
| Knolle, J | 1 |
| Florschütz, A | 1 |
| Kachel, R | 1 |
| Schreiber, J | 1 |
| Dürk, HA | 1 |
| Natori, K | 1 |
| Izumi, H | 1 |
| Kaneko, K | 1 |
| Ishihara, S | 1 |
| Nagase, D | 1 |
| Fujimoto, Y | 1 |
| Kato, M | 4 |
| Kuraishi, Y | 1 |
| Suvannasankha, A | 1 |
| Fausel, C | 1 |
| Juliar, BE | 1 |
| Yiannoutsos, CT | 1 |
| Fisher, WB | 1 |
| Ansari, RH | 1 |
| Wood, LL | 1 |
| Smith, GG | 1 |
| Cripe, LD | 1 |
| Rubin, SH | 1 |
| Dolan, SP | 1 |
| Grewal, KS | 1 |
| Walde, D | 1 |
| Barr, R | 2 |
| Wilson, J | 1 |
| Gill, K | 1 |
| Vickars, L | 1 |
| Rudinskas, L | 1 |
| Sicheri, DA | 1 |
| Wilson, K | 3 |
| Shepherd, LE | 1 |
| Usui, N | 1 |
| Gokden, N | 1 |
| Elici, F | 1 |
| Kumar, J | 1 |
| Ishizawa, K | 1 |
| Strasser-Weippl, K | 1 |
| Schreder, M | 1 |
| Yang, X | 1 |
| Shao, K | 1 |
| Ye, X | 1 |
| Meng, H | 1 |
| Zhou, Y | 1 |
| Qian, W | 1 |
| Fassas, AB | 2 |
| Tricot, G | 3 |
| Martin, C | 1 |
| Peest, D | 8 |
| Ganser, A | 1 |
| Faiman, B | 1 |
| Baz, R | 1 |
| Fanning, S | 1 |
| Kunkel, L | 1 |
| Gaballa, S | 1 |
| Karam, MA | 1 |
| Reed, J | 1 |
| Kelly, M | 1 |
| Hussein, M | 1 |
| Darre, S | 1 |
| Menon, SP | 1 |
| Lacy, M | 1 |
| King, MT | 1 |
| Garcia-Sanchez, P | 1 |
| Montanaro, M | 1 |
| Capaldi, A | 1 |
| Dore, F | 1 |
| Caggiano, V | 1 |
| Cuttner, J | 4 |
| Solomon, A | 4 |
| Shadduck, RK | 1 |
| Schilling, A | 3 |
| Brandes, LJ | 3 |
| Israels, LG | 3 |
| Bonnet, JD | 4 |
| Alexanian, R | 26 |
| Dixon, DO | 3 |
| Gomez, GA | 2 |
| Han, T | 2 |
| Ozer, H | 3 |
| Henderson, ES | 5 |
| Freireich, EJ | 1 |
| Keating, M | 1 |
| Cabanillas, F | 3 |
| Hassner, A | 1 |
| Saxon, A | 1 |
| Brun, B | 1 |
| Kuentz, M | 1 |
| Man, NG | 1 |
| Feuilhade, F | 1 |
| Bierling, P | 1 |
| Vernant, JP | 1 |
| Farcet, JP | 1 |
| Cordonnier, C | 1 |
| Reyes, F | 1 |
| Dreyfus, B | 1 |
| Rochant, H | 1 |
| Kelly, JJ | 1 |
| Miles, JM | 1 |
| Dyck, PJ | 1 |
| Donofrio, PD | 1 |
| Albers, JW | 1 |
| Greenberg, HS | 1 |
| Mitchell, BS | 1 |
| Ahre, A | 4 |
| Björkholm, M | 8 |
| Mellstedt, H | 6 |
| Holm, G | 2 |
| Brenning, G | 7 |
| Engstedt, L | 2 |
| Hällen, J | 1 |
| Johansson, B | 5 |
| Johansson, SG | 1 |
| Karnström, L | 1 |
| Killander, A | 1 |
| Lockner, D | 1 |
| Lönnqvist, B | 1 |
| Simonsson, B | 2 |
| Stalfelt, AM | 1 |
| Ternstedt, B | 1 |
| Wadman, B | 1 |
| Dreicer, R | 1 |
| Pacilli, L | 2 |
| Ferraro, P | 1 |
| Cochi, S | 1 |
| De Laurenzi, A | 2 |
| Louria, DB | 1 |
| Peter, HH | 1 |
| Dziuba-Traber, H | 1 |
| Boerner, D | 1 |
| Pavlovsky, S | 5 |
| Saslavsky, J | 2 |
| Tezanos Pinto, M | 1 |
| Palmer, L | 1 |
| Curuchet, M | 1 |
| Lein, JM | 3 |
| Garay, G | 1 |
| Dragosky, M | 1 |
| Quiroga-Micheo, E | 1 |
| Huberman, AB | 1 |
| Abbrederis, K | 1 |
| Gattringer, C | 1 |
| König, P | 1 |
| Gastl, G | 1 |
| Gyllenhammar, H | 6 |
| Järnmark, M | 2 |
| Morstyn, G | 1 |
| Schechter, GP | 1 |
| Ihde, DC | 1 |
| Carney, DN | 1 |
| Eddy, JL | 1 |
| Cohen, MH | 1 |
| Minna, JD | 1 |
| Bunn, PA | 1 |
| Adelstein, DJ | 1 |
| Herzig, RH | 1 |
| Smith, MC | 1 |
| Emmerich, B | 1 |
| Assaf, ME | 1 |
| Pizzolato, MA | 1 |
| De María, HE | 1 |
| Gasparini, S | 1 |
| Burucua, JE | 1 |
| Cohen, HJ | 7 |
| Silberman, HR | 4 |
| Tornyos, K | 2 |
| Bartolucci, AA | 4 |
| Campbell, KL | 1 |
| Latimer, KS | 1 |
| Venturino, M | 1 |
| Geniram, A | 1 |
| Guarino, P | 1 |
| Scio, P | 1 |
| Marini, U | 1 |
| Estape, J | 6 |
| Antón, I | 1 |
| Daniels, M | 1 |
| Domingo, A | 1 |
| Rubio, D | 1 |
| Voltarelli, JC | 1 |
| Falcão, RP | 1 |
| Bottura, C | 1 |
| Smith, L | 1 |
| Steinke, B | 2 |
| Busch, FW | 2 |
| Stapelfeld, S | 1 |
| Ostendorf, P | 2 |
| Waller, HD | 2 |
| Gössinger, H | 1 |
| Bettelheim, P | 1 |
| Neumann, E | 1 |
| Hinterberger, W | 1 |
| Korninger, K | 1 |
| Niessner, H | 1 |
| Pabinger-Fasching, I | 1 |
| Bauer, K | 1 |
| Iwata, Y | 1 |
| Karitani, Y | 1 |
| Tanaka, I | 1 |
| Kageyama, S | 1 |
| Katayama, N | 1 |
| Kataoka, Y | 1 |
| Kamio, N | 1 |
| Ohota, C | 1 |
| Montalbán, C | 3 |
| Zapatero, A | 3 |
| Blanco, L | 3 |
| Sevilla, F | 3 |
| García Laraña, J | 1 |
| Odriozola, J | 2 |
| Harris, DC | 1 |
| Ibels, LS | 2 |
| Ravich, RB | 2 |
| Isbister, JP | 1 |
| Wells, JV | 1 |
| Krykowski, E | 1 |
| Płuzańska, A | 1 |
| Olszańska-Skorek, T | 1 |
| Urbańska-Ryś, H | 1 |
| Polkowska-Kulesza, E | 1 |
| Błasińska-Morawiec, M | 1 |
| Mazurowa, A | 1 |
| Norberg, B | 1 |
| Holm, J | 2 |
| Winqvist, E | 1 |
| Wahlin, A | 2 |
| Bergsagel, D | 4 |
| Gobbi, M | 4 |
| Lipizer, A | 1 |
| van Dobbenburgh, OA | 3 |
| Houwen, B | 4 |
| Halie, MR | 3 |
| Marrink, J | 4 |
| Ockhuizen, T | 3 |
| Nieweg, HO | 4 |
| Schieppati, G | 1 |
| Franchi, F | 1 |
| Valagussa, P | 1 |
| Monfardini, S | 1 |
| Paccagnella, A | 3 |
| Cartei, G | 1 |
| Fosser, V | 1 |
| Salvagno, L | 3 |
| Bolzonella, S | 2 |
| Chiarion Sileni, V | 2 |
| Fiorentino, MV | 2 |
| Wutke, K | 1 |
| Anger, G | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 2 |
| Piersma, H | 1 |
| Le Loët, X | 3 |
| Menard, JF | 4 |
| Deshayes, P | 1 |
| Grobois, B | 1 |
| Tanguy, A | 1 |
| Prevost, E | 1 |
| Piguet, H | 1 |
| Savelli, G | 1 |
| Krebs, A | 1 |
| Müller, A | 1 |
| Sala, P | 1 |
| Tonutti, E | 1 |
| Ruscio, M | 1 |
| Colle, R | 1 |
| Antonutto, G | 1 |
| Falconieri, G | 1 |
| Sølling, K | 1 |
| Sølling, J | 1 |
| Ellegaard, J | 3 |
| Ganeval, D | 1 |
| Cathomen, M | 1 |
| Noël, LH | 1 |
| Grünfeld, JP | 1 |
| Monti, G | 1 |
| Cereda, UG | 1 |
| Pessina, E | 1 |
| De Micheli, N | 1 |
| Grisetti, GC | 1 |
| Invernizzi, F | 1 |
| Jurjens, H | 1 |
| Scolozzi, R | 1 |
| Boccafogli, A | 1 |
| Feliú, E | 2 |
| Rozman, C | 7 |
| Millá, A | 1 |
| Montserrat, E | 7 |
| Yap, BS | 1 |
| Bodey, GP | 2 |
| Tirelli, U | 1 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Veronesi, A | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Recht, LD | 1 |
| Davies, SF | 1 |
| Eckman, MR | 1 |
| Sarosi, GA | 1 |
| Chikkappa, G | 1 |
| Chanana, AD | 1 |
| Chandra, P | 1 |
| Cronkite, EP | 1 |
| Thompson, KH | 1 |
| Van Acker, A | 1 |
| Carmagnola, A | 1 |
| Conte, F | 1 |
| Pileri, A | 9 |
| Case, DC | 7 |
| Cavagnaro, F | 2 |
| Becherini, JO | 1 |
| Pileggi, JE | 1 |
| Micheo, EQ | 1 |
| Jait, C | 1 |
| Musso, A | 1 |
| Suárez, A | 1 |
| Pizzolato, M | 2 |
| Beacham, BE | 1 |
| Greer, KE | 1 |
| Andrews, BS | 1 |
| Cooper, PH | 1 |
| Snigurowicz, J | 2 |
| Kraj, M | 4 |
| Rostkowska, J | 4 |
| Maj, S | 3 |
| Mariańska, B | 2 |
| Mendek, E | 1 |
| Roszkowski, S | 1 |
| Kilian, Z | 1 |
| Kołakowski, L | 1 |
| Tribalto, M | 6 |
| Arcese, W | 1 |
| Colombo, R | 1 |
| Pastore, S | 1 |
| Franchii, A | 1 |
| Broun, GO | 1 |
| Petruska, PJ | 1 |
| Hiramoto, RN | 2 |
| Abramson, N | 2 |
| Lurie, P | 1 |
| Mietlowski, WL | 1 |
| Bennett, JM | 1 |
| Horton, J | 1 |
| Bonnet, J | 4 |
| Salmon, S | 2 |
| Bottomley, R | 1 |
| Amare, M | 1 |
| Dixon, D | 3 |
| Pajak, TF | 7 |
| Nawabi, IU | 1 |
| Brunner, K | 3 |
| Henry, PH | 1 |
| McIntyre, OR | 11 |
| Holland, JF | 4 |
| McLaughlin, P | 1 |
| Cornwell, GG | 4 |
| Kochwa, S | 4 |
| Glowienka, LP | 2 |
| Rafla, S | 2 |
| Silver, RT | 3 |
| Cooper, MR | 9 |
| Henderson, E | 2 |
| Haurani, FI | 1 |
| Ricci, C | 1 |
| Coscia, GC | 1 |
| Uberti, M | 1 |
| Discalzi, G | 1 |
| Racca, P | 1 |
| Hatake, K | 1 |
| Saito, K | 1 |
| Ghanta, VK | 1 |
| Durant, JR | 2 |
| Morlock, G | 1 |
| Rosenberg, F | 1 |
| Lopitaux, R | 1 |
| Blotman, F | 1 |
| Sany, J | 1 |
| Ciurana, AJ | 1 |
| Rampon, S | 1 |
| Bussière, JL | 1 |
| Simon, L | 2 |
| Serre, H | 1 |
| Rubio Felix, D | 1 |
| Giraldo, MP | 1 |
| Raichs, A | 1 |
| García Zueco, JC | 1 |
| Mur, P | 1 |
| Faura, MV | 1 |
| Ruíz-Marcuello, E | 1 |
| Piñan, MA | 1 |
| Luikart, S | 1 |
| Weininger, RB | 1 |
| Drewinko, B | 2 |
| Boyer, H | 1 |
| Rubinow, SI | 1 |
| Gassel, WD | 1 |
| Sodomann, CP | 1 |
| Capnist, G | 1 |
| Vespignani, M | 1 |
| Spriano, M | 1 |
| Damasio, E | 1 |
| Craviotto, L | 1 |
| Rizzoli, V | 1 |
| Contu, A | 1 |
| Olmeo, N | 1 |
| Tedeschi, L | 1 |
| Fabris, P | 1 |
| Smith, AM | 1 |
| Szczepek, A | 1 |
| Mant, MJ | 1 |
| Pilarski, LM | 1 |
| Pelliniemi, TT | 2 |
| Irjala, K | 1 |
| Mattila, K | 1 |
| Pulkki, K | 1 |
| Rajamäki, A | 1 |
| Tienhaara, A | 2 |
| Laakso, M | 1 |
| Lahtinen, R | 1 |
| Ghosh, K | 1 |
| Sivakumaran, M | 1 |
| Murphy, P | 1 |
| Chapman, CS | 1 |
| Wood, JK | 1 |
| Shimada, H | 1 |
| Nishinarita, S | 1 |
| Kishigami, Y | 1 |
| Hayama, T | 1 |
| Sawada, U | 1 |
| Horie, T | 1 |
| Nakamura, N | 1 |
| Nakamura, O | 1 |
| Roldán, V | 1 |
| García, MC | 1 |
| Gil, MT | 1 |
| Rivas, C | 1 |
| Sangfelt, O | 1 |
| Osterborg, A | 7 |
| Grandér, D | 2 |
| Anderbring, E | 1 |
| Ost, A | 1 |
| Einhorn, S | 2 |
| Cohen, AM | 4 |
| Meytes, D | 1 |
| Many, A | 2 |
| Brenner, B | 1 |
| Aghai, E | 1 |
| Shaklai, M | 1 |
| Kaufman, S | 1 |
| Shtalrid, M | 1 |
| Attias, D | 1 |
| Manor, Y | 1 |
| Kedar, I | 1 |
| Segal, A | 1 |
| Moran, CA | 1 |
| Suster, S | 1 |
| Fishback, NF | 1 |
| Koss, MN | 1 |
| Guillemin, F | 1 |
| Guerci, AP | 1 |
| Feugier, P | 1 |
| Péré, P | 1 |
| Pourel, J | 1 |
| Guerci, O | 1 |
| Purvin, VA | 1 |
| Browman, GP | 1 |
| Sicheri, D | 1 |
| O'Reilly, S | 1 |
| Wilson, KS | 1 |
| Rubin, S | 1 |
| Walker, I | 1 |
| Polliack, A | 1 |
| Huber, H | 3 |
| Nachbaur, D | 2 |
| Senn, HJ | 2 |
| Eckhardt, S | 2 |
| Günczler, P | 2 |
| Seewann, HL | 2 |
| Tarella, C | 1 |
| Bondesan, P | 1 |
| Caracciolo, D | 1 |
| Frieri, R | 5 |
| Bregni, M | 1 |
| Siena, S | 1 |
| Gianni, AM | 1 |
| Bergsagel, DE | 11 |
| Deicher, H | 7 |
| Coldewey, R | 5 |
| Leo, R | 2 |
| Bartl, R | 2 |
| Bartels, H | 2 |
| Braun, HJ | 2 |
| Fett, W | 1 |
| Fischer, JT | 2 |
| Göbel, B | 1 |
| Westin, J | 11 |
| Rödjer, S | 5 |
| Cortelezzi, A | 6 |
| Zador, G | 2 |
| Zervas, K | 3 |
| Constantinou, N | 1 |
| Karakantza, M | 1 |
| Tsigalidou-Balla, V | 1 |
| González, M | 2 |
| Ortega, F | 2 |
| Borrego, D | 1 |
| Carnero, M | 3 |
| Casanova, F | 1 |
| Jiménez, R | 1 |
| Aström, G | 1 |
| Nyman, R | 1 |
| Ahlström, H | 1 |
| Michaux, JL | 3 |
| Euller-Ziegler, L | 2 |
| Bernard, JF | 3 |
| Daragon, A | 2 |
| Courouble, Y | 1 |
| Kaplan, G | 1 |
| Gupta, V | 1 |
| Thompson, EB | 1 |
| Stock-Novack, D | 1 |
| Pierce, HI | 1 |
| Chilton, D | 1 |
| Beckford, J | 1 |
| Mittelman, M | 2 |
| Lewinski, UH | 1 |
| Weiss, H | 1 |
| Djaldetti, M | 1 |
| Pick, AI | 1 |
| Colović, MD | 1 |
| Janković, GM | 1 |
| Nikolov, VS | 1 |
| Suvajdzić, ND | 1 |
| Miletić, VD | 1 |
| Betticher, DC | 1 |
| Cerny, T | 1 |
| Fey, MF | 1 |
| Grogan, TM | 2 |
| Finley, P | 2 |
| Pugh, RP | 2 |
| Delain, M | 1 |
| Linassier, C | 2 |
| Petitdidier, C | 1 |
| Goupille, P | 2 |
| Luthier, F | 2 |
| Combe, M | 1 |
| Reisenleiter, M | 1 |
| Lamagnère, JP | 1 |
| Colombat, P | 2 |
| Shulman, LN | 1 |
| Buswell, L | 1 |
| Kalish, LA | 1 |
| Coleman, CN | 1 |
| Lenhard, RE | 3 |
| Daniels, MJ | 1 |
| Glick, JH | 3 |
| Ettinger, DS | 1 |
| Kalish, L | 1 |
| O'Connell, MJ | 1 |
| Toussirot, E | 1 |
| Bille, F | 1 |
| Henry, JF | 1 |
| Acquaviva, PC | 1 |
| van Tol, KM | 1 |
| Fedder, G | 1 |
| Annoh, S | 1 |
| Takata, M | 1 |
| Shikoshi, K | 3 |
| Katoh, M | 2 |
| Shirai, T | 3 |
| Faltýnek, L | 1 |
| Papajík, T | 1 |
| Indrák, K | 1 |
| Gancel, A | 1 |
| Lévesque, H | 1 |
| Mabilais, P | 1 |
| Courtois, H | 1 |
| Gola, A | 1 |
| Usnarska-Zubkiewicz, L | 2 |
| Wołowiec, D | 1 |
| Urbaniak-Kujda, D | 1 |
| Kotlarek-Haus, S | 1 |
| Nara, M | 1 |
| Inoue, Y | 1 |
| Enomoto, H | 1 |
| Saito, T | 1 |
| Fujioka, S | 1 |
| Garino, LA | 2 |
| Gallone, G | 3 |
| Dimopoulos, M | 1 |
| Sakalová, A | 4 |
| Holománová, D | 2 |
| Mikulecký, M | 1 |
| Mistrík, M | 2 |
| Lipsic, T | 1 |
| Steruská, M | 2 |
| Meerkin, D | 1 |
| Ashkenazi, Y | 1 |
| Gottschalk-Sabag, S | 1 |
| Hershko, C | 1 |
| Weber, D | 1 |
| Delasalle, KB | 1 |
| Dolgos, J | 1 |
| Patakfalvi, A | 1 |
| Dear, K | 1 |
| Ellerton, J | 1 |
| Canellos, G | 1 |
| Bernhardt, B | 1 |
| Duggan, D | 1 |
| Faragher, D | 1 |
| Schiffer, C | 1 |
| Hellquist, L | 2 |
| Magnusson, B | 2 |
| Björeman, M | 5 |
| Celsing, F | 2 |
| Grimfors, G | 4 |
| Hast, R | 5 |
| Vincent, SD | 1 |
| Lilly, GE | 1 |
| Hupp, JR | 1 |
| Maldonado, J | 5 |
| Sanz, MA | 4 |
| García-Conde, J | 6 |
| Alonso, C | 2 |
| Zubizarreta, A | 2 |
| Togawa, A | 1 |
| Kuliszkiewicz-Janus, M | 1 |
| Baczyński, S | 1 |
| Weh, HJ | 1 |
| Seeger, D | 1 |
| Junge, I | 1 |
| Hossfeld, DK | 1 |
| Ucci, G | 6 |
| Piva, N | 1 |
| Di Stasi, M | 2 |
| Trotti, G | 1 |
| Petrini, M | 2 |
| Eika, S | 1 |
| Hippe, E | 4 |
| Kaasa, S | 2 |
| Palva, I | 4 |
| Modiano, MR | 1 |
| Villar-Werstler, P | 1 |
| Crowley, J | 4 |
| Grignani, G | 1 |
| Gobbi, PG | 1 |
| Formisano, R | 1 |
| Pieresca, C | 1 |
| Heyll, A | 1 |
| Aul, C | 1 |
| Przedlacki, J | 1 |
| Paluszewska, M | 1 |
| Ostrowski, G | 1 |
| Paprocka, E | 1 |
| Swieboda, A | 1 |
| Niesiobedzka-Krezel, J | 1 |
| Walter, Z | 1 |
| Ostrowski, K | 1 |
| Kuratowska, Z | 1 |
| Weber, CK | 1 |
| Friedrich, JM | 1 |
| Merkle, E | 1 |
| Prümmer, O | 1 |
| Hoffmeister, A | 1 |
| Mattfeldt, T | 1 |
| Frickhofen, N | 1 |
| Sotto, JJ | 2 |
| Fuzibet, JG | 1 |
| Ifrah, N | 1 |
| Payen, C | 2 |
| Gripenberg, M | 1 |
| Handelsman, H | 1 |
| Borbujo, J | 1 |
| de Lucas, R | 1 |
| Manzano, R | 1 |
| Casado, M | 1 |
| Martini, R | 1 |
| Santini, S | 1 |
| Bottari, G | 1 |
| Conde, E | 2 |
| Conzález-Brito, G | 1 |
| Escudero, ML | 3 |
| Pascual, A | 1 |
| Vivancos, P | 1 |
| Palou, J | 1 |
| Valls, A | 1 |
| Garćia, J | 1 |
| Grañena, A | 2 |
| Vesole, DH | 1 |
| Bracy, D | 1 |
| Desikan, KR | 1 |
| Siegel, D | 1 |
| Tsiatis, A | 1 |
| Gregory, SA | 1 |
| Spiegel R, J | 1 |
| O'Connell M, J | 1 |
| Liu, P | 1 |
| Quam, L | 1 |
| Billadeau, D | 1 |
| Greipp, P | 1 |
| Pouli, A | 2 |
| Perifanis, V | 1 |
| Papanastasiou, K | 1 |
| Chatziyianni, M | 1 |
| Mitsouli, C | 1 |
| Muñoz, M | 1 |
| Besses, C | 3 |
| Nagura, E | 3 |
| Ichikawa, A | 3 |
| Kamiya, O | 3 |
| Kato, R | 1 |
| Utsumi, M | 1 |
| Tanaka, M | 1 |
| Shimizu, K | 3 |
| Naito, K | 1 |
| Nishiwaki, H | 1 |
| Mizuno, H | 3 |
| Hirabayashi, N | 2 |
| Nitta, M | 3 |
| Kato, Y | 1 |
| Shibata, T | 2 |
| Kawashima, K | 3 |
| Saito, H | 3 |
| Argentino, C | 1 |
| Dominietto, A | 1 |
| Comotti, B | 3 |
| Lauta, VM | 2 |
| Liberati, M | 2 |
| Marmont, F | 5 |
| Keimowitz, RM | 2 |
| Harrington, DP | 1 |
| Knospe, W | 1 |
| Avilés, A | 1 |
| Huerta-Guzmán, J | 1 |
| Delgado, S | 1 |
| Fernández, A | 1 |
| Díaz-Maqueo, JC | 1 |
| Joshua, DE | 2 |
| Penny, R | 1 |
| Matthews, JP | 1 |
| Laidlaw, CR | 1 |
| Gibson, J | 2 |
| Bradstock, K | 1 |
| Wolf, M | 1 |
| Goldstein, D | 1 |
| Lila, AM | 1 |
| Mazurov, VI | 1 |
| Novik, AA | 1 |
| Wada, M | 1 |
| Mizoguchi, H | 1 |
| Seidel, C | 2 |
| Børset, M | 1 |
| Sundan, A | 2 |
| Raaijmakers, HG | 1 |
| Izquierdo, MA | 1 |
| de Leeuw, C | 1 |
| Belien, JA | 1 |
| Dekker, AW | 1 |
| Scheper, RJ | 1 |
| Balcerzak, SP | 1 |
| Roach, RW | 1 |
| Taylor, SA | 1 |
| Rivkin, SE | 1 |
| Samlowski, W | 1 |
| Sokołowska, B | 2 |
| Wojtaszko, M | 1 |
| Bernat, S | 1 |
| Gozalbo, T | 1 |
| García-Boyero, R | 1 |
| Guinot, M | 1 |
| Quaglino, D | 1 |
| Di Leonardo, G | 1 |
| Pasqualoni, E | 1 |
| Furia, N | 1 |
| Di Simone, S | 1 |
| Celik, I | 1 |
| Apraş, S | 1 |
| Kars, A | 1 |
| Barişta, I | 1 |
| Güllü, I | 1 |
| Güler, N | 1 |
| Kansu, E | 1 |
| Arias, J | 1 |
| Fritz, E | 3 |
| Krömer, E | 1 |
| Schuster, R | 1 |
| DeSantis, M | 1 |
| Fiegl, M | 1 |
| Roka, S | 1 |
| Heinz, R | 1 |
| Bragantini, G | 1 |
| Bresciani, P | 1 |
| Chuba, J | 1 |
| Vidal, R | 1 |
| Rostagno, A | 1 |
| Ghiso, J | 1 |
| Zee, B | 1 |
| Cole, B | 1 |
| Browman, G | 1 |
| James, K | 1 |
| Johnston, D | 1 |
| Sugano, D | 1 |
| Pater, J | 1 |
| Bessmel'tsev, SS | 1 |
| Rukavitsyn, OA | 1 |
| Otsubo, H | 1 |
| Utsunomiya, Y | 1 |
| Ikeda, M | 1 |
| Kaito, K | 1 |
| Kawamura, T | 1 |
| Hosoya, T | 1 |
| Boccacio, C | 1 |
| Bettini, R | 1 |
| Tonolini, M | 1 |
| Bernasconi, M | 1 |
| Mineur, P | 1 |
| Pollet, JP | 2 |
| Laporte, JP | 2 |
| De Gramont, A | 1 |
| Peny, AM | 1 |
| Tabernero, MD | 1 |
| Pérez-Simón, JA | 1 |
| Rasillo, A | 1 |
| Albitar, S | 1 |
| Bourgeon, B | 1 |
| Genin, R | 1 |
| Jacquesson, M | 1 |
| Riviere, JP | 1 |
| Serveaux, MO | 1 |
| Ribera, A | 1 |
| Serveaux, JP | 1 |
| Inwards, DJ | 1 |
| Chen, MG | 1 |
| Pineda, AA | 1 |
| Gastineau, DA | 1 |
| Tefferi, A | 1 |
| Witzig, TE | 1 |
| Litzow, MR | 1 |
| Reichardt, VL | 1 |
| Okada, CY | 1 |
| Liso, A | 1 |
| Benike, CJ | 1 |
| Stockerl-Goldstein, KE | 1 |
| Engleman, EG | 1 |
| Blume, KG | 1 |
| Levy, R | 1 |
| Bladé Creixenti, J | 1 |
| Nord, E | 2 |
| Ampil, FL | 1 |
| Wislöff, F | 1 |
| Polak, G | 1 |
| Tomczak-Watras, W | 1 |
| Nartowicz, E | 1 |
| Sao, H | 1 |
| Ataga, KI | 1 |
| Graham, ML | 1 |
| Evans, HN | 1 |
| Braeuning, P | 1 |
| Orringer, EP | 1 |
| del Potro Gómez, E | 1 |
| Morales Sanz, D | 1 |
| Krieger, MS | 1 |
| Schiller, G | 1 |
| Noga, SJ | 1 |
| Ballester, O | 1 |
| Tarantolo, S | 1 |
| Stiff, P | 1 |
| Kuhn, D | 1 |
| Scherzo, E | 1 |
| Sing, A | 1 |
| Jacobs, C | 1 |
| White, JM | 1 |
| DiPersio, J | 1 |
| Christou, L | 1 |
| Hatzimichael, EC | 1 |
| Sotsiou-Candila, F | 1 |
| Siamopoulos, K | 1 |
| Bourantas, KL | 1 |
| Biriukova, LS | 1 |
| Volodiaeva, EB | 1 |
| Fetisova, EV | 1 |
| Pivnik, AV | 1 |
| Margolin, OV | 1 |
| Lefrere, F | 1 |
| Makke, J | 1 |
| Fermand, J | 1 |
| Marolleau, J | 1 |
| Dal Cortivo, L | 1 |
| Alberti, C | 1 |
| Mouton, V | 1 |
| Benbunan, M | 1 |
| Miclea, J | 1 |
| Sanchis-Bayarri Bernal, V | 1 |
| García Gascó, P | 1 |
| Tordera Higón, P | 1 |
| Micó Giner, L | 1 |
| Calabuig Alborch, JR | 1 |
| Dunkley, S | 1 |
| Iland, H | 1 |
| Li, C | 1 |
| Joshua, D | 1 |
| Borset, M | 1 |
| Ahmed, I | 1 |
| Cronk, JS | 1 |
| Crutchfield, CE | 1 |
| Dahl, MV | 1 |
| Lebrun, C | 1 |
| Chanalet, S | 1 |
| Frenay, M | 1 |
| Chatel, M | 1 |
| Shirakawa, S | 1 |
| Shimamoto, Y | 2 |
| Araki, K | 1 |
| Miura, A | 1 |
| Ohno, Y | 1 |
| Ichimaru, M | 1 |
| Hanada, S | 1 |
| Inaba, S | 1 |
| Konishi, H | 1 |
| Toki, H | 1 |
| Tajima, K | 1 |
| Niimi, M | 1 |
| Valentini, D | 1 |
| Kim, YM | 1 |
| Lee, KK | 1 |
| Oh, HS | 1 |
| Won, JH | 1 |
| Hong, DS | 1 |
| Park, HS | 1 |
| Lee, DW | 1 |
| Zeidman, A | 1 |
| Sender, BZ | 1 |
| Yarmolovsky, A | 1 |
| Fradin, Z | 1 |
| Elloumi, M | 1 |
| Frikha, M | 1 |
| Masmoudi, H | 1 |
| Mseddi, S | 1 |
| Ben Ayed, M | 1 |
| Bouaziz, M | 1 |
| Makni, F | 1 |
| Souissi, T | 1 |
| Renner, S | 1 |
| Weisz, J | 1 |
| Krajewski, S | 1 |
| Krajewska, M | 1 |
| Reed, JC | 1 |
| Lichtenstein, A | 1 |
| Egerer, G | 1 |
| Rapoport, AP | 1 |
| Cottler-Fox, M | 1 |
| Chen, T | 1 |
| Gauvain, JB | 1 |
| Maigre, M | 1 |
| Dugay, J | 1 |
| Lucas, V | 1 |
| Gregoraki, B | 1 |
| Anagnostopoulos, N | 1 |
| Bourantas, K | 1 |
| Tzilianos, M | 1 |
| Barbarousi, D | 1 |
| Venetis, E | 1 |
| Vyniou, N | 1 |
| Colombi, M | 1 |
| Guffanti, A | 1 |
| Alietti, A | 1 |
| Latargia, ML | 1 |
| Vener, C | 1 |
| Maiolo, AT | 2 |
| de Weerdt, O | 1 |
| Veth, G | 1 |
| Hagenbeek, A | 1 |
| Jacobson, J | 1 |
| Bock, PR | 1 |
| Dedík, L | 1 |
| Hanisch, J | 1 |
| Schiess, W | 1 |
| Gazová, S | 2 |
| Chabronová, I | 1 |
| Hrubisko, M | 2 |
| Genvresse, I | 1 |
| Wedding, U | 1 |
| Bokemeyer, C | 1 |
| Späth-Schwalbe, E | 1 |
| Tangen, JM | 1 |
| Brinch, L | 1 |
| Gruber, FX | 1 |
| Hammerstrøm, J | 1 |
| Ernst, P | 1 |
| Pelizzari, A | 1 |
| Motta, M | 1 |
| Puoti, M | 1 |
| Santos-Juanes, J | 1 |
| Osuna, CG | 1 |
| Iglesias, JR | 1 |
| De Quiros, JF | 1 |
| del Río, JS | 1 |
| Desikan, RK | 1 |
| Le Blanc, R | 1 |
| Montminy-Métivier, S | 1 |
| Bélanger, R | 1 |
| Busque, L | 1 |
| Fish, D | 1 |
| Roy, DC | 1 |
| Kassis, J | 1 |
| Boileau, J | 1 |
| Lavallée, R | 1 |
| Bélanger, D | 1 |
| Letendre, F | 1 |
| Hébert, J | 1 |
| Sauvageau, G | 1 |
| Perreault, C | 1 |
| Zaja, F | 1 |
| Silvestri, F | 1 |
| Sperotto, A | 1 |
| Scalise, A | 1 |
| Gigli, G | 1 |
| Fanin, R | 1 |
| Artusi, T | 1 |
| Bonacorsi, G | 1 |
| Arigliano, V | 1 |
| Sen, F | 1 |
| Mann, KP | 1 |
| Medeiros, LJ | 1 |
| Neki, NS | 1 |
| Sharma, RK | 1 |
| Sharma, N | 1 |
| Multani, LS | 1 |
| Garban, F | 1 |
| Gallagher, M | 1 |
| Jouvin-Marche, E | 1 |
| Jacob, MC | 1 |
| Moine, A | 1 |
| Marche, PN | 1 |
| Esteve, J | 1 |
| Brunet, S | 1 |
| Hernández-Martín, J | 1 |
| Zangmeister, J | 1 |
| Briggs, AD | 1 |
| Mills, GM | 1 |
| Ahmad, I | 1 |
| Islam, T | 1 |
| Hahn, T | 1 |
| Wentling, D | 1 |
| Becker, JL | 1 |
| Alam, AR | 1 |
| Huijgens, PC | 1 |
| Yamao, H | 1 |
| Wakita, A | 1 |
| Urbauer, E | 1 |
| Kaufmann, H | 1 |
| Nösslinger, T | 1 |
| Raderer, M | 1 |
| Finkel, HE | 1 |
| Russell, DH | 1 |
| Russell, SD | 1 |
| Zilko, PJ | 1 |
| Dawkins, RL | 1 |
| Alberts, DS | 1 |
| Brunner, KW | 1 |
| Wagner, HP | 1 |
| Phadke, KP | 1 |
| Kwan, YL | 1 |
| Young, SG | 1 |
| Cornell, CJ | 1 |
| Weksler, BB | 1 |
| Ferraris, AM | 1 |
| Haupt, E | 1 |
| Ratti, M | 1 |
| Cardamone, JM | 1 |
| Foa, J | 1 |
| Carcassonne, Y | 1 |
| von Eyben, F | 1 |
| Olsen, TS | 1 |
| Locatelli, F | 1 |
| Giovanelli, E | 1 |
| Neretto, G | 2 |
| Furno, F | 1 |
| Pellerito, R | 1 |
| Doll, DC | 1 |
| Weiss, RB | 1 |
| Gailani, S | 2 |
| Seon, BK | 1 |
| Sieber, SM | 2 |
| Silberman, H | 1 |
| Drobná, V | 1 |
| Hrubisková, D | 1 |
| Taetle, R | 1 |
| Dickman, PS | 1 |
| Feldman, PS | 1 |
| Tortarolo, M | 2 |
| Cantore, N | 1 |
| Russolillo, S | 2 |
| Castaldo, C | 2 |
| Buonanno, G | 2 |
| Gonzalez, F | 1 |
| Trujillo, JM | 1 |
| Jänner, M | 1 |
| Lippert, HD | 1 |
| Stolzenbach, G | 1 |
| Valente, A | 1 |
| Gonnella, F | 1 |
| Stegman, R | 1 |
| Harley, JB | 4 |
| Coleman, M | 3 |
| Mayans, J | 2 |
| Martínez, J | 1 |
| Caballero, O | 1 |
| Marty, ML | 2 |
| Larsen, WE | 1 |
| Johnson, L | 1 |
| Seligman, BR | 1 |
| Blom, J | 1 |
| Bailey, AJ | 1 |
| Langley, GR | 1 |
| MacDonald, RN | 1 |
| White, DF | 1 |
| Miller, AB | 1 |
| Miller, S | 1 |
| Perrotta, AL | 1 |
| Felder, M | 1 |
| Keiser, G | 1 |
| Wirth, W | 1 |
| Gehan, E | 3 |
| Weick, J | 2 |
| Redon, J | 1 |
| Badia, L | 1 |
| Herranz, C | 1 |
| Calabuig, JR | 1 |
| Caballero, M | 1 |
| Lee, DJ | 1 |
| Clarkson, BD | 2 |
| Jordan, E | 1 |
| Burnstein, SL | 1 |
| Calabro, JJ | 1 |
| Saiki, J | 1 |
| Simon, TL | 1 |
| Rughani, IK | 1 |
| Pierson, DJ | 1 |
| Hebard, DW | 1 |
| Sonntag, RW | 5 |
| Presant, CA | 1 |
| Klahr, C | 1 |
| Mehta, AD | 1 |
| Belpomme, D | 1 |
| Simon, F | 1 |
| Pouillart, P | 1 |
| Amor, B | 1 |
| Feuilhade de Chauvin, F | 1 |
| Belpomme, A | 1 |
| Menkes, C | 1 |
| Delrieu, A | 1 |
| Depierre, R | 1 |
| Le Mevel, B | 1 |
| Serrou, B | 1 |
| Fries, D | 1 |
| Delbarre, F | 1 |
| Mathé, G | 1 |
| Ardouin, M | 1 |
| Urvoy, M | 1 |
| Eon, JY | 1 |
| Le Blay, R | 1 |
| Pruzanski, W | 1 |
| McLaughlin, CL | 1 |
| Capra, JD | 1 |
| Coutant, G | 1 |
| Hamers, J | 1 |
| Baele, G | 1 |
| Van Hove, W | 1 |
| Newton, PA | 1 |
| Swan, GW | 1 |
| Vincent, TL | 1 |
| Yalon, M | 1 |
| Levo, Y | 1 |
| Ramot, B | 1 |
| Albert, P | 1 |
| Zsuzsa, M | 1 |
| Kapadia, SB | 1 |
| Krause, JR | 1 |
| Hokanson, JA | 1 |
| Brown, BW | 1 |
| Thompson, JR | 1 |
| Rickel, L | 1 |
| Bayrd, ED | 2 |
| Wands, JR | 1 |
| Chura, CM | 1 |
| Roll, FJ | 1 |
| Maddrey, WC | 1 |
| Adamson, RH | 1 |
| Rosen, BJ | 1 |
| Waldmann, TA | 1 |
| Broder, S | 1 |
| Krakauer, R | 1 |
| MacDermott, RP | 1 |
| Durm, M | 1 |
| Goldman, C | 1 |
| Meade, B | 1 |
| Jungi, WF | 2 |
| Abdou, NI | 1 |
| Abdou, NL | 1 |
| Jowsey, J | 1 |
| Kelly, PJ | 1 |
| Taves, DR | 1 |
| Frenkel, JK | 1 |
| Nelson, BM | 1 |
| Arias-Stella, J | 1 |
| Harbaugh, ME | 1 |
| Hill, EM | 1 |
| Conn, RB | 1 |
| Jacobs, P | 1 |
| Dubovsky, D | 1 |
| Balcerzak, S | 1 |
| Gehan, EA | 1 |
| Hewlett, JS | 1 |
| Monto, RW | 1 |
| Wasserman, LR | 1 |
| Martz, G | 2 |
| Spurr, C | 1 |
| Wiernik, PM | 1 |
| Falkson, G | 2 |
| Glidewell, O | 2 |
| Wallack, EM | 1 |
| Rosen, C | 1 |
| Segal, H | 1 |
| Hartz, CE | 1 |
| Mroz, F | 1 |
| Carlton, E | 1 |
| Camba, L | 1 |
| Blumenreich, M | 1 |
| Hadley, T | 1 |
| Joseph, G | 1 |
| Marcelli, C | 1 |
| Aboukrat, P | 1 |
| Stenke, L | 1 |
| Hansson, H | 1 |
| Pisa, P | 1 |
| MacKenzie, MR | 1 |
| Wold, H | 1 |
| George, C | 1 |
| Gandara, D | 1 |
| Ray, G | 1 |
| Schiff, S | 1 |
| Shields, J | 1 |
| Artim, R | 1 |
| Davidson, H | 1 |
| Meyers, F | 1 |
| Popp, W | 1 |
| Vahrenholz, C | 1 |
| Schürfeld, C | 1 |
| Schmieding, W | 1 |
| Hoster, M | 1 |
| Bach, I | 1 |
| Norpoth, K | 1 |
| Pais, JR | 1 |
| Pascual, J | 1 |
| Pérez Vaquero, MA | 1 |
| Hernando, JC | 1 |
| Coppetelli, U | 1 |
| Cantonetti, M | 4 |
| Petrucci, T | 1 |
| Stasi, R | 1 |
| Papa, G | 2 |
| Pastor Rubín de Celis, E | 1 |
| Ruiz Salmerón, RJ | 1 |
| Aguirre Jaca, M | 1 |
| Rivas Manga, MC | 1 |
| Marín Hernández, G | 1 |
| Delasalle, K | 1 |
| Rosner, F | 2 |
| Grünwald, HW | 1 |
| Kalman, AC | 1 |
| Huguet, F | 1 |
| Schlaifer, D | 1 |
| Laroche, M | 1 |
| Fournie, B | 1 |
| Mazieres, B | 1 |
| Pris, J | 1 |
| Laurent, G | 1 |
| Hedenus, M | 2 |
| Talstad, I | 1 |
| Lombardi, C | 1 |
| Calvi, A | 1 |
| Bonera, E | 1 |
| Savio, A | 1 |
| Savio, E | 1 |
| Hashimoto, S | 1 |
| Kawano, E | 1 |
| Hirasawa, A | 1 |
| Morio, S | 1 |
| Aotuka, N | 1 |
| Nakamura, H | 1 |
| Oh, H | 1 |
| Asai, T | 1 |
| Yoshida, S | 1 |
| Invernizzi, R | 1 |
| Luoni, R | 2 |
| Zambelli, ML | 1 |
| Rastaldi, MP | 1 |
| Tamura, K | 1 |
| Kosaka, M | 1 |
| Mizuguchi, T | 1 |
| Miyamoto, Y | 1 |
| von Stedingk, LV | 1 |
| von Stedingk, M | 1 |
| Wasserman, J | 1 |
| Corrado, C | 2 |
| Cantore, M | 1 |
| Smerieri, F | 1 |
| Bucalossi, A | 1 |
| Leoncini, L | 1 |
| Senn, H | 1 |
| Schüller, J | 1 |
| Matsuzaki, M | 1 |
| Yamaguchi, M | 1 |
| Raya Sánchez, JM | 1 |
| González Brito, G | 1 |
| Marsá Vila, L | 1 |
| Brito Barroso, ML | 1 |
| Hernández Nieto, L | 1 |
| Mendek-Czajkowska, E | 2 |
| Pogłód, R | 2 |
| Sabliński, J | 1 |
| Kowalewski, J | 1 |
| Kurowska, M | 1 |
| Sokołowska, U | 1 |
| Pasqualetti, P | 1 |
| Casale, R | 1 |
| Colantonio, D | 1 |
| Collacciani, A | 1 |
| Natali, G | 1 |
| Golenkov, AK | 1 |
| Tsukahara, T | 1 |
| Yamauchi, M | 3 |
| Arai, N | 1 |
| Kosuge, T | 1 |
| Anno, S | 1 |
| Chiarion-Sileni, V | 1 |
| Soesan, M | 1 |
| Baggio, G | 1 |
| De Besi, P | 2 |
| Casara, D | 2 |
| Frizzarin, M | 2 |
| Favaretto, A | 1 |
| Annou, S | 1 |
| Takada, M | 1 |
| Moro, S | 1 |
| Beckord, J | 1 |
| Bjerrum, OW | 1 |
| Brandt, E | 1 |
| Evensen, SA | 1 |
| Hansen, MM | 1 |
| Keldsen, N | 1 |
| Andriani, A | 1 |
| Carotenuto, M | 1 |
| Dammacco, F | 4 |
| Levis, A | 1 |
| Falda, M | 1 |
| Resegotti, L | 2 |
| Radaelli, F | 1 |
| Chiorboli, O | 1 |
| Fumagalli, S | 1 |
| Cro, L | 1 |
| Segala, M | 1 |
| Cesana, BM | 1 |
| Polli, EE | 1 |
| von Broen, IM | 2 |
| Gramatzki, M | 2 |
| Fujii, H | 1 |
| Yashige, H | 1 |
| Urata, Y | 1 |
| Kuzuyama, Y | 1 |
| Kitagawa, Y | 1 |
| Horishi, M | 1 |
| Suyama, Y | 1 |
| Miyoshi, M | 1 |
| Uchida, S | 1 |
| Matsuda, O | 1 |
| Yokota, T | 1 |
| Takemura, T | 1 |
| Ando, R | 1 |
| Kanemitsu, H | 1 |
| Hamaguchi, H | 1 |
| Miyake, S | 1 |
| Marumo, F | 1 |
| Tesh, D | 1 |
| Saeed, S | 1 |
| Milder, MS | 1 |
| Hutchins, LF | 1 |
| Coltman, CA | 1 |
| Cheson, B | 3 |
| Cammerer, U | 1 |
| Hein, R | 1 |
| Hoffmann, L | 1 |
| Konyar, H | 1 |
| Kreuser, ED | 1 |
| Selbach, J | 1 |
| Antela López, A | 1 |
| Requena Caballero, I | 1 |
| Masa Vázquez, L | 1 |
| Antela Carrera, C | 1 |
| Barrio Gómez, E | 1 |
| Sanz Sanz, MA | 1 |
| van Hoeven, KH | 1 |
| Reed, LJ | 1 |
| Factor, SM | 1 |
| Dicke, K | 2 |
| Zagars, G | 1 |
| Lemaistre, FC | 1 |
| Smallwood, L | 2 |
| Pruitt, K | 1 |
| Alberts, AS | 1 |
| Rapoport, BL | 1 |
| Uys, A | 1 |
| Montuoro, A | 1 |
| De Blasio, A | 1 |
| Petti, N | 1 |
| Cavo-Comotti, BM | 1 |
| Gallamini, A | 2 |
| Ehrsson, H | 1 |
| Eksborg, S | 1 |
| Wallin, I | 1 |
| Urbano, A | 1 |
| López Guillermo, A | 1 |
| Rozman, M | 1 |
| Rovira, M | 1 |
| Freedman, J | 1 |
| Garvey, MB | 1 |
| Pecherstorfer, M | 1 |
| Schmoranzer, F | 1 |
| Vesely, M | 1 |
| Fortelny, A | 1 |
| Baumgartner, G | 1 |
| Lowenthal, RM | 1 |
| Jestrimski, KW | 1 |
| Welander, CE | 1 |
| Coiffier, B | 1 |
| Paule, B | 2 |
| Quillard, J | 1 |
| Bisson, M | 2 |
| Massias, P | 2 |
| Imamura, Y | 2 |
| Preis, P | 1 |
| Scheithauer, W | 4 |
| Zielinski, C | 1 |
| Kuehrer, I | 1 |
| Polli, E | 4 |
| Pirker, R | 1 |
| Kriegisch, A | 1 |
| Kührer, I | 1 |
| Sinoff, CL | 1 |
| Blumsohn, A | 1 |
| Bergmann, OJ | 1 |
| Boesen, AM | 1 |
| Pedersen, BB | 1 |
| Bastrup-Madsen, P | 1 |
| Tsykalov, VA | 1 |
| Zhuravlev, VS | 1 |
| Mokeeva, RA | 1 |
| Velasquez, WS | 1 |
| Elezović, I | 1 |
| Djukanović, R | 1 |
| Rolović, Z | 1 |
| Miglietta, A | 1 |
| Perfetto, SC | 1 |
| Parra, R | 1 |
| Fernandez, JM | 1 |
| Garcia-Bragado, F | 1 |
| Bueno, J | 1 |
| Biosca, M | 1 |
| Schmoll, HJ | 2 |
| Schedel, I | 2 |
| Dhingra, K | 1 |
| Piatkowska-Jakubas, B | 1 |
| Skotnicki, AB | 1 |
| Blicharski, J | 1 |
| Misiani, R | 1 |
| Tiraboschi, G | 1 |
| Mingardi, G | 1 |
| Mecca, G | 1 |
| Tsiatis, AA | 1 |
| Silverstein, MN | 1 |
| Wysenbeek, AJ | 1 |
| Leibovici, L | 1 |
| Mor, F | 1 |
| Atsmon, A | 1 |
| Heo, DS | 1 |
| Bang, YJ | 1 |
| Lee, SJ | 1 |
| Choi, DH | 1 |
| Park, SY | 1 |
| Kim, BK | 1 |
| Kim, NK | 1 |
| Heo, M | 1 |
| Lee, M | 1 |
| Tefft, M | 1 |
| Propert, K | 1 |
| Wolf, DJ | 1 |
| Leone, L | 2 |
| Eaton, W | 1 |
| Zimmer, B | 1 |
| Engel, M | 1 |
| Hartlapp, JH | 1 |
| Hügl, E | 1 |
| Dengler, HJ | 1 |
| Dörmer, P | 1 |
| Shelley, W | 2 |
| Klimo, P | 2 |
| Willan, A | 2 |
| Santarelli, MT | 1 |
| Palau, M | 1 |
| de Tezanos Pinto, M | 1 |
| Huberman, A | 1 |
| Bury, J | 1 |
| Salmon, J | 1 |
| Fillet, G | 2 |
| Costanzi, JJ | 2 |
| Pollard, RB | 1 |
| Medicis, P | 1 |
| Clerc, D | 1 |
| Bennet, P | 1 |
| Tassi, C | 1 |
| Palmer, M | 2 |
| Hanson, J | 1 |
| Brox, L | 2 |
| Görg, C | 1 |
| Adler, G | 1 |
| Görg, K | 2 |
| Pflüger, KH | 1 |
| Havemann, K | 1 |
| Prematilleke, MN | 1 |
| Cristoffanini, AP | 1 |
| Vidal, MA | 1 |
| Cea, X | 1 |
| Zapata, C | 1 |
| Osby, E | 1 |
| Forman, WB | 1 |
| Prümmerová, J | 1 |
| Carter, S | 1 |
| Stephens, R | 1 |
| Rivkin, S | 1 |
| Dabich, L | 1 |
| Files, JC | 1 |
| Boll, J | 1 |
| Essers, U | 1 |
| Gamm, H | 1 |
| Glück, S | 1 |
| Sporn, JR | 1 |
| Van Camp, BG | 2 |
| Kuzmits, R | 2 |
| Peetermans, M | 1 |
| Flener, R | 2 |
| Kildahl-Andersen, O | 1 |
| Bjark, P | 1 |
| Bondevik, A | 1 |
| Bull, O | 1 |
| Dehli, O | 1 |
| Kvambe, V | 1 |
| Nordahl, E | 1 |
| Ytrehus, K | 1 |
| Lamvik, J | 1 |
| Palva, IP | 1 |
| Ahrenberg, P | 1 |
| Ala-Harja, K | 1 |
| Almqvist, A | 1 |
| Apajalahti, J | 1 |
| Hallman, H | 1 |
| Hänninen, A | 1 |
| Ilvonen, M | 1 |
| Isomaa, B | 1 |
| Järvenpää, E | 1 |
| Lira, P | 1 |
| Walker, B | 1 |
| Grebe, G | 1 |
| Richardson, JL | 1 |
| Marks, G | 1 |
| Johnson, CA | 1 |
| Graham, JW | 1 |
| Chan, KK | 1 |
| Selser, JN | 1 |
| Kishbaugh, C | 1 |
| Barranday, Y | 1 |
| Levine, AM | 1 |
| Fefer, A | 2 |
| Thompson, J | 2 |
| Kempf, R | 2 |
| Sacher, R | 2 |
| Neefe, J | 2 |
| Bickers, J | 2 |
| Scarffe, JH | 2 |
| Spiegel, RJ | 1 |
| Salvi, A | 1 |
| Brianzoni, MF | 1 |
| Centurioni, R | 2 |
| Montillo, M | 1 |
| Olivieri, A | 1 |
| Pollock, E | 1 |
| Koch, M | 1 |
| Brandes, L | 1 |
| Yamaguchi, R | 1 |
| Masaki, T | 1 |
| Ishikawa, I | 1 |
| Kiga, Y | 1 |
| Hara, A | 1 |
| Nojima, Z | 1 |
| Spiegel, R | 1 |
| Matus, RE | 1 |
| Leifer, CE | 1 |
| MacEwen, EG | 1 |
| Hurvitz, AI | 1 |
| Carter, C | 1 |
| Greaves, M | 1 |
| Preston, FE | 1 |
| van Dijk, JM | 1 |
| Sonnenblick, M | 1 |
| Weissberg, N | 1 |
| Rosin, A | 1 |
| Wittkamp, S | 1 |
| Theml, H | 1 |
| Keilholz, U | 1 |
| Hunstein, W | 1 |
| Sonneborn, HL | 2 |
| Paul, SD | 2 |
| Hiebel, J | 1 |
| Boyd, MA | 1 |
| Shepp, MA | 1 |
| Dorsk, BM | 2 |
| Bonnem, E | 1 |
| Merlini, G | 2 |
| Montecucco, C | 1 |
| Cassano, E | 1 |
| Cervantes, F | 1 |
| Marín, P | 1 |
| Nomdedeu, B | 1 |
| Becherer, C | 1 |
| Sabán, J | 1 |
| Serrano, M | 1 |
| Serrano Ríos, M | 1 |
| Wilmanns, W | 1 |
| Binsack, T | 1 |
| Sauer, H | 1 |
| Hayes, DM | 1 |
| Carroll, RJ | 1 |
| Bove, L | 1 |
| MacLennan, IC | 1 |
| Cusick, J | 1 |
| Bartolucci, A | 1 |
| Amadori, S | 1 |
| Franchi, A | 1 |
| Vacca, A | 1 |
| Zurborn, KH | 1 |
| Sondermann, I | 1 |
| Gross, WL | 1 |
| Hansen, OP | 4 |
| Clausen, NA | 1 |
| Laursen, B | 1 |
| Raper, RF | 1 |
| Wearne, A | 1 |
| Kronenberg, H | 1 |
| van der Lelie, H | 1 |
| Monasch, E | 1 |
| Pegels, HG | 1 |
| von dem Borne, AE | 1 |
| Savage, D | 1 |
| Garrett, TJ | 1 |
| Lukitsch, O | 1 |
| Gebhardt, KP | 1 |
| Kövary, PM | 1 |
| Calomeni, JA | 1 |
| Smith, JR | 1 |
| Escribano, L | 1 |
| Pasquali, S | 1 |
| Cagnoli, L | 1 |
| Rovinetti, C | 1 |
| Rigotti, A | 1 |
| Zucchelli, P | 1 |
| Riccardi, PG | 1 |
| Montecucco, CM | 1 |
| Pavesi, F | 1 |
| Moran, TJ | 1 |
| Totten, RS | 1 |
| Khaleeli, M | 1 |
| Keane, WM | 1 |
| Lee, GR | 1 |
| Maroncelli, P | 1 |
| Casalino, C | 1 |
| Kiang, DT | 1 |
| Theologides, A | 1 |
| Fortuny, I | 1 |
| Kennedy, BJ | 1 |
| Spengler, GA | 1 |
| Bütler, R | 1 |
| Pflugshaupt, R | 1 |
| Lopez, V | 1 |
| Barandun, S | 1 |
| Stephens, PJ | 1 |
| Hudson, P | 1 |
| Pronk, EA | 1 |
| Elkerbout, F | 1 |
| Klein, F | 1 |
| Radema, H | 1 |
| Cleton, FJ | 1 |
| Videbaek, A | 4 |
| Mansa, B | 1 |
| Kjems, E | 1 |
| Cline, MJ | 2 |
| Hoogstraten, B | 1 |
| Mendes da Costa, P | 1 |
| Jortay, A | 1 |
| Noterman, J | 1 |
| Ramanan, SV | 1 |
| Thiagarajan, PV | 1 |
| Chen, JH | 1 |
| Gomez, R | 1 |
| Koppel, D | 1 |
| Hyde, F | 1 |
| Gustke, S | 1 |
| Krall, J | 1 |
| Riedler, GF | 1 |
| Vorburger, E | 1 |
| Maier, C | 1 |
| Latos, DL | 1 |
| Valentine, AM | 1 |
| Frei, E | 2 |
| Schabel, FM | 1 |
| Goldin, A | 1 |
| Parker, AC | 1 |
| Ho, DH | 1 |
| Freireich, E | 1 |
| Sonntag, R | 1 |
| Favre, E | 1 |
| Carter, SK | 1 |
| Grünwald, H | 1 |
| Weksler, B | 1 |
| Rodriguez, LH | 1 |
| Finkelstein, JB | 1 |
| Shullenberger, CC | 1 |
| Cowan, DH | 1 |
| Hasselback, R | 1 |
| Hoppe, D | 1 |
| Bronsch, T | 1 |
| Gudowski, J | 1 |
| Costa, G | 1 |
| Ogawa, M | 1 |
| Brody, JI | 1 |
| Samitz, MH | 1 |
| Wildiers, J | 1 |
| Drochmans, A | 1 |
| Van der Schueren, G | 1 |
| Jessen, B | 2 |
| Ungaro, P | 1 |
| Lee, BJ | 1 |
| Sahakian, G | 1 |
| Krakoff, IH | 1 |
| Andaloro, VA | 1 |
| Babott, D | 1 |
| Badrinas, F | 1 |
| Rodriguez-Roisin, R | 1 |
| Rives, A | 1 |
| Picado, C | 1 |
| Bernard, DB | 1 |
| Lynch, SR | 1 |
| Bothwell, TH | 1 |
| Bezwoda, WR | 1 |
| Stevens, K | 1 |
| Shulman, G | 1 |
| Harris, RI | 1 |
| Kohn, J | 1 |
| Booth, LJ | 1 |
| Minielly, JA | 1 |
| Smith, EK | 1 |
| Gunz, FW | 1 |
| Mani, MK | 1 |
| Speden, J | 1 |
| Vincent, PC | 1 |
| Scott, WP | 1 |
| Bureau, Y | 1 |
| Barrière, H | 1 |
| Senelar, R | 1 |
| Litoux, P | 1 |
| Bureau, B | 1 |
| Clément, F | 2 |
| Bischof, B | 1 |
| Sullivan, PW | 1 |
| Hewlett, J | 1 |
| Lane, M | 2 |
| Monto, R | 1 |
| Wilson, H | 1 |
| Beevers, DG | 1 |
| Estrada, PC | 1 |
| Scardino, PL | 1 |
| Yium, J | 1 |
| Martinez-Maldonado, M | 1 |
| Eknoyan, G | 1 |
| Suki, WN | 1 |
| Bollag, W | 1 |
| Ladefoged, J | 1 |
| Nielsen, B | 1 |
| Pedersen, K | 1 |
| McArthur, JR | 1 |
| Athens, JW | 1 |
| Wintrobe, MM | 1 |
| Cartwright, GE | 1 |
| Muggia, FM | 1 |
| Heinemann, HO | 1 |
| Kittel, K | 1 |
| Pirofsky, B | 1 |
| Maldonado, JE | 1 |
| Korst, DR | 1 |
| Basch, CM | 1 |
| Rosenbaum, EH | 1 |
| Khan, AU | 1 |
| McKelvey, EM | 1 |
| Migliore, PJ | 1 |
| Stuckey, WJ | 1 |
| Wilson, HE | 1 |
| Rivera, JV | 1 |
| Reyes, FM | 1 |
| Menéndez-Corrada, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.[NCT05527340] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)[NCT04891809] | Phase 2 | 198 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, P[NCT01093196] | Phase 3 | 660 participants (Anticipated) | Interventional | 2009-10-31 | Active, not recruiting | ||
| Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).[NCT02237261] | Phase 2 | 46 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Connect® MM- The Multiple Myeloma Disease Registry[NCT01081028] | 3,011 participants (Actual) | Observational | 2009-09-01 | Active, not recruiting | |||
| A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma[NCT05199311] | Phase 1/Phase 2 | 66 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | ||
| A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy[NCT02195479] | Phase 3 | 706 participants (Actual) | Interventional | 2014-12-09 | Active, not recruiting | ||
| A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936] | Phase 3 | 1,623 participants (Actual) | Interventional | 2008-08-21 | Completed | ||
| Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transplantation[NCT05697913] | 66 participants (Actual) | Interventional | 2014-07-01 | Completed | |||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603] | 100 participants (Anticipated) | Observational | 2021-11-30 | Recruiting | |||
| A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS[NCT01063179] | Phase 3 | 511 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study[NCT03143049] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-09-13 | Recruiting | ||
| A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide[NCT01166113] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma[NCT00911859] | Phase 2 | 118 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial[NCT03336073] | Phase 2 | 199 participants (Actual) | Interventional | 2017-12-18 | Active, not recruiting | ||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma[NCT00049673] | Phase 3 | 332 participants (Actual) | Interventional | 2002-10-15 | Completed | ||
| Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.[NCT00889798] | 3,795 participants (Actual) | Observational [Patient Registry] | 2009-04-30 | Completed | |||
| Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma.[NCT01279694] | Phase 1/Phase 2 | 72 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [NCT01376401] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-07-31 | Completed | ||
| An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose T[NCT00602641] | Phase 3 | 306 participants (Actual) | Interventional | 2008-02-29 | Active, not recruiting | ||
| A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects[NCT01091831] | Phase 3 | 389 participants (Actual) | Interventional | 2009-07-31 | Active, not recruiting | ||
| A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd)[NCT01237249] | Phase 2 | 250 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma[NCT01352338] | Phase 1/Phase 2 | 82 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915] | Phase 1 | 3 participants (Actual) | Interventional | 2019-01-12 | Terminated (stopped due to Company decision) | ||
| An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma[NCT00111319] | Phase 3 | 0 participants | Interventional | 2004-12-31 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma[NCT01484626] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2011-05-05 | Terminated (stopped due to Celgene would no longer supply lenalidomide for the study) | ||
| A Phase II Trial Of Thalidomide/Dexamethasone Induction Followed By Tandem Melphalan Transplant And Prednisone/Thalidomide Maintenance (A BMT Study)[NCT00040937] | Phase 2 | 147 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients[NCT00406978] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| A Phase 3 Study With Randomization to Melphalan/Prednisone/Thalidomide Versus Melphalan/Prednisone/Placebo to Patients With Previously Untreated Multiple Myeloma[NCT00218855] | Phase 3 | 363 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies[NCT00051311] | Phase 2 | 62 participants (Actual) | Interventional | 2003-01-03 | Completed | ||
| Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation[NCT00006184] | Phase 2 | 20 participants (Actual) | Interventional | 2001-02-08 | Completed | ||
| Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome[NCT00074490] | Phase 2 | 442 participants (Actual) | Interventional | 2004-01-01 | Terminated (stopped due to Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2) | ||
| Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation[NCT00001830] | Phase 1 | 110 participants (Actual) | Interventional | 1999-07-20 | Completed | ||
| Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma[NCT00934154] | Phase 3 | 122 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In[NCT00405756] | Phase 3 | 459 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma[NCT00305812] | Phase 2 | 51 participants (Actual) | Interventional | 2006-03-09 | Completed | ||
| An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome[NCT00101829] | Phase 1 | 12 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Randomized Phase II Dose Finding Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma[NCT00006890] | Phase 2 | 67 participants (Actual) | Interventional | 2000-07-12 | Completed | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients[NCT00396045] | Phase 1/Phase 2 | 54 participants | Interventional | 2005-01-31 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study[NCT01675141] | Phase 2 | 11 participants (Actual) | Interventional | 2012-08-20 | Terminated (stopped due to Original investigator left the NIH and the primary outcome was not reached) | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma[NCT02416206] | Phase 2 | 65 participants (Actual) | Interventional | 2015-04-27 | Completed | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study[NCT00002548] | Phase 3 | 899 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934] | Phase 3 | 400 participants | Interventional | 2002-01-31 | Completed | ||
| Comparative Study of Dexamethasone vs Prednisone (Both in Combination With Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma With an Additional Assessment of Dexamethasone vs no Additional Treatment as Maintenance Therapy in Non-Progressing[NCT00002678] | Phase 3 | 595 participants (Actual) | Interventional | 1995-06-02 | Completed | ||
| Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma[NCT00644306] | Phase 3 | 232 participants (Actual) | Interventional | 2002-04-30 | Terminated (stopped due to survival advantage demonstrated) | ||
| Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.[NCT00367185] | Phase 3 | 500 participants | Interventional | 2000-05-31 | Completed | ||
| Rituxan in the Management of Multiple Myeloma[NCT00003554] | Phase 2 | 0 participants | Interventional | 1998-11-30 | Completed | ||
| An Exploratory, Randomized, Double-blind, Parallel-group, Multicenter Study to Compare Secukinumab 300 mg With Placebo After 16 Weeks of Treatment in Adults With Moderate to Severe Plaque Psoriasis and Subclinical Enthesitis Measured by Musculoskeletal Ul[NCT04488185] | Phase 4 | 0 participants (Actual) | Interventional | 2020-11-02 | Withdrawn (stopped due to low recruitment) | ||
| A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.[NCT00391157] | Phase 2 | 40 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [NCT00222053] | Phase 3 | 800 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation.[NCT02791373] | Phase 2 | 136 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma[NCT01207765] | Phase 2 | 8 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to changes in practice) | ||
| Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).[NCT00430365] | Phase 3 | 614 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA[NCT00002630] | Phase 2 | 50 participants (Anticipated) | Interventional | 1993-06-30 | Completed | ||
| Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease[NCT01430039] | 42 participants (Actual) | Observational | 2011-10-31 | Completed | |||
| Pulse Dexamethasone in Focal Segmental Glomerulosclerosis[NCT00004990] | Phase 2 | 20 participants | Interventional | 2000-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR: participants with a confirmed response (PR or better) as time between first documentation of response and disease progression, IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase>=0.5 g/dL); Urine M-component (absolute increase>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase >10 mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%>=10%); Bone marrow PC's %: absolute%>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02195479)
Timeframe: Up to 2.4 years
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 21.3 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (>=) 50 percentage(%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, >=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was >=30%, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 73.9 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 90.9 |
Overall Survival (OS) was defined as the number of days the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method. (NCT02195479)
Timeframe: From randomization to death (up to approximately 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 24.4 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 42.6 |
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR). (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 6.2 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 22.3 |
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; <5% plasma cells (PCs) in bone marrow. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 9.3 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 20.3 |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response[sCR]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or >= 90% reduction in serum M-protein plus urine M-protein level less than (<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and < 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 49.7 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 71.1 |
PFS- duration from date of randomization to Progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum and urine M-component (absolute increase >=0.5 gram per deciliter [g/dL] and >=200 milligram [mg]/24 hours respectively); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase>10 mg/dL); Only participants without measurable serum and urine M-protein levels,without measurable disease by FLC levels,bone marrow Plasma cells (PC) %(absolute % >=10%);Bone marrow PC%: absolute% >10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to the PC proliferative disorder. (NCT02195479)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 18.14 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment. (NCT02195479)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum and urine M-component (absolute increase >=0.5 gram per deciliter [g/dL] and >=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase >10 milligram per deciliter [mg/dL]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % >=10%); Bone marrow PC %: absolute % >10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to the PC proliferative disorder. (NCT02195479)
Timeframe: From randomization to either disease progression or death due to PD whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 19.35 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Time to next treatment is defined as the time from randomization to the start of the next-line treatment. (NCT02195479)
Timeframe: Approximately up to 2.4 years
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: >=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to <200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, >=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was >=30%. (NCT02195479)
Timeframe: From randomization to first documented PR or better (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 0.82 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 0.79 |
"The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from 1-not at all to 4-very much to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values indicate deterioration in quality of life or functioning and positive values indicate improvement." (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 8.8 | 10.6 | 11.1 | 12.6 | 11.4 |
| Velcade, Melphalan and Prednisone (VMP) | 9.4 | 10.5 | 11.9 | 11 | 12.7 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm. (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 0.57 | 0.12 | 0.13 | 0.16 | 0.17 | 0.13 |
| Velcade, Melphalan and Prednisone (VMP) | 0.59 | 0.09 | 0.12 | 0.16 | 0.15 | 0.13 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 57.90 | 9.28 | 10.83 | 12.50 | 10.79 | 12.04 |
| Velcade, Melphalan and Prednisone (VMP) | 60.33 | 4.20 | 7.40 | 9.89 | 10.80 | 7.65 |
Percentage of participants with Best M- protein response of 100% reduction and >=90% to < 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC). (NCT02195479)
Timeframe: Approximately up to 2.4 years
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Best M-protein response in serum: 100% reduction | Best M-protein response in serum:>= 90 to < 100% | Best M-protein response in urine:100% reduction | Best M-protein response in urine:>=90 to < 100% | Best response in dFLC:100% reduction | Best response in dFLC: >=90% to < 100% reduction | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 58.5 | 15.2 | 90.5 | 7.1 | 0 | 100.0 |
| Velcade, Melphalan and Prednisone (VMP) | 38.7 | 14.6 | 69.4 | 13.9 | 0 | 77.8 |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 39.1 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 31.5 |
| Lenalidomide and Dexamethasone Rd18 | 21.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.1 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 35.0 |
| Lenalidomide and Dexamethasone Rd18 | 22.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.3 |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 59.1 |
| Lenalidomide and Dexamethasone Rd18 | 62.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 49.1 |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 36.7 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 26.0 |
| Lenalidomide and Dexamethasone Rd18 | 21.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.9 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 25.5 |
| Lenalidomide and Dexamethasone Rd18 | 20.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 70.0 |
| Lenalidomide and Dexamethasone Rd18 | 69.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 81.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of particpants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 74.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 60.5 |
| Lenalidomide and Dexamethasone Rd18 | 76.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 57.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 46.2 |
| Lenalidomide and Dexamethasone Rd18 | 53.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 45.7 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.7 |
| Lenalidomide and Dexamethasone Rd18 | 78.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 67.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 75.1 |
| Lenalidomide and Dexamethasone Rd18 | 73.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 62.3 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.9 | -3.3 | -8.6 | -6.4 | -5.1 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.3 | -5.9 | -9.8 | -7.3 | -8.1 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | -6.2 | -13.5 | -10.5 | -12.2 | -2.6 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.7 | 1.8 | 0.9 | -1.2 | -2.8 | -2.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.2 | -0.7 | -0.9 | -1.6 | -2.2 | -4.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.8 | -1.5 | -0.3 | -0.6 | -0.7 | -7.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 6.3 | 0.0 | -5.1 | -5.2 | -5.9 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 8.3 | 1.8 | -2.4 | -2.4 | -4.5 | -7.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 18.4 | 13.9 | 6.8 | 3.7 | 0.0 | -2.2 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.3 | 3.4 | 6.0 | 9.1 | 10.9 | 6.4 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 3.8 | 3.7 | 8.2 | 11.8 | 14.8 | 10.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.6 | -2.4 | -2.2 | -2.5 | -1.7 | -0.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.6 | -1.9 | -2.9 | -1.6 | 2.9 | 0.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.9 | -0.8 | -2.3 | -3.5 | -1.8 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.2 | 2.0 | 0.1 | -1.6 | 0.4 | 7.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 0.1 | 3.9 | 5.8 | 4.9 | 3.1 | 3.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.6 | 3.8 | 4.6 | 4.6 | 5.8 | 2.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 2.1 | 5.5 | 5.1 | 5.1 | -0.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.4 | -3.4 | -5.9 | -2.3 | 0.1 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.6 | -2.5 | -3.7 | -4.3 | -3.1 | 0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 | -1.8 | -4.5 | -3.9 | -4.3 | 2.7 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.3 | -0.4 | -0.3 | 1.6 | 1.8 | 0.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 1.9 | 1.4 | 0.4 | 2.0 | 1.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.5 | 1.9 | 0.7 | 1.1 | 0.4 | 5.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.2 | -1.3 | -1.9 | 1.1 | 1.4 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 0.2 | -1.2 | -1.0 | -0.5 | -5.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -10.5 | -8.9 | -11.6 | -9.6 | -6.0 | -4.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.5 | -2.5 | -4.0 | -3.6 | -2.7 | -4.2 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 | -1.1 | -1.3 | -2.2 | -2.3 | 0.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.0 | -1.2 | -3.9 | -3.9 | -3.9 | 1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.4 | -13.1 | -16.1 | -14.7 | -12.4 | -7.9 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -5.4 | -13.4 | -14.4 | -14.0 | -14.4 | -8.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | -7.8 | -12.1 | -13.4 | -14.3 | -14.7 | -6.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.4 | 4.7 | 7.6 | 7.4 | 6.8 | 3.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.7 | 3.4 | 4.7 | 5.0 | 6.9 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.9 | 2.2 | 5.3 | 6.9 | 8.3 | -0.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.6 | 6.3 | 8.6 | 9.4 | 9.1 | 3.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -2.7 | 2.4 | 6.3 | 7.8 | 8.0 | -0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | -2.4 | 4.1 | 8.2 | 11.8 | 14.5 | -1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -2.2 | 2.0 | 5.2 | 3.8 | 3.2 | 2.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.3 | 0.7 | 4.0 | 2.9 | 4.2 | -1.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.4 | 2.4 | 3.4 | 5.8 | 6.0 | -3.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Study discontinuation | |
| Lenalidomide and Dexamethasone Rd18 | -1.3 | 4.7 | 5.4 | 3.2 | 5.7 | 5.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.4 | 4.8 | 5.9 | 4.8 | 6.4 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 4.3 | 6.1 | 6.5 | 4.8 | 0.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.5 | 0.8 | 1.5 | -0.4 | -0.3 | 1.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.5 | -1.7 | -1.4 | -1.4 | -2.3 | -5.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.6 | -3.0 | -2.8 | -2.6 | -1.1 | -5.6 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.1 | -10.0 | -9.9 | -8.7 | -6.2 | -4.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.0 | -9.1 | -8.8 | -7.8 | -8.7 | -3.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | -4.4 | -7.0 | -7.9 | -6.5 | -7.9 | -3.7 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.9 | 9.2 | 12.3 | 12.1 | 11.7 | 8.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 4.7 | 8.5 | 9.8 | 10.8 | 12.7 | 5.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 3.3 | 6.3 | 8.0 | 10.0 | 9.5 | 3.2 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.0 | 1.2 | -0.4 | 1.2 | 2.3 | -1.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.5 | 1.0 | 1.7 | 1.9 | 2.2 | 0.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 5.6 | 3.5 | 2.9 | 4.7 | 4.3 | 3.8 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 adverse event (AE) | ≥ 1 grade (Gr) 3 or 4 AE | ≥ 1 grade (Gr) 5 AE | ≥ 1 serious adverse event (SAE) | ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | ≥ 1 AE related to Lenalidomide | ≥ 1 AE related to dexamethasone | ≥ 1 AE related to melphalan | ≥ 1 AE related to prednisone | ≥ 1 AE related to thalidomide | ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 grade 3 or 4 AE related to Lenalidomide | ≥ 1 grade 3 or 4 AE related to dexamethasone | ≥ 1 grade 3 or 4 AE related to melphalan | ≥ 1 grade 3 or 4 AE related to prednisone | ≥ 1 grade 3 or 4 AE related to Thalidomide | ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Lenalidomide | ≥ 1 Grade 5 AE related to Dexamethasone | ≥ 1 Grade 5 AE related to melphalan | ≥ 1 Grade 5 AE related to prednisone | ≥ 1 Grade 5 AE related to Thalidomide | ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | ≥1 SAE related to Len/Dex/Mel/Pred/Thal | ≥1 SAE related to Lenalidomide | ≥1 SAE related to dexamethasone | ≥1 SAE related to melphalan | ≥1 SAE related to prednisone | ≥1 SAE related to thalidomide | ≥1 SAE related to Len/Dex or Mel/Pred/Thal | ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | ≥1 AE leading to Lenalidomide withdrawal | ≥1 AE leading to dexamethasone withdrawal | ≥1 AE leading to melphalan withdrawal | ≥1 AE leading to prednisone withdrawal | ≥1 AE leading to Thalidomide withdrawal | ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | ≥1 AE leading to Lenalidomide reduction | ≥1 AE leading to dexamethasone reduction | ≥1 AE leading to melphalan reduction | ≥1 AE leading to prednisone reduction | ≥1 AE leading to thalidomide reduction | ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | ≥1 AE leading to Rd or MPT interruption | ≥1 AE leading to Lenalidomide interruption | ≥1 AE leading to dexamethasone interruption | ≥1 AE leading to melphalan interruption | ≥1 AE leading to prednisone interruption | ≥1 AE leading to Thalidomide interruption | ≥1 AE leading to Len and Dex or MPT interruption | |
| Lenalidomide and Dexamethasone Rd18 | 536 | 433 | 36 | 308 | 501 | 481 | 410 | 0 | 0 | 0 | 269 | 326 | 290 | 177 | 0 | 0 | 0 | 104 | 11 | 9 | 7 | 0 | 0 | 0 | 5 | 158 | 130 | 97 | 0 | 0 | 0 | 64 | 109 | 93 | 104 | 0 | 0 | 0 | 84 | 214 | 155 | 118 | 0 | 0 | 0 | 20 | 321 | 301 | 280 | 0 | 0 | 0 | 241 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 529 | 453 | 50 | 359 | 506 | 482 | 429 | 0 | 0 | 0 | 269 | 373 | 342 | 229 | 0 | 0 | 0 | 131 | 17 | 12 | 16 | 0 | 0 | 0 | 11 | 195 | 165 | 130 | 0 | 0 | 0 | 95 | 157 | 109 | 152 | 0 | 0 | 0 | 96 | 279 | 203 | 170 | 0 | 0 | 0 | 30 | 368 | 353 | 319 | 0 | 0 | 0 | 290 |
| Melphalan + Prednisone + Thalidomide (MPT) | 539 | 480 | 38 | 270 | 527 | 0 | 0 | 441 | 326 | 493 | 145 | 423 | 0 | 0 | 307 | 118 | 316 | 49 | 10 | 0 | 0 | 6 | 5 | 5 | 2 | 142 | 0 | 0 | 75 | 62 | 94 | 27 | 153 | 0 | 0 | 83 | 78 | 146 | 71 | 348 | 0 | 0 | 199 | 47 | 254 | 2 | 419 | 0 | 0 | 328 | 324 | 388 | 249 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline Grade | Grade 4 Baseline to Grade 1 postbaseline Grade | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline Grade to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 133 | 85 | 109 | 71 | 30 | 6 | 11 | 15 | 30 | 4 | 0 | 1 | 11 | 18 | 5 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 103 | 96 | 121 | 70 | 21 | 7 | 8 | 17 | 25 | 9 | 1 | 1 | 14 | 18 | 9 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 37 | 79 | 128 | 141 | 45 | 2 | 2 | 11 | 20 | 21 | 0 | 1 | 7 | 21 | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CrCl< 30 mL/min to CrCl< 30 mL/min | CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl< 30 mL/min to ≥ 80 mL/min | CrCl≥ 30 but < 50 mL/min to < 30 mL/min | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | CrCl ≥ 80 mL/min to CrCl< 30 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | |
| Lenalidomide and Dexamethasone Rd18 | 17 | 14 | 8 | 2 | 2 | 41 | 55 | 12 | 0 | 1 | 130 | 99 | 1 | 0 | 10 | 114 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 15 | 18 | 7 | 2 | 1 | 37 | 67 | 9 | 0 | 4 | 112 | 107 | 0 | 0 | 6 | 109 |
| Melphalan + Prednisone + Thalidomide (MPT) | 19 | 19 | 5 | 0 | 0 | 41 | 65 | 2 | 0 | 4 | 102 | 97 | 0 | 0 | 9 | 121 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade 1 Baseline to Grade 1 postbaseline | Grade1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline | Grade 4 Baseline to Grade 1 postbaseline | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 10 | 30 | 8 | 1 | 0 | 0 | 126 | 123 | 17 | 5 | 0 | 12 | 135 | 41 | 9 | 0 | 1 | 4 | 8 | 3 | 0 | 0 | 0 | 1 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 6 | 39 | 8 | 0 | 0 | 0 | 106 | 128 | 25 | 2 | 0 | 8 | 125 | 48 | 4 | 0 | 0 | 12 | 10 | 5 | 0 | 0 | 0 | 0 | 1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 9 | 25 | 4 | 1 | 0 | 0 | 110 | 123 | 20 | 4 | 0 | 14 | 133 | 47 | 11 | 0 | 0 | 10 | 10 | 2 | 0 | 0 | 1 | 0 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade1 Baseline to Normal postbaseline Grade | Grade 1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline Grade | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline Grade | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 197 | 211 | 30 | 12 | 5 | 3 | 38 | 19 | 12 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 197 | 216 | 24 | 15 | 4 | 1 | 34 | 15 | 10 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 165 | 208 | 27 | 31 | 11 | 6 | 51 | 7 | 10 | 1 | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 0 |
The 1-year PFS rate was defined as the percentage of participants surviving 1 year after randomization without disease progression or death. (NCT00911859)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 77.5 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 72.1 |
Percentage of participants who are alive at the end of year 1 after randomization (NCT00911859)
Timeframe: 1 year
| Intervention | Percentage of participants (Number) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 87.8 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 87.5 |
"Global health status/quality of life is a subscale of the EORTC QOL C30, which comprises two questions related to overall health/quality of life during the past week. The raw score to each question ranged from 1 (very poor) to 7 (excellent). The raw mean score of health status/quality of life subscale is calculated for each participant and a linear transformation applied to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher (better) health and quality of life." (NCT00911859)
Timeframe: Baseline (Day 1 predose) and Cycle 9 (Week 54)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 14.78 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 8.33 |
DOR was defined as length from the earliest date a participant achieved a complete response (CR) or partial response (PR) to either date for disease progression (including relapse from CR) or the censoring date for progressive disease. Responders without disease progression were censored at the last efficacy assessment for disease progression. (NCT00911859)
Timeframe: From the date participants achieved CR or PR to either date for disease progression (including relapse from CR) or the censoring date for progressive disease, as assessed Up to 30 days after last dose of study medication
| Intervention | Days (Median) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 497 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 583 |
Overall survival is defined as the time interval in days between the date of randomization and the participant's death from any cause. (NCT00911859)
Timeframe: From the date of randomization till the date of death, as assessed up to the end of study (approximately 3 years)
| Intervention | Days (Median) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | NA |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | NA |
CR was assessed using EMBT criteria: disappearance of the original monoclonal paraprotein from the blood and urine on at least 2 determinations for a minimum of 6 weeks by immunofixation studies, <5% plasma cells in the bone marrow on at least 1 determination, if skeletal survey is available: no increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response), disappearance of soft tissue plasmacytomas for at least 6 weeks. (NCT00911859)
Timeframe: Up to disease progression, approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 22.4 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 26.5 |
CR or PR was assessed using EBMT criteria. CR: disappearance of the original monoclonal paraprotein from the blood and urine on at least 2 determinations for a minimum of 6 weeks by immunofixation studies, <5% plasma cells in the bone marrow on at least 1 determination, if skeletal survey is available: no increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response), disappearance of soft tissue plasmacytomas for at least 6 weeks; PR: >=50% reduction in the level of serum monoclonal paraprotein for at least 2 determinations 6 weeks apart, if present, reduction in 24-hour urinary light chain excretion by either >=90% or to <200 mg for at least 2 determinations 6 weeks apart, >=50% reduction in the size of soft tissue plasmacytomas (by clinical or radiographic examination) for at least 6 weeks, if skeletal survey is available: no increase in size or number of lytic bone lesions (NCT00911859)
Timeframe: Up to disease progression, approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 79.6 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 87.8 |
sCR was assesses by IMWG Criteria: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, <=5% plasma cells in bone marrow, normal free light chain ratio, absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. sCR is a CR that has been confirmed by immunofixation + free light chain assay + either bone marrow immunohistochemistry or immunofluorescence (NCT00911859)
Timeframe: Up to disease progression, approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 6.1 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 4.1 |
PFS was defined as the time between randomization and either disease progression or death, whichever occurred first. (NCT00911859)
Timeframe: From the date of randomization until disease progression or death, whichever occurred first, as assessed up to the last efficacy assessment for disease progression (approximately 3 years)
| Intervention | Days (Median) |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 518 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 519 |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
A combined scale was used to assess the quality of life (QOL) comprising of the well established and validated functional well-being (FWB) and physical well-being (PWB) components of FACT-G version 4 (14 questions), which will address the physical and functional well-being of multiple myeloma patients plus the FACT-neurotoxicity (NTX, 11 questions), which will evaluate symptoms of neurotoxicity. This pooled scale is referred to as the FACT Ntx TOI. The FACT-Ntx TOI has 25 items and the score ranges from 0 (worst possible outcome) to 100 (best possible outcome). (NCT00602641)
Timeframe: Administered at registration, the beginning of cycle 7 d1, the end of cycle 12 d28, then at the end of cycle 18, 24, and 38 d28. For patients who discontinue treatment early, assessed at time of discontinuation and at the next quarterly follow-up visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (MPT-T) | -2.8 |
| Arm II (mPR-R) | 3.3 |
Overall survival was defined as time from randomization to death from any cause. (NCT00602641)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 10 years from the date of randomization.
| Intervention | months (Median) |
|---|---|
| Arm I (MPT-T) | 52.6 |
| Arm II (mPR-R) | 47.7 |
PFS is defined as the time from randomization to the earlier of progression or death of any cause. (NCT00602641)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 10 years from the date of randomization.
| Intervention | months (Median) |
|---|---|
| Arm I (MPT-T) | 21.0 |
| Arm II (mPR-R) | 18.7 |
Response evaluation was based on the International Myeloma Working Group (IMWG) response criteria. VGPR rate was defined as patients achieving at least VGPR which include patients who achieving complete response (CR) and VGPR. CR refers to patients who have complete disappearance of an M-protein and no evidence of myeloma in the bone marrow. VGPR refers to patients who meet the following criteria: Serum and urine M-component detectable by immunofixation but not on electrophoresis; Or 90% or greater reduction in serum M-component plus urine M-component <100 mg per 24 hours; If the serum and urine M protein are unmeasurable and the immunoglobulin free light chain parameter is being used to measure response, a ≥ 90% decrease in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M protein criteria. (NCT00602641)
Timeframe: Assessed every cycle (1 cycle=28 days) for the first 12 cycles, and then every 2 cycles while on treatment. Post treatment assessed every 3 months < 2 years from study entry, every 6 months if 2-5 years, every 12 months if 6-10 years from study entry.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (MPT-T) | 0.247 |
| Arm II (mPR-R) | 0.316 |
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
To assess Grade 3-5 AE related to thalidomide/dexamethasone when administered as a pre-transplant induction regimen. (NCT00040937)
Timeframe: Induction
| Intervention | Participants (Number) |
|---|---|
| Induction/PBSC Mobilization | 2 |
(NCT00040937)
Timeframe: 4-7 years
| Intervention | proportion surviving at 4 years (Number) |
|---|---|
| Treatment Arm | .64 |
Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients. (NCT00051311)
Timeframe: Up to cycle 3
| Intervention | Cycles (Median) |
|---|---|
| Recipient | 2 |
Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant
| Intervention | Days (Median) |
|---|---|
| Recipient | 14 |
Platelet recovery is defined as >50,000 mm3 platelet cell count after transfusion. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant
| Intervention | Days (Median) |
|---|---|
| Recipient | 13 |
Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy. (NCT00051311)
Timeframe: Day+100
| Intervention | Participants (Count of Participants) |
|---|---|
| Recipient | 29 |
Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)
| Intervention | Participants (Count of Participants) |
|---|---|
| Recipient | 23 |
Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence. (NCT00051311)
Timeframe: Date treatment consent signed to date off study, approximately 58 months and 13 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Recipient | 31 |
Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy. (NCT00051311)
Timeframe: Day+14
| Intervention | percentage of recipients (Number) |
|---|---|
| Recipient | 90 |
Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade I GVHD | Grade II GVHD | Grade III GVHD | Grade IV GVHD | |
| Recipient | 1 | 7 | 6 | 0 |
Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass > 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s). (NCT00051311)
Timeframe: At least 100 days after post reduced-intensity stem cell transplantation (RIST).
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete Remission or Complete Remission Unconfirmed | Progressive Disease | |
| Recipient | 15 | 16 |
Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) > 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells. (NCT00006184)
Timeframe: 105 days
| Intervention | Particpants (Number) |
|---|---|
| Recipient - Chemotherapy Group | 7 |
Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00006184)
Timeframe: 9 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Recipient - Chemotherapy Group | 10 |
| Donor - Vaccination Generation Group | 10 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00074490)
Timeframe: Date treatment consent signed to date off study, approximately 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | 1 |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | 27 |
| Arm IVA (12-day Expanded Th2 DLI) | 40 |
| Arm IVB (6-day Expanded Th2 DLI) | 44 |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | 42 |
T cells administered by intravenous infusion after patient received transplant. (NCT00074490)
Timeframe: first 100 days post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | 100 |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | 100 |
| Arm IVA (12-day Expanded Th2 DLI) | 100 |
| Arm IVB (6-day Expanded Th2 DLI) | 100 |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | 100 |
GVHD of the skin, liver and gut were graded on a scale of 1, 2, 3, and 4 (e.g. the grades are not added together) using the National Institutes of Health Consensus Criteria. Grade 1 is minimal GVHD, Grade 2 is moderate GVHD, Grade 3 is severe GVHD and Grade 4 is very severe GVHD. Grade 4 is a worse outcome than Grade 1. (NCT00074490)
Timeframe: first 100 days post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | 0 |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | 11.11 |
| Arm IVA (12-day Expanded Th2 DLI) | 10 |
| Arm IVB (6-day Expanded Th2 DLI) | 40.91 |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | 40.48 |
Participants are susceptible to opportunistic infections such as bacterial, fungal, viral, protozoan infections and more due to immune suppression from chemotherapy drugs used to treat their disease. (NCT00074490)
Timeframe: First 100 days post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Arm IVD Cohort 1 (Th2 DLI) | 0 |
| Arm IVD Cohort 3 (Multiple Th2 DLI) | 11.11 |
| Arm IVA (12-day Expanded Th2 DLI) | 7.50 |
| Arm IVB (6-day Expanded Th2 DLI) | 9.09 |
| Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus) | 11.90 |
"Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: Up to 149 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 121.6 |
| MPR+p | 56.1 |
| MPp+p | 55.4 |
Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00405756)
Timeframe: Up to 168 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 128.9 |
| MPR+p | 66.1 |
| MPp+p | 66.3 |
Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier. (NCT00405756)
Timeframe: up to 177 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | NA |
| MPR+p | NA |
| MPp+p | NA |
"Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: up to 165 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 136.1 |
| MPR+p | 62.1 |
| MPp+p | 56.1 |
"Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause.~PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: Approximately week 37 (start of cycle 10) to week 165
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 112.0 |
| MPR+p | 32.3 |
"Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry [EBMT/IBMTR/ABMTR] criteria.~PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia." (NCT00405756)
Timeframe: up to 165 weeks
| Intervention | weeks (Median) |
|---|---|
| MPR+R | 148.1 |
| MPR+p | 62.7 |
| MPp+p | 61.3 |
Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria. (NCT00405756)
Timeframe: Up to 66 weeks
| Intervention | weeks (Mean) |
|---|---|
| MPR+R | 10.0 |
| MPR+p | 9.3 |
| MPp+p | 16.2 |
Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,121,125) | Cycle 7 - approximately Month 7 (n=96,108,110) | Cycle 10 - approximately Month 10 (n=84,86,96) | Cycle 13 - approximately Month 13 (n=70,70,82) | Cycle 16 - approximately Month 16 (n=61,50,62) | |
| MPp+p | 6.1 | 4.2 | 6.2 | 5.4 | 8.1 |
| MPR+p | 5.6 | 8.1 | 8.8 | 8.8 | 7.2 |
| MPR+R | 2.3 | 8.0 | 12.4 | 7.6 | 10.7 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,125,130) | Cycle 7 - approximately Month 7 (n=99,111,111) | Cycle 10 - approximately Month 10 (n=87,93,96) | Cycle 13 - approximately Month 13 (n=75,72,83) | Cycle 16 - approximately Month 16 (n=64,52,63) | |
| MPp+p | -5.6 | -5.7 | -8.0 | -4.8 | -6.4 |
| MPR+p | 1.9 | -5.7 | -5.4 | -8.8 | -16.0 |
| MPR+R | 1.7 | -3.7 | -5.0 | -6.2 | -7.8 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | Cycle 7 - approximately Month 7 (n=98,111,113) | Cycle 10 - approximately Month 10 (n=87,92,97) | Cycle 13 - approximately Month 13 (n=73,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 1.3 | 0.7 | -2.7 | -1.4 | -4.0 |
| MPR+p | -2.0 | 0.1 | -4.4 | -3.0 | -3.5 |
| MPR+R | 0.3 | 2.9 | 1.0 | -0.0 | 0.3 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,124,128) | Cycle 7 - approximately Month 7 (n=96,111,112) | Cycle 10 - approximately Month 10 (n=86,93,97) | Cycle 13 - approximately Month 13 (n=73,73,81) | Cycle 16 - approximately Month 16 (n=63,51,62) | |
| MPp+p | -4.9 | -2.7 | -1.7 | -3.3 | -2.2 |
| MPR+p | 4.8 | 0.6 | -1.1 | -2.7 | -5.2 |
| MPR+R | -1.8 | -3.5 | -5.0 | -5.0 | -1.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,124) | Cycle 7 - approximately Month 7 (n=98,109,112) | Cycle 10 - approximately Month 10 (n=87,92,95) | Cycle 13 - approximately Month 13 (n=73,73,80) | Cycle 16 - approximately Month 16 (n=63,52,61) | |
| MPp+p | 3.2 | 0.9 | -0.0 | 0.8 | 0.5 |
| MPR+p | 1.9 | -1.2 | 1.4 | -1.4 | 1.3 |
| MPR+R | 2.3 | 3.4 | 1.1 | 5.5 | 10.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=117,126,126) | Cycle 7 - approximately Month 7 (n=100,110,110) | Cycle 10 - approximately Month 10 (n=86,93,96) | Cycle 13 - approximately Month 13 (n=73,73,81) | Cycle 16 - approximately Month 16 (n=62,53,62) | |
| MPp+p | -0.0 | 2.1 | 3.8 | -0.0 | 1.6 |
| MPR+p | -6.4 | -8.5 | -4.3 | -2.3 | -6.3 |
| MPR+R | -2.6 | -1.7 | -4.3 | -5.0 | -3.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | Cycle 7 - approximately Month 7 (n=98,111,112) | Cycle 10 - approximately Month 10 (n=86,92,97) | Cycle 13 - approximately Month 13 (n=73,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 6.8 | 5.0 | 4.7 | 6.6 | 6.9 |
| MPR+p | 2.7 | 4.2 | 1.6 | 1.1 | -0.2 |
| MPR+R | 4.8 | 8.8 | 9.0 | 8.2 | 9.9 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | Cycle 7 - approximately Month 7 (n=100,112,110) | Cycle 10 - approximately Month 10 (n=87,95,95) | Cycle 13 - approximately Month 13 (n=74,74,82) | Cycle 16 - approximately Month 16 (n=64,53,62) | |
| MPp+p | -5.1 | -5.7 | -6.9 | -7.5 | -4.1 |
| MPR+p | -5.5 | -9.5 | -7.5 | -10.7 | -9.7 |
| MPR+R | -3.0 | -7.6 | -7.5 | -7.1 | -10.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=111,123,125) | Cycle 7 - approximately Month 7 (n=94,111,112) | Cycle 10 - approximately Month 10 (n=84,92,97) | Cycle 13 - approximately Month 13 (n=70,72,83) | Cycle 16 - approximately Month 16 (n=61,52,63) | |
| MPp+p | -2.9 | -2.1 | -1.7 | -4.0 | -5.3 |
| MPR+p | -1.1 | -0.6 | 0.7 | -0.5 | -0.6 |
| MPR+R | 2.4 | 2.1 | 6.0 | 4.8 | 1.6 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=118,124,128) | Cycle 7 - approximately Month 7 (n=100,109,111) | Cycle 10 - approximately Month 10 (n=87,94,96) | Cycle 13 - approximately Month 13 (n=75,73,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | -5.0 | -5.7 | -1.7 | -6.8 | -3.7 |
| MPR+p | -1.6 | -6.4 | -2.5 | 0.9 | -0.6 |
| MPR+R | 2.0 | -1.0 | -5.0 | -4.9 | -4.7 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | Cycle 7 - approximately Month 7 (n=99,112,112) | Cycle 10 - approximately Month 10 (n=87,95,97) | Cycle 13 - approximately Month 13 (n=75,72,83) | Cycle 16 - approximately Month 16 (n=64,52,62) | |
| MPp+p | -0.0 | 0.7 | 0.3 | -0.4 | -1.3 |
| MPR+p | -1.3 | -0.7 | -1.4 | -3.0 | -4.2 |
| MPR+R | 3.3 | 0.5 | 1.9 | 0.7 | 1.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | Cycle 7 - approximately Month 7 (n=100,112,113) | Cycle 10 - approximately Month 10 (n=88,95,97) | Cycle 13 - approximately Month 13 (n=74,74,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | -13.4 | -11.5 | -9.8 | -12.1 | -12.2 |
| MPR+p | -13.8 | -16.5 | -15.6 | -14.9 | -11.0 |
| MPR+R | -14.4 | -17.8 | -17.2 | -13.7 | -20.3 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | Cycle 7 - approximately Month 7 (n=100,112,112) | Cycle 10 - approximately Month 10 (n=88,95,96) | Cycle 13 - approximately Month 13 (n=75,74,83) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | 4.5 | 2.7 | 5.1 | 3.3 | 1.1 |
| MPR+p | 3.3 | 8.1 | 8.5 | 9.7 | 7.6 |
| MPR+R | 1.9 | 8.2 | 8.9 | 8.6 | 10.0 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,127,130) | Cycle 7 - approximately Month 7 (n=99,112,113) | Cycle 10 - approximately Month 10 (n=86,95,95) | Cycle 13 - approximately Month 13 (n=74,74,82) | Cycle 16 - approximately Month 16 (n=64,53,63) | |
| MPp+p | 7.4 | 6.9 | 5.6 | 5.7 | 7.1 |
| MPR+p | 3.0 | 8.0 | 7.5 | 11.7 | 8.5 |
| MPR+R | 1.8 | 5.7 | 9.3 | 9.7 | 12.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,127) | Cycle 7 - approximately Month 7 (n=98,111,112) | Cycle 10 - approximately Month 10 (n=87,92,97) | Cycle 13 - approximately Month 13 (n=72,73,83) | Cycle 16 - approximately Month 16 (n=63,52,63) | |
| MPp+p | 6.0 | 6.1 | 4.1 | 6.2 | 9.8 |
| MPR+p | 0.3 | 4.4 | 4.5 | 7.5 | 6.1 |
| MPR+R | 5.1 | 8.3 | 10.9 | 11.8 | 13.2 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,121,127) | Cycle 7 - approximately Month 7 (n=96,109,112) | Cycle 10 - approximately Month 10 (n=85,91,95) | Cycle 13 - approximately Month 13 (n=72,73,82) | Cycle 16 - approximately Month 16 (n=62,51,62) | |
| MPp+p | -5.4 | -6.0 | -5.4 | -6.3 | -3.3 |
| MPR+p | -8.7 | -9.7 | -7.1 | -8.8 | -5.9 |
| MPR+R | -8.9 | -9.0 | -7.9 | -7.2 | -10.5 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=110,117,119) | Cycle 7 - approximately Month 7 (n=88,104,108) | Cycle 10 - approximately Month 10 (n=79,83,94) | Cycle 13 - approximately Month 13 (n=68,72,79) | Cycle 16 - approximately Month 16 (n=59,52,61) | |
| MPp+p | 4.5 | 5.2 | 3.9 | 5.1 | 2.7 |
| MPR+p | -0.3 | 2.6 | -4.0 | -0.5 | 6.4 |
| MPR+R | 2.1 | 3.8 | 7.6 | 1.0 | 3.4 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=112,121,124) | Cycle 7 - approximately Month 7 (n=93,108,112) | Cycle 10 - approximately Month 10 (n=83,88,97) | Cycle 13 - approximately Month 13 (n=71,73,81) | Cycle 16 - approximately Month 16 (n=62,52,62) | |
| MPp+p | 7.6 | 9.8 | 14.5 | 11.9 | 14.4 |
| MPR+p | 4.3 | 7.7 | 6.6 | 6.3 | 7.7 |
| MPR+R | 4.7 | 14.6 | 17.3 | 17.3 | 18.5 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology. (NCT00405756)
Timeframe: Baseline (Day 0), Months 4, 7, 10, 13, 16
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,120,125) | Cycle 7 - approximately Month 7 (n=95,108,111) | Cycle 10 - approximately Month 10 (n=85,89,94) | Cycle 13 - approximately Month 13 (n=72,72,81) | Cycle 16 - approximately Month 16 (n=62,50,61) | |
| MPp+p | 0.6 | 1.8 | 0.3 | 0.3 | -0.9 |
| MPR+p | 0.1 | -1.7 | 0.0 | -1.0 | -2.9 |
| MPR+R | 1.3 | 0.4 | -1.6 | -3.8 | -2.1 |
Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus >=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE). (NCT00405756)
Timeframe: Up to 165 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) | Response not evaluable (NE) | |
| MPp+p | 5 | 72 | 70 | 0 | 7 |
| MPR+p | 5 | 99 | 40 | 2 | 7 |
| MPR+R | 15 | 102 | 28 | 0 | 7 |
Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption. (NCT00405756)
Timeframe: Up to 169 weeks (Double-blind therapy period plus 4 weeks)
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=1 adverse event (AE) | >=1 CTCAE grade 3-4 AE | >=1 CTCAE grade 5 AE | >=1 serious AE (SAE) | >=1 AE related to Lenaldomide/Placebo | >=1 AE related to Melphalan | >=1AE related to Prednisone | >=1 Grade 3-4 AE related to Lenaldomide/Placebo | >=1 Grade 3-4 AE related to Melphalan | >=1 Grade 3-4 AE related to Prednisone | >=1 Grade 5 AE related to Lenalidomide/Placebo | >=1 Grade 5 AE related to Melphalan | >=1 Grade 5 AE related to Prednisone | >=1 SAE related to Lenalidomide/Placebo | >=1 SAE related to Melphalan | >=1 SAE related to Prednisone | >=1 AE leading to Lenalidomide/Placebo withdrawal | >=1 AE leading to Melphalan withdrawal | >=1 AE leading to Prednisone withdrawal | >=1 AE leading to Lenalidomide/Plac dose reduction | >=1 AE leading to Melphalan dose reduction | >=1 AE leading to Prednisone dose reduction | >=1 AE leading to Lenalidomide/Plac dose interrupt | >=1 AE leading to Melphalan dose interruption | >=1 AE leading to Prednisone dose interruption | |
| MPp+p | 153 | 107 | 7 | 56 | 131 | 126 | 93 | 68 | 62 | 22 | 2 | 3 | 1 | 11 | 11 | 5 | 14 | 10 | 10 | 26 | 21 | 5 | 51 | 0 | 15 |
| MPR+p | 151 | 129 | 6 | 62 | 145 | 134 | 94 | 117 | 110 | 29 | 2 | 1 | 1 | 32 | 24 | 16 | 24 | 19 | 19 | 70 | 58 | 7 | 82 | 1 | 39 |
| MPR+R | 150 | 137 | 7 | 66 | 148 | 140 | 87 | 128 | 118 | 32 | 3 | 3 | 1 | 38 | 27 | 19 | 26 | 20 | 20 | 71 | 47 | 15 | 92 | 5 | 28 |
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
Duration of response is defined as time from response to disease progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Here is the number of serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01675141)
Timeframe: 37 months and 12 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | 11 |
PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 28 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 60 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 37 |
Number of days from stem cell infusion (day +0) to day of neutrophil engraftment (first of three consecutive days with absolute neutrophil count > 500) (NCT01207765)
Timeframe: Transplant through day 42
| Intervention | Days (Median) |
|---|---|
| Zevalin | 13 |
Efficacy: objective response rate (CR + PR) at 12 and 104 days following radioimmunotherapy. Safety: the rate of occurrence of defined toxic events including non-engraftment and unacceptable biodistribution of 90Y Zevalin occurring by day +42 following transplant. Response determined according to Blade' Criteria (Bladé J, Br J Haematol.1998 Sep;102(5):1115-23) for multiple myeloma; Response based on reduction of monoclonal protein (M-protein) from initial presentation. (NCT01207765)
Timeframe: Through day +104 following immunotherapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| CR/PR at +12 days | CR/PR at +104 days | Participants with toxic events | |
| Zevalin | 1 | 5 | 5 |
110 reviews available for prednisone and Multiple Myeloma
| Article | Year |
|---|---|
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 | 2021 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenali | 2022 |
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2020 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans | 2017 |
Fixed duration vs continuous therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free | 2017 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2019 |
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2019 |
Persistent Mild Anemia and Hypercalcemia were Ignored as Normal Reaction Secondary to Oral Calcium Supplementation in a Steroid-Dependent Asthma Patient Ultimately Diagnosed as Multiple Myeloma: a Case Report and Literature Review.
Topics: Aged; Anemia; Asthma; Calcium; Diagnosis, Differential; Dietary Supplements; Glucocorticoids; Humans | 2019 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; | 2014 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction C | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2015 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematolog | 2015 |
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2016 |
Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Th | 2016 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Fr | 2008 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide | 2010 |
Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma.
Topics: Anticonvulsants; Cyclophosphamide; Epilepsy; Humans; Immunosuppressive Agents; Lymphohistiocytosis, | 2011 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
Multiple myeloma in the elderly: when to treat, when to go to transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transpl | 2010 |
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle A | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; D | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose | 2011 |
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Hum | 2011 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2012 |
Evolving therapeutic paradigms for multiple myeloma: back to the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Glucocorticoids; Humans; | 2013 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2012 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2003 |
Pharmacotherapy of multiple myeloma: an economic perspective.
Topics: Aged; Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Humans; Melphalan; Middle Aged | 2003 |
[An autopsy case of the hepatocellular carcinoma associated with multiple myeloma which developed fatal massive hemolysis due to the Clostridium perfringens septicemia following TAE].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clostridi | 2003 |
[Malignant lymphoma, multiple myeloma and myeloproliferative diseases in the elderly].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2004 |
Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
Topics: Aged; Amyloidosis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; C | 2005 |
Multiple myeloma: diagnosis and treatment.
Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexametha | 2005 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Int | 2006 |
[Hematological malignancies].
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2007 |
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cli | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2004 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; | 2007 |
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Top | 2007 |
The hematologic malignancies. Leukemia, lymphoma, and myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxor | 1984 |
Kidney involvement in multiple myeloma and related disorders.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amyloidosis; Bence Jones Protein; Cyclophosphamide; Fe | 1982 |
[Chemotherapy of multiple myeloma. Review of the recent trials].
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combi | 1981 |
Interferon in multiple myeloma--does it pay?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1995 |
[Diagnosis and therapy of multiple myeloma: current aspects].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Diagnosis, Differ | 1995 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubi | 1994 |
Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Diffe | 1994 |
Haematopoietic stem-cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 1996 |
Hematopoietic stem cell transplants for multiple myeloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1996 |
Diagnosis, prognosis, and standard treatment of multiple myeloma.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating | 1997 |
[Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Dexam | 1997 |
[Therapy of multiple myeloma].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 1997 |
[Progress in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cytarabine; | 1997 |
Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: Multiple myeloma and Waldenström's macroglobulinemia.
Topics: Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Diagnosis, Differential; | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Treatment of multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplanta | 1999 |
Therapeutic strategies and controversies in the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Drug | 1999 |
Breast metastasis from multiple myeloma: report of a case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatal Outcome; Female; Humans; Mel | 1998 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1999 |
Maintenance therapy and supportive care for patients with multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; In | 1999 |
Myeloma-associated systemic amyloidosis presenting as chronic paronychia and palmodigital erythematous swelling and induration of the hands.
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Chronic Disease; Drug Therapy, Combination; Erythema | 2000 |
Autologous and allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Graft vs Tumor Effect; He | 2000 |
Multiple myeloma in elderly patients: presenting features and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Comorbidity | 2001 |
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Humans; Melph | 2001 |
[Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Diphosphonates; Geri | 2001 |
Management of patients with multiple myeloma: emphasizing the role of high-dose therapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2001 |
Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 2001 |
Multiple myeloma in association with sarcoidosis.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Cells; Drug Therapy, Combination; Female; Granuloma; | 2002 |
Treatment of myeloma: recent developments.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2002 |
[Treatment of Kahler's disease].
Topics: Bone Neoplasms; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple | 1976 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; | 1977 |
Pulmonary histopathologic changes associated with melphalan therapy.
Topics: Aged; Drug Therapy, Combination; Epithelium; Humans; Lung; Male; Melphalan; Middle Aged; Multiple My | 1978 |
[Recent progress in chemotherapy of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; | 1978 |
Current concepts in cancer. Multiple myeloma.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobul | 1979 |
The treatment of plasma cell myeloma.
Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Me | 1976 |
Neutrophil migration in health and disease.
Topics: Adult; Age Factors; Anemia, Aplastic; Antigens, Bacterial; Cell Movement; Child; Dexamethasone; Eosi | 1975 |
Multiple myeloma. New treatment options.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1992 |
Meta-analysis of chemotherapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Meta-Analysis as Topic; Multiple | 1992 |
[Recent biological and therapeutic advances in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Interferon-alph | 1992 |
Ten-year survival in multiple myeloma: report of two cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Male; Melphalan; Middle A | 1992 |
Myeloma, melphalan, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Meta-Analysis as Topic; Multiple | 1992 |
Standard chemotherapy for myelomatosis: an area of great controversy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone; Pro | 1992 |
[Multiple myeloma. Biological, prognostic, and therapeutic aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Comb | 1990 |
[Chemotherapy of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Eval | 1991 |
[Polyneuropathy associated with osteosclerotic myeloma. Excellent response to chemotherapy].
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Nervous System D | 1990 |
[Therapy of multiple myeloma and its complications].
Topics: Acute Kidney Injury; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1990 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast | 1986 |
Diagnosis and management of multiple myeloma and related disorders.
Topics: Alkylating Agents; Amyloidosis; Anemia; Anemia, Refractory; Animals; Antibodies, Monoclonal; Antineo | 1986 |
Interferons in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Clinical Trials as Topic; Cyclophosp | 1986 |
Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone; Pro | 1989 |
[Recent progress in the treatment of hematological malignancies. V. Therapy of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1989 |
Melphalan/prednisone versus drug combinations for plasma cell myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1989 |
[Possibility of using interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; | 1988 |
[Value of protocols of alternating chemotherapy versus melphalan-prednisone during the induction phase of stage III myelomas. Critical review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Melphalan; Mul | 1987 |
Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; | 1986 |
Multiple myeloma: current therapy and a glimpse of the future.
Topics: Acute Kidney Injury; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 1985 |
Adrenal steroids in the treatment of malignant hematologic disease.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Antineoplastic Agents; Glucocorticoids; Hodgkin Disease; | 1973 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
Steroid therapy of multiple myeloma and macroglobulinemia.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic, Autoimmune; Blood U | 1973 |
Plasma cell myeloma. An interpretive review.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; Drug Re | 1972 |
Amyloid joint disease.
Topics: Adult; Alkylating Agents; Amyloidosis; Arthritis; Arthritis, Rheumatoid; Bence Jones Protein; Blood | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Drug Therapy, Combination; Femal | 1974 |
271 trials available for prednisone and Multiple Myeloma
| Article | Year |
|---|---|
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2020 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; P | 2020 |
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; | 2020 |
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Dise | 2020 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Hu | 2020 |
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Pr | 2021 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2017 |
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Resistan | 2017 |
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2017 |
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dis | 2018 |
Daratumumab for untreated multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Confidence Inter | 2018 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mel | 2020 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mel | 2020 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mel | 2020 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mel | 2020 |
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bayes Theorem; Drug Therapy, Combina | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2014 |
Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor | 2014 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Diseas | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2014 |
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fe | 2015 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Comb | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Combined Modality The | 2015 |
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relat | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; De | 2015 |
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Monitorin | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomid | 2015 |
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Female; F | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Surviv | 2015 |
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cycl | 2015 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethaso | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosph | 2015 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexameth | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemothera | 2016 |
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2016 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Surviv | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocortic | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; | 2008 |
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relations | 2009 |
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death | 2009 |
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
Topics: Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transpla | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 2010 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dis | 2009 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuv | 2010 |
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Melphalan; | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Fema | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug R | 2010 |
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Mel | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie | 2010 |
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kap | 2010 |
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Hu | 2010 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Stu | 2011 |
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Doxorub | 2011 |
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2011 |
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Glucocorticoids; Humans; Immunos | 2011 |
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects a | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular | 2011 |
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose | 2012 |
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
[Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Be | 2012 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomid | 2013 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv | 2013 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Len | 2013 |
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor | 2013 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemother | 2013 |
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Topics: Academies and Institutes; Antineoplastic Combined Chemotherapy Protocols; Canada; Female; Hematopoie | 2013 |
Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2002 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fe | 2002 |
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Drug Evaluatio | 2003 |
Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cost-Benefit Analysis; | 2003 |
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2004 |
Early response to therapy and survival in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immu | 2004 |
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Foll | 2004 |
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2004 |
Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 2005 |
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Aged; Antigens, CD; Antineoplastic Agents; Antineoplasti | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; | 2006 |
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr | 2005 |
Sequential, cycling maintenance therapy for post transplant multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2006 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose- | 2005 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 2006 |
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2006 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2006 |
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxo | 2006 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Toleran | 2007 |
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2007 |
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationsh | 2007 |
A new standard of care for elderly patients with myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Hum | 2007 |
Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Topics: Adult; Age Factors; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Comb | 1983 |
Chemotherapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1984 |
The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Topics: Adjuvants, Immunologic; Aziridines; Azirines; Clinical Trials as Topic; Cyclophosphamide; Double-Bli | 1984 |
A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Clinical Trials as Topic; Cyclophosp | 1984 |
Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Immu | 1984 |
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1984 |
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium Gluconate; Carmustine; Clini | 1984 |
[Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; | 1984 |
Peptichemio in multiple myeloma. (Preliminary results).
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Melphalan; M | 1981 |
Chemotherapy of plasma-cell myeloma.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan | 1980 |
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1980 |
Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hemo | 1980 |
Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studi | 1980 |
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug The | 1981 |
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Clinical Trials as | 1982 |
Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1982 |
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials a | 1982 |
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap | 1982 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferons; Male; Melphalan; | 1994 |
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined | 1995 |
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Humans; Interferon-alpha; Melpha | 1995 |
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1995 |
Development of a criterion for response to therapy at 6 months in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; D | 1995 |
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Chi-Square Distribution; Combined Moda | 1995 |
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1995 |
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female | 1995 |
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Combined Mo | 1995 |
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; | 1994 |
VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1994 |
Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etanidazole; Humans; Infusions, Intravenous; Melphal | 1994 |
An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 1994 |
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Inte | 1993 |
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1993 |
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon-a | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 1996 |
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1996 |
Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon alpha-2; Interferon | 1996 |
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Carmustine; Cohort Studies; Cyclophosp | 1996 |
A prognostic index for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Disease-Free Survival; Female; Follow-Up Studies; Humans; | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1996 |
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Feeding a | 1996 |
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 1996 |
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; C | 1996 |
Oral idarubicin and prednisone for advanced, previously untreated, multiple myeloma: a pilot study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Drug Thera | 1996 |
Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethason | 1996 |
Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclo | 1996 |
A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Melphalan; Mi | 1997 |
Standard therapy versus autologous transplantation in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Improved outcome in solitary bone plasmacytomata with combined therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chem | 1996 |
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Forecasti | 1997 |
Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1997 |
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hum | 1998 |
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hum | 1998 |
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hum | 1998 |
Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hum | 1998 |
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosph | 1998 |
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease P | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1998 |
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1998 |
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ca | 1999 |
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
Topics: Aged; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Interferon-alpha; Male; Melphalan; M | 1997 |
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG).
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Huma | 1999 |
Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cyc | 1999 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Disea | 1999 |
Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Topics: Biomarkers; Disease-Free Survival; Humans; Interferon-alpha; Melphalan; Membrane Glycoproteins; Mult | 2000 |
Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1999 |
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2000 |
Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Health Status; | 2000 |
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2001 |
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
Topics: Cost-Benefit Analysis; Female; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; M | 2001 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2000 |
Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.
Topics: Administration, Oral; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cy | 2001 |
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Dose-R | 2001 |
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2002 |
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2002 |
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2002 |
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2002 |
Thromboembolic events during treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2002 |
Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Alkylating Agents; Clinical Trials as Topic; Drug Resistance; Dru | 1977 |
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melp | 1979 |
Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Topics: Carmustine; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multipl | 1979 |
The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combinati | 1979 |
Combination therapy for multiple myeloma.
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combin | 1977 |
Nitrosoureas in multiple myeloma.
Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human | 1976 |
Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.
Topics: Bone and Bones; Bone Diseases; Calcium Carbonate; Clinical Trials as Topic; Fluorides; Humans; Melph | 1975 |
Remission maintenance therapy for multiple myeloma.
Topics: Bone Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; | 1975 |
Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.
Topics: Azathioprine; Blood Urea Nitrogen; Bone Neoplasms; Chlorambucil; Drug Therapy, Combination; Fluoxyme | 1975 |
Sequential therapy compared with combination therapy in multiple myeloma.
Topics: Autoradiography; Bence Jones Protein; Bone Neoplasms; Cell Count; Drug Therapy, Combination; Humans; | 1975 |
Prognostic factors in multiple myeloma.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Immunoglobulins; Male; Melph | 1975 |
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Pr | 1975 |
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 1992 |
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 1992 |
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 1992 |
Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 1992 |
Intensive combined therapy for previously untreated aggressive myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality | 1992 |
Intensive combined therapy for previously untreated aggressive myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality | 1992 |
Intensive combined therapy for previously untreated aggressive myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality | 1992 |
Intensive combined therapy for previously untreated aggressive myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality | 1992 |
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Dru | 1992 |
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexametha | 1992 |
Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1991 |
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1991 |
Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Interferon-alpha; | 1991 |
[Therapeutic plasmapheresis in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1991 |
[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubic | 1991 |
[Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Treatment of multiple myeloma with interferon alpha: the Scandinavian experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Interferon-alpha; | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorub | 1991 |
Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; | 1991 |
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Calcium; Cyclopho | 1991 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dexamethasone | 1990 |
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Carmustine; | 1990 |
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1990 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Foll | 1990 |
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Admi | 1990 |
Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Topics: Actuarial Analysis; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Ch | 1990 |
A phase II study of idarubicin and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Idarubicin; Male; M | 1990 |
Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon alpha-2; Int | 1990 |
Oral melphalan pharmacokinetics: influence of interferon-induced fever.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Drug Interactions; Female; F | 1990 |
Interferons in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Clinical Trials as Topic; Cyclophosp | 1986 |
VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Moda | 1989 |
Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 1989 |
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical | 1989 |
Melphalan/prednisone versus drug combinations for plasma cell myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1989 |
Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon Type I; Melphalan; Multicenter St | 1989 |
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Cycle; Cyclophosphamid | 1989 |
Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; H | 1988 |
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Drug Administr | 1988 |
Treatment of multiple myeloma: an Argentine Group for the Treatment of Acute Leukemia Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Clinical Trials as Topic; Cyclophosphamid | 1988 |
[Possibility of using interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; | 1988 |
Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, | 1987 |
Multiple myeloma in Korea--clinical analysis and treatment results in 61 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; | 1987 |
Melphalan and prednisone plus total bone marrow irradiation as initial treatment for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; | 1988 |
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Male; Melp | 1988 |
[Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Humans; Melphalan | 1988 |
An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Melphalan; Multipl | 1988 |
The use of interferon in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1987 |
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Carmustine; Clinical Trials as Topic; | 1986 |
Results and further perspectives of plasmocytoma chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trial | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1986 |
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1987 |
Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multip | 1986 |
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Melph | 1985 |
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trial | 1985 |
Treatment of multiple myeloma: a randomized study of three different regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as | 1985 |
Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
[Interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Response rate and survival in myeloma patients receiving prednisone alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Male; Melphalan; Middle | 1985 |
Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma.
Topics: Aged; Bence Jones Protein; Cyclophosphamide; Diuresis; Female; Follow-Up Studies; Humans; Kidney Fai | 1985 |
Hormone therapy for malignant myeloma.
Topics: Androgens; Cyclophosphamide; Hemoglobinometry; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Pre | 1973 |
Therapy of macroglobulinaemia. Comparison of the effect of therapy on the level of monoclonal immunoglobulins and on clinical symptoms in four cases of waldenström's macroglobulinaemia and one case of IgA myeloma.
Topics: Agar; Aged; Alkylating Agents; Anemia, Hemolytic; Blood Coagulation Disorders; Blood Protein Disorde | 1969 |
[Therapeutic experiences in multiple myeloma].
Topics: Aniline Compounds; Antineoplastic Agents; Blood Sedimentation; Carmustine; Clinical Trials as Topic; | 1972 |
Evaluation of aniline mustard in patients with multiple myeloma.
Topics: Adult; Aged; Aniline Compounds; Female; Hematocrit; Humans; Leukocyte Count; Leukopenia; Male; Middl | 1973 |
Combination chemotherapy for multiple myeloma.
Topics: Antineoplastic Agents; Benzoates; Drug Combinations; Evaluation Studies as Topic; Humans; Immunoglob | 1972 |
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M | 1969 |
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M | 1969 |
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M | 1969 |
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; M | 1969 |
538 other studies available for prednisone and Multiple Myeloma
| Article | Year |
|---|---|
Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2022 |
Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital.
Topics: Adult; Aged; Bortezomib; Dexamethasone; Diabetes Mellitus, Type 2; Female; Humans; Immunoglobulin G; | 2022 |
[BILATERAL OCULAR PLASMACYTOMA PRESENTING AS ACUTE ANTERIOR UVEITIS].
Topics: Female; Glaucoma; Humans; Middle Aged; Multiple Myeloma; Plasmacytoma; Prednisone; Uveitis, Anterior | 2022 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pre | 2023 |
Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.
Topics: Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Melphalan; Multiple Myeloma; Poland; P | 2023 |
Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.
Topics: Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Melphalan; Multiple Myeloma; Poland; P | 2023 |
Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.
Topics: Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Melphalan; Multiple Myeloma; Poland; P | 2023 |
Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.
Topics: Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Melphalan; Multiple Myeloma; Poland; P | 2023 |
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Mel | 2023 |
Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; H | 2020 |
Quadruplets come of age for newly diagnosed multiple myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
ALCYONE - lighting the way for quadruplet therapy of NDMM.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
Non-transplant eligible multiple myeloma: deciphering optimal first line regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; | 2020 |
[Expression of Blimp1、ATF4 and CHOP in Multiple Myeloma Cells and Effect of Aspirin on Their Expression].
Topics: Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspiri | 2020 |
Bortezomib use and outcomes for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Bortezomib; Humans; Melphalan; Mult | 2020 |
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agent | 2021 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; | 2020 |
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antine | 2021 |
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2021 |
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Cost-Bene | 2021 |
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor | 2021 |
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bortezomib; D | 2017 |
[Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016].
Topics: Aged; Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Female; Health Ser | 2017 |
Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hu | 2018 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; | 2018 |
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progres | 2019 |
Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; | 2019 |
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Human | 2019 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome A | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphal | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
[Current technologies in radiotherapy for non-Hodgkin lymphomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2013 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2013 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2013 |
Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.
Topics: Adult; Cost-Benefit Analysis; Female; Humans; Italy; Male; Melphalan; Middle Aged; Multiple Myeloma; | 2013 |
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melph | 2014 |
"A fortuitous combination of circumstances".
Topics: Cyclophosphamide; Female; Humans; Male; Multiple Myeloma; Prednisone; Thalidomide | 2013 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Huma | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bor | 2014 |
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, | 2015 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecu | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrati | 2015 |
[Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Heart Failure; | 2015 |
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Ma | 2015 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia | 2015 |
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2015 |
The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplas | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezom | 2015 |
Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antigens, CD34; Apoptosis; ATP Binding Cas | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethaso | 2016 |
Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 2015 |
Continued role for ASCT in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Hum | 2015 |
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bon | 2016 |
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoi | 2016 |
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; | 2016 |
Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclopho | 2016 |
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Fema | 2017 |
Bilateral Osteonecrosis of the Femoral and Humeral Heads after Short Term Corticosteroid Therapy. A Case Study.
Topics: Femur Head Necrosis; Humans; Humerus; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle A | 2016 |
Percutaneous vertebroplasty in multiple myeloma vertebral involvement.
Topics: Aged; Aged, 80 and over; Back Pain; Bone Cements; Female; Humans; Lumbar Vertebrae; Male; Middle Age | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Huma | 2008 |
Erythrophagocytic multiple myeloma in a cat.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Male; Melphalan; Multiple Myeloma; Prednisone | 2008 |
Non-secretory myeloma: a rare variant of multiple myeloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Glucocorticoids; Humans; Male; Melphalan; Multiple Myeloma | 2008 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamet | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Le | 2008 |
New evidence in oncologic and cardiocirculatory medicine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic A | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multip | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2008 |
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglo | 2009 |
Erythema multiforme-like presentation of chronic graft versus host disease.
Topics: Erythema Multiforme; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; M | 2008 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2009 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2009 |
Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Eu | 2009 |
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2009 |
Treatment of multiple myeloma in patients with Gaucher disease.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Ga | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; De | 2009 |
IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Diphosphonates; Drug Therapy, Combinatio | 2010 |
Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Magnetic Resonance Ima | 2009 |
Impedance cardiography in the diagnosis of capillary leak syndrome caused by doxorubicin therapy in a patient with myeloma multiplex.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Sy | 2010 |
Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hu | 2010 |
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Topics: Aged; Consensus; Europe; Guidelines as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Risk | 2010 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; M | 2010 |
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; D | 2010 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2011 |
High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2010 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Ph | 2010 |
Effect of cobalt-60 (γ radiation) on multidrug-resistant multiple myeloma cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cobalt Radioisotopes; Drug Resistance, | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomid | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, | 2011 |
Central nervous system myelomatosis with optic neuropathy and intramedullary spinal cord compression responding to radiation therapy.
Topics: Central Nervous System Neoplasms; Dexamethasone; Female; Glucocorticoids; Humans; Magnetic Resonance | 2011 |
Pustular pyoderma gangrenosum.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Combined Modality Therapy; Debridement; False | 2011 |
Is the low-thalidomide dose MPT regimen beneficial?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Pre | 2011 |
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; C | 2011 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Bindin | 2012 |
Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melpha | 2012 |
[New concept of the treatment in elderly patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunologic | 2011 |
Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.
Topics: ADAM Proteins; ADAM17 Protein; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Re | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; | 2012 |
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2013 |
Differential oncogene-related gene expressions in myeloma cells resistant to prednisone and vincristine.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Dose-Response | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2013 |
Lenalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphal | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Mod | 2012 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid | 2013 |
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2002 |
Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Drug Administr | 2002 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Multiple myeloma associated with systemic lupus erythematosus.
Topics: Aged; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Melphalan; Multiple Myeloma; Parap | 2003 |
[Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bronchopneumonia; Combined Modality T | 2003 |
[Pleural effusion as a first sign of Ig D lambda multiple myeloma].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Dyspne | 2003 |
Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Unusual IgM-secreting multiple myeloma in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Blood Protein Electroph | 2003 |
Fatal duodenal perforation during prednisone therapy.
Topics: Cell- and Tissue-Based Therapy; Duodenal Ulcer; Humans; Multiple Myeloma; Peptic Ulcer Perforation; | 1957 |
[Use of prednisone in the treatment of multiple myeloma].
Topics: Cell- and Tissue-Based Therapy; Humans; Multiple Myeloma; Plasma Cells; Prednisone | 1957 |
[Treatment of plasmocytoma and macroglobulinemia].
Topics: Globulins; Multiple Myeloma; Neoplasms, Plasma Cell; Plasma Cells; Plasmacytoma; Prednisone; Serum G | 1960 |
[Experiences with high dosage prednisone therapy and its side-effects in hemoblastosis, especially in plasmocytoma].
Topics: Cell- and Tissue-Based Therapy; Hematologic Diseases; Multiple Myeloma; Neoplasms, Plasma Cell; Plas | 1960 |
[Considerations on the therapy of plasmocytoma (on the basis of 6 personal cases].
Topics: Antineoplastic Agents; Multiple Myeloma; Neoplasms, Plasma Cell; Plasma; Plasma Cells; Plasmacytoma; | 1959 |
[Massive doses of prednisone in the treatment of plasmocytoma].
Topics: Cell- and Tissue-Based Therapy; Multiple Myeloma; Neoplasms, Plasma Cell; Plasma; Plasma Cells; Plas | 1962 |
Metabolic balance and Sr85 study of a patient with multiple myeloma treated with corticosteroids and androgens.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Androgens; Cardiovascular Agents; Glucocortico | 1962 |
Multiple myeloma with a large extramedullary plasmacytoma of the thorax treated with prednisone and radiation. metabolic balance study demonstrating unusual beneficial systemic effects of radiation ablation of the plasmacytoma.
Topics: Humans; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Plasma Cells; Plasmacytoma; Prednisone; | 1962 |
MULTIPLE MYELOMATOSIS ASSOCIATED WITH HYPERCALCAEMIA.
Topics: Africa; Africa, Eastern; Humans; Hypercalcemia; Kidney Diseases; Multiple Myeloma; Prednisone; Radio | 1963 |
MECHANISM OF ADRENAL-STEROID REVERSAL OF HYPERCALCEMIA IN MULTIPLE MYELOMA.
Topics: Blood Chemical Analysis; Bone Resorption; Calcium Isotopes; Humans; Hypercalcemia; Kidney Function T | 1964 |
DRUG THERAPY OF MULTIPLE MYELOMA.
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone; Radiography; Stilbamidines; Urethane | 1964 |
PNEUMOCYSTIS CARINII PNEUMONIA: REPORT OF A CASE IN AN ADULT.
Topics: Adult; Autopsy; Humans; Interstitial Cells of Cajal; Multiple Myeloma; Nitrogen Mustard Compounds; P | 1964 |
REED EC JR,+REED EC JR, LINMAN JW: GASTROINTESTINAL PARAMYLOIDOSIS IN PLASMACYTIC MYELOMA.
Topics: Amyloidosis; Bone Marrow Examination; Celiac Disease; Cyclophosphamide; Diagnosis, Differential; Hum | 1964 |
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II].
Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X- | 1964 |
[KAHLER'S DISEASE TREATED BY THE CORTICOID-CYCLOPHOSPHAMIDE COMBINATION].
Topics: Adrenal Cortex Hormones; Blood Protein Electrophoresis; Cyclophosphamide; Dexamethasone; Humans; Imm | 1964 |
SPLEENS, AMINES AND PROTEINS: A SKETCH OF SOME OF THE GLOBULIN DISORDERS.
Topics: Amines; Antineoplastic Agents; Blood Protein Disorders; Globulins; Humans; Mononuclear Phagocyte Sys | 1964 |
METABOLIC RELATIONSHIPS BETWEEN TUMOR AND HOST DURING MASSIVE DOSES OF PREDNISONE IN HUMAN NEOPLASTIC DISEASE.
Topics: 17-Ketosteroids; Adenocarcinoma; Biomedical Research; Blood; Calcium; Chlorides; Creatine; Creatinin | 1964 |
TURNOVER RATE OF PARAPROTEINS IN MYELOMATOSIS. STUDIES ON THE TURNOVER RATE OF SERUM PARAPROTEINS AFTER LABELLING IN VIVO, WITH SPECIAL REFERENCE TO REPEATED TURNOVER-RATE DETERMINATIONS.
Topics: Blood Proteins; Carbon Isotopes; Glycine; Humans; Immunoelectrophoresis; Melphalan; Multiple Myeloma | 1964 |
THE EFFECT OF PREDNISONE ON CALCIUM METABOLISM AND CA47 KINETICS IN PATIENTS WITH MULTIPLE MYELOMA AND HYPERCALCEMIA.
Topics: Blood Chemical Analysis; Body Fluids; Bone Regeneration; Bone Resorption; Calcium; Calcium Isotopes; | 1964 |
POLYMYOSITIS ASSOCIATED WITH ACUTE MONOCYTIC LEUKEMIA: CASE REPORT AND REVIEW OF THE LITERATURE.
Topics: Biopsy; Bone Marrow Cells; Carcinoma; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloi | 1964 |
MEDICAL GRAND ROUNDS FROM THE UNIVERSITY OF ALABAMA MEDICAL CENTER.
Topics: Beta-Globulins; Blood Protein Disorders; Bone Marrow Examination; Bone Resorption; Chlorambucil; Dia | 1964 |
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Drug Therapy; Humans; Infant; | 1965 |
[Paradoxical association of myelomatous osteolysis with intense hyperosteoidosis. Inverse sensitivity to vitamin D and prednisone].
Topics: Bone Diseases; Cartilage Diseases; Humans; Medical Records; Multiple Myeloma; Osteolysis; Plasma Cel | 1960 |
A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma.
Topics: Cell- and Tissue-Based Therapy; Humans; Multiple Myeloma; Plasma; Plasma Cells; Prednisone | 1962 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aut | 2004 |
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; | 2004 |
Phenotypical alterations induced by glucocorticoids resistance in RPMI 8226 human myeloma cells.
Topics: Antigens, CD; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Regulation | 2004 |
Low dose thalidomide in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cy | 2003 |
Multiple myeloma presenting with widespread osteosclerotic lesions.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2004 |
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents | 2004 |
Hb H disease and multiple myeloma.
Topics: Aged; alpha-Thalassemia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans | 2004 |
Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraprotein | 2003 |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2004 |
[Multiple myeloma and HIV infection: report of 3 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; HIV Infections; Hum | 2004 |
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intraven | 2004 |
Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; CD4 Antigens; CD4 Lymphocyte Count; C | 2004 |
Multiple complications in multiple myeloma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fractures, Spontaneous; Hip Fr | 2005 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Drug Therapy, Combination; Hu | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disea | 2005 |
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality | 2005 |
Nuclear chromatin patterns in 3 glucocorticoid-resistant RPMI 8226 human myeloma cell sub-lines: correlations with cell growth and immunological phenotype.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents, Hormonal; Cell Cycle; Cell Line, Tumor; Cell Nucleus; | 2005 |
Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Apolipoprotein E2; Apolipoprotein E3; Apolipoproteins E; Co | 2005 |
Free plasma amino acids in patients with multiple myeloma.
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; H | 1989 |
Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2006 |
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combin | 2005 |
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; | 2005 |
Skin lesions induced by bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethaso | 2005 |
Long-term complete remission in IgD-myeloma.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Humans; Immuno | 2006 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fat | 2006 |
Thalidomide gives food for thought in multiple myeloma.
Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; H | 2006 |
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 2006 |
[Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Drug Administrati | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; | 2006 |
Effects of prednisone on the International Normalized Ratio.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antineoplastic Agents, Hormonal; Glucocorticoids; Hu | 2006 |
Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Autoimmune Diseases; Case-Control Studies; | 2006 |
Advances in the treatment of elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Mye | 2006 |
[Pulmonary and pleural manifestations of multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Immunoglobulin | 2006 |
[Four cases of therapy-related leukemia in multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxo | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Potential effect of zoledronate therapy in heavy proteinuria.
Topics: Biopsy; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Humans; Hypercalc | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tri | 2007 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combinati | 2008 |
Making quality-of-life results more meaningful for clinicians.
Topics: Antineoplastic Combined Chemotherapy Protocols; Health Status; Humans; Interferons; Melphalan; Multi | 2008 |
Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.
Topics: Adult; Aged; Bence Jones Protein; Blood Proteins; Densitometry; Electrophoresis; Female; Humans; Imm | 1967 |
Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone | 1967 |
Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone.
Topics: Aged; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mal | 1982 |
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Doxorubicin; Drug | 1984 |
Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Female; Ho | 1984 |
Inhibition of ongoing myeloma IgE synthesis in vitro by activated human T cells.
Topics: Adult; Concanavalin A; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Interleukin-2; | 1983 |
[Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lom | 1983 |
Osteosclerotic myeloma and peripheral neuropathy.
Topics: Adult; Aged; Antibodies, Monoclonal; Bone Neoplasms; Female; Humans; Immunoglobulin kappa-Chains; Ma | 1983 |
Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy.
Topics: Adult; Drug Therapy, Combination; Electrodiagnosis; Female; Humans; Melphalan; Multiple Myeloma; Ost | 1984 |
Plasma cell leukemia: a report on three patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Female; Humans | 1983 |
Symposium on infectious complications of neoplastic disease (Part I). Introduction and epidemiology.
Topics: Abscess; Adult; Bacterial Infections; Bacteroides Infections; Cyclophosphamide; Escherichia coli Inf | 1984 |
[Long-term osteoporosis with multiple fractures as the early monosymptomatic stage of multiple myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fractures, Spontaneous; Hum | 1984 |
Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cy | 1983 |
[Therapy of malignant gammopathies].
Topics: Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Melphalan | 1984 |
[IgM myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Female; Humans; Immunoglobulin | 1983 |
Transient diabetes mellitus associated with prednisone therapy in a dog.
Topics: Animals; Diabetes Mellitus; Dog Diseases; Dogs; Male; Multiple Myeloma; Pancreas; Pancreatitis; Pred | 1984 |
[Evaluation of the prognosis and response to therapy in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle | 1984 |
[Chemotherapy of multiple myeloma].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug | 1984 |
Antibody-dependent cellular cytotoxicity in some lymphoreticular diseases.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1984 |
Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; | 1984 |
[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Creatinine; Cyclophosphamid | 1984 |
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Co | 1984 |
[Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1984 |
Multiple myeloma with renal failure. A case for intensive treatment.
Topics: Adult; Aged; Creatinine; Diuretics; Female; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle | 1983 |
[Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow- | 1983 |
Treatment of advanced bone marrow neoplasms with ifosfamide combinations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphami | 1984 |
Progress in the treatment of plasma cell myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone | 1983 |
Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma.
Topics: Adult; Aged; Bone Marrow; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm S | 1983 |
Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
Topics: Antineoplastic Agents; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multiple Myelo | 1983 |
Clinical staging and therapeutic results in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Melp | 1983 |
Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 1983 |
[Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Male; | 1983 |
Prednisone treatment of myeloma.
Topics: Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Multiple Myeloma; Prednisone | 1984 |
Long-term survival of a patient with multiple myeloma--a cure? A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Protein Electrophoresis; Humans; Immuno | 1984 |
Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 1984 |
[Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; France; Humans; Lomustine; | 1984 |
Treatment of multiple myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow Examination; Drug Therapy, Combination; Humans | 1980 |
Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
Topics: Adult; Aged; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1980 |
[Lichen myxedematosus and multiple myeloma type IgG/kappa].
Topics: Blood Protein Electrophoresis; Fluorescent Antibody Technique; Humans; Immunoglobulin kappa-Chains; | 1980 |
IgE myeloma. Report of a new case and review of the literature.
Topics: Aged; Drug Therapy, Combination; Female; Fructose; Humans; Immunoglobulin E; Indomethacin; Leukemia, | 1981 |
Hexamethylmelamine and prednisone in the treatment of refractory multiple myeloma.
Topics: Altretamine; Bone Marrow; Digestive System; Drug Evaluation; Drug Resistance; Drug Therapy, Combinat | 1982 |
Free light chains of immunoglobulins in serum from patients with leukaemias and multiple myeloma.
Topics: Adolescent; Adult; Aged; Child; Chlorambucil; Humans; Immunoglobulin kappa-Chains; Immunoglobulin la | 1982 |
[Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leu | 1983 |
Plasma spermidine concentrations as early indication of response to therapy in human myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Prednisone; Prognosis; Spermidine; Time Factors; Vi | 1983 |
[Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
Topics: Blood Transfusion; Erythrocyte Transfusion; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma | 1983 |
Cross-resistance to alkylating agents in multiple myeloma.
Topics: Alkylating Agents; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; | 1983 |
Prednisone pulse therapy for refractory myeloma.
Topics: Bone Marrow; Doxorubicin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; | 1983 |
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycl | 1982 |
Blastomycosis in immunosuppressed patients.
Topics: Adult; Aged; Amphotericin B; Blastomycosis; Female; Humans; Immunosuppression Therapy; Leukemia; Leu | 1982 |
Cyclic oscillation of blood neutrophils in a patient with multiple myeloma.
Topics: Agranulocytosis; Cell Transformation, Neoplastic; Colony-Stimulating Factors; Cyclophosphamide; DNA; | 1980 |
Monitoring of a long survival myeloma patient.
Topics: Adult; B-Lymphocytes; Chlorambucil; Follow-Up Studies; Humans; Immunoglobulin Idiotypes; Kinetics; M | 1981 |
Bullous amyloidosis.
Topics: Aged; Amyloidosis; Humans; Immunoglobulin A; Male; Melphalan; Multiple Myeloma; Prednisone; Skin Dis | 1980 |
Myeloma protein kinetics following chemotherapy.
Topics: Alkylating Agents; Bence Jones Protein; Doxorubicin; Drug Therapy; Humans; Kinetics; Multiple Myelom | 1982 |
[Reclassification of multiple myeloma and calculation of the myelomatous mass as prognostic and therapeutic indications].
Topics: Antineoplastic Agents; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis | 1982 |
Concomitant association of pyroglobulinemia and cryoglobulinemia in 2 patients in multiple myeloma.
Topics: Bone Marrow; Cryoglobulins; Humans; Leukemia, Plasma Cell; Male; Mercaptopurine; Middle Aged; Multip | 1982 |
Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
Topics: Animals; Antineoplastic Agents; Azathioprine; Doxorubicin; Drug Therapy, Combination; Female; Humans | 1981 |
Vindesine therapy in melphalan-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Adminis | 1980 |
Therapy of myeloma.
Topics: Carmustine; Cyclophosphamide; Humans; Multiple Myeloma; Prednisone | 1980 |
[Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myelo | 1980 |
The management of multiple myeloma.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cyclophosphamide; Drug T | 1980 |
The growth fraction of human myeloma cells.
Topics: Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Th | 1981 |
[Therapy of plasmacytoma].
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Middle Aged; Multiple Myeloma; | 1980 |
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD19; Antigens, Differentiation; | 1995 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin | 1994 |
[IgD-lambda type multiple myeloma associated with IgG-kappa type benign monoclonal gammopathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunoglobulin D; Immunoglobulin kappa | 1995 |
[Pneumonia caused by Salmonella in a patient with myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorub | 1995 |
Extramedullary plasmacytomas presenting as mediastinal masses: clinicopathologic study of two cases preceding the onset of multiple myeloma.
Topics: Chest Pain; Combined Modality Therapy; Diagnosis, Differential; Dyspnea; Fatal Outcome; Female; Huma | 1995 |
Anterior ischemic optic neuropathy secondary to interferon alfa.
Topics: Acute Disease; Adult; Aspirin; Carcinoma, Renal Cell; Fundus Oculi; Humans; Interferon-alpha; Ischem | 1995 |
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cel | 1993 |
Do glucocorticoids influence the survival of myeloma patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; Prednisone; Survival Rate | 1995 |
Who benefits from high-dose therapy for multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Gr | 1995 |
Anaplastic myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Th | 1995 |
A new staging system for multiple myeloma based on the number of S-phase plasma cells.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, | 1995 |
MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Femur; Humans; Magnetic R | 1995 |
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
Topics: Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Cyclophosphamide; Disease Progression; Female; | 1995 |
Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Middle Aged; Multiple Myeloma; Predni | 1994 |
Secondary myelodysplastic syndrome in multiple myeloma--a study of nine patients with an attempt to detect myeloma patients at risk.
Topics: Aged; Female; Humans; Israel; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myelo | 1994 |
The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1994 |
Coexisting kappa light chain multiple myeloma and primary hyperparathyroidism.
Topics: Aged; Aged, 80 and over; Female; Humans; Hypercalcemia; Hyperparathyroidism; Immunoglobulin kappa-Ch | 1994 |
[Skin lesions as a rare initial symptom of Kahler's disease].
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Humans; Male; Melphalan; Multiple Myelom | 1994 |
[Relationship between prognosis of multiple myeloma and response to VCAP therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1994 |
[Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Female; Humans; Male; | 1993 |
[Remission under treatment of cutaneous xanthomatosis disclosing myeloma: apropos of a case with a three-year course].
Topics: Cyclophosphamide; Female; Humans; Middle Aged; Multiple Myeloma; Paraproteinemias; Prednisone; Skin | 1993 |
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 1993 |
A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Nucleus; Cyclophosphamide; D | 1993 |
Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma.
Topics: Aged; Aged, 80 and over; Dexamethasone; Female; Glucocorticoids; Humans; Interferon alpha-2; Interfe | 1993 |
Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; | 1993 |
Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1993 |
[Smoldering myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Combined Modality The | 1993 |
Paresthesia of the mandibular division, trigeminal nerve.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Humans | 1993 |
[Recent therapy for refractory myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dexam | 1993 |
Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Carmustine; Cholesterol; Cyclo | 1995 |
Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, H | 1996 |
[Indications for chemotherapy in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melphalan; Middle Aged; Multiple Myelo | 1996 |
[Effect of calcitonin treatment on bone mineralization in patients with multiple myeloma].
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Calcification, Physiologic; Calcitonin; Calcium Carbon | 1995 |
Reversible metastatic pulmonary calcification in a patient with multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Calcinosis; Diphosphonates; Fema | 1996 |
[Long-term fever and light-chain myeloma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 1995 |
[Sweet's syndrome and multiple myeloma].
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 1996 |
IgD multiple myeloma. A report of three cases.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 1996 |
Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Mod | 1996 |
Conventional induction treatments do not influence overall survival in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1997 |
Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.
Topics: Alzheimer Disease; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Hum | 1997 |
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Female; Hepatocyte Growth Factor; Humans; Male | 1998 |
Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1998 |
[The influence of verapamil on platelet function in patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1997 |
Primary systemic amyloidosis with delayed progression to multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Disease Progr | 1998 |
[Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progressio | 1998 |
Persistent hypercalcemia leading to acute pancreatitis in a patient with relapsed myeloma and renal failure.
Topics: Calcitonin; Calcium; Humans; Hypercalcemia; Male; Middle Aged; Multiple Myeloma; Pancreatitis; Predn | 1998 |
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Chromosomes, Human, | 1998 |
IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 1998 |
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Health Status; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multi | 1998 |
[The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic | 1998 |
[IgD-type multiple myeloma with confirmation of improvement in renal pathology achieved by chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunoglobulin D; K | 1998 |
Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; | 1998 |
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Immuno | 1999 |
POEMS syndrome, steroid-dependent diabetes mellitus, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia.
Topics: Adult; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Erythema; Humans; Immunoglobulin A; Male; M | 1998 |
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carm | 1999 |
[Multiple myeloma nephropathy as a cause of renal failure--diagnostic difficulties and prospects for treatment].
Topics: Aged; Erythropoietin; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinan | 1998 |
Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule | 1999 |
Multiple myeloma in the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Doxorubicin; Fatal | 1999 |
A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.
Topics: Adult; Amyloidosis; Antineoplastic Agents; Humans; Immunoglobulin Light Chains; Interferon-alpha; Ma | 1999 |
[Acute and chronic renal failure in patients with myeloma].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophospham | 1999 |
Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Combined Modality Therapy; | 1999 |
[Lumbago radiating to the right leg as a form of onset of multiple myeloma in a 33-year-old patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Doxoru | 1999 |
Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
Leukoencephalopathy in multiple myeloma: two case reports.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans; Leukoencephalopat | 1999 |
Myelomatous effusion with poor response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Melphalan; Middle | 2000 |
Severe amyloidosis with mild multiple myeloma--an unusual course.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Colchicine; Disease Progression; Fatal | 2000 |
[Plasmocytic pleural effusion disclosing multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineop | 2000 |
Expression of BAX in plasma cell dyscrasias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biopsy; Blott | 2000 |
Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Female; Follow-Up Studies; Glucocorticoids; Graft | 2000 |
Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera | 2001 |
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; | 2001 |
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2001 |
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cy | 2001 |
Treatment with chemotherapy of scleredema associated with Ig A myeloma.
Topics: Aged; Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin A | 2001 |
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
Topics: Adult; Angiogenesis Inhibitors; Drug Therapy, Combination; Female; Glucocorticoids; Hematopoietic St | 2001 |
Meningeal and cerebral involvement in multiple myeloma patients.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Com | 2001 |
Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality | 2002 |
Multiple myeloma presenting as proptosis and sixth nerve palsy.
Topics: Abducens Nerve Diseases; Adult; Antineoplastic Combined Chemotherapy Protocols; Cranial Nerve Neopla | 2001 |
Immunotherapy by non-myeloablative stem cell transplantation: study of the immune reconstitution. Arguments for distinct cell subsets in skin and blood.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blood; Blood Cells; Carmustine; CD8-P | 2000 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melphalan; M | 2002 |
Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen.
Topics: Androgens; Bone Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Fluorides; Fluoxy | 1975 |
Relative usefulness of measuring polyamines in serum, plasma, and urine as biochemical markers of cancer.
Topics: Bleomycin; Cadaverine; Chromatography, Ion Exchange; Cytarabine; Diamines; Humans; Multiple Myeloma; | 1975 |
Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy.
Topics: Agammaglobulinemia; Amyloidosis; Bence Jones Protein; Dermatomyositis; gamma-Globulins; Humans; Immu | 1975 |
Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse.
Topics: Alkylating Agents; Blood Cell Count; Carmustine; Cell Count; Doxorubicin; Drug Therapy, Combination; | 1976 |
[Chemotherapy of malignant skeletal tumors (author's transl)].
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Humans; Lymphoma; Melphalan; Multiple Myeloma; N | 1979 |
Sideroblastic anaemia and leukaemia in multiple myeloma.
Topics: Anemia, Sideroblastic; Female; Humans; Immunoglobulin A; Immunoglobulin kappa-Chains; Leukemia; Male | 1978 |
Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience.
Topics: Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Melp | 1979 |
Multiple myeloma without detectable Ig synthesis.
Topics: Bone Marrow; Drug Therapy, Combination; Female; Humans; Immunoglobulins; Melphalan; Middle Aged; Mul | 1979 |
Four months with a dull pain in the back.
Topics: Back Pain; Blood Protein Electrophoresis; Bone Marrow Examination; Female; Humans; Melphalan; Middle | 1977 |
Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case.
Topics: Cytomegalovirus Infections; Humans; Lung; Male; Melphalan; Middle Aged; Multiple Myeloma; Pneumonia, | 1978 |
[Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Com | 1979 |
Multiple myeloma management.
Topics: Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1977 |
Plasma cell leukemia: response to conventional myeloma therapy.
Topics: Aged; Humans; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone | 1977 |
[Various immunologic indicators of cytostatic therapy in patients with malignant lymphoproliferative processes].
Topics: Cyclophosphamide; Humans; Immunologic Techniques; Leukemia, Lymphoid; Lymphocytes; Multiple Myeloma; | 1977 |
Acute leukemia in multiple myeloma.
Topics: Aged; Chromosomes; Diploidy; Female; Humans; Leukemia, Myeloid, Acute; Long-Term Care; Male; Melphal | 1977 |
[Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
Topics: Amyloidosis; Drug Therapy, Combination; Humans; Immunoglobulin D; Immunoglobulin Light Chains; Male; | 1977 |
Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
Topics: Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Evaluation; Drug Resistance; Drug | 1978 |
Solid tumors in multiple myeloma.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neo | 1979 |
[Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)].
Topics: Female; Humans; Immunoglobulin G; Lymphatic Metastasis; Melphalan; Middle Aged; Multiple Myeloma; Ne | 1979 |
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Multiple Mye | 1979 |
Multiple myeloma: results with the M-2 protocol in a community hospital.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Hospitals, Community | 1979 |
[Current treatment of myeloma].
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone | 1979 |
[2 cases of multiple myeloma with osteosclerosis].
Topics: Aged; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Multipl | 1979 |
[Analysis of the results of treatment of multiple myeloma].
Topics: Adult; Aged; Antibodies, Neoplasm; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up | 1979 |
[Multiple myeloma transforming into acute leukaemia (author's transl)].
Topics: Cell Transformation, Neoplastic; Humans; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; P | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.
Topics: Adult; Aged; Bence Jones Protein; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Mid | 1978 |
Multiple myeloma complicating the course of seronegative systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow; Drug Therapy, Combination; Female; Humans; Lupus Erythe | 1978 |
Unmaintained remissions in multiple myeloma.
Topics: Cell Transformation, Neoplastic; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Mye | 1978 |
Multiple plasmacytomas with thoracic and biliary involvement.
Topics: Aged; Bone Neoplasms; Cholestasis; Cyclophosphamide; Female; Humans; Lung Neoplasms; Multiple Myelom | 1978 |
[Prognosis and therapy of multiple myeloma].
Topics: Blood Transfusion; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; | 1978 |
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance | 1978 |
Regression of amyloidosis in multiple myeloma.
Topics: Amyloidosis; Drug Therapy, Combination; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pr | 1978 |
Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone.
Topics: Adult; Aged; Creatinine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; | 1978 |
[Ophthalmoplegia revealing Kahler's disease].
Topics: Aged; Bone Neoplasms; Female; Humans; Melphalan; Multiple Myeloma; Ophthalmoplegia; Prednisone | 1978 |
Expansion of the growth fraction in multiple myeloma with alkylating agents.
Topics: Adult; Bone Marrow; Cell Count; DNA Replication; Humans; Kinetics; Male; Melphalan; Multiple Myeloma | 1975 |
Treatment of plasma cell myeloma with cytotoxic agents.
Topics: Acute Disease; Alkylating Agents; Bence Jones Protein; Bone Neoplasms; Carmustine; Cell Count; Cyclo | 1975 |
Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.
Topics: Amino Acid Sequence; Antineoplastic Agents; Bence Jones Protein; Bone Marrow; Bone Marrow Cells; Car | 1975 |
Simultaneous occurrence of hypocholesterolemia, hypocalcemia and hypofibrinogenemia in a case of multiple myeloma.
Topics: Afibrinogenemia; Blood Proteins; Cholesterol; Drug Therapy, Combination; Female; Follow-Up Studies; | 1975 |
Multiple myeloma: uncommon or uncommonly diagnosed?
Topics: Adult; Anemia; Blood Sedimentation; Bone Diseases; Female; Humans; Male; Melphalan; Middle Aged; Mul | 1977 |
Optimal control analysis in the chemotherapy of IgG multiple myeloma.
Topics: Bone Neoplasms; Cell Division; Cell Survival; Cyclophosphamide; Drug Administration Schedule; Humans | 1977 |
[Intermittent low dose melphalan and prednisone in multiple myeloma].
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone | 1977 |
[Combined cytostatic therapy of plasmacytoma].
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Melph | 1977 |
Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma.
Topics: Aged; Alkylating Agents; Humans; Male; Melphalan; Multiple Myeloma; Neoplasms, Multiple Primary; Pre | 1977 |
[Therapy of myeloma].
Topics: Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone | 1977 |
Tumor growth patterns in multiple myeloma.
Topics: Cell Division; Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Models, Biological; Multiple | 1977 |
Grand rounds: Multiple myeloma.
Topics: Diagnosis, Differential; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1976 |
Emotional support for the multiple myeloma patient.
Topics: Fear; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nurse-Patient Relations; Prednisone | 1976 |
Multiple myeloma and acute leukemia associated with alkylating agents.
Topics: Acute Disease; Aged; Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Bone Neoplasms; Hemogl | 1975 |
Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.
Topics: Adolescent; Adult; Antibodies, Viral; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubi | 1975 |
Letter: Maintenance therapy in myeloma: risk versus benefit.
Topics: Carmustine; Humans; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Prednisone | 1975 |
Multiple myeloma. A clinical review.
Topics: Alkylating Agents; Amyloidosis; Antibodies, Anti-Idiotypic; Bence Jones Protein; Blood Cell Count; B | 1975 |
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.
Topics: Agammaglobulinemia; Antibody Formation; Antibody-Producing Cells; B-Lymphocytes; Cell Differentiatio | 1976 |
The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy.
Topics: Animals; B-Lymphocytes; Binding Sites, Antibody; Cell Division; Cells, Cultured; Clone Cells; Fluore | 1975 |
Immunosuppression and toxoplasmic encephalitis: clinical and experimental aspects.
Topics: Adult; Animals; Cortisone; Cricetinae; Cyclophosphamide; Encephalitis; Female; Hodgkin Disease; Huma | 1975 |
Multiple myeloma: review of 869 cases.
Topics: Adult; Aged; Bacterial Infections; Blood Cell Count; Blood Sedimentation; Bone and Bones; Calcium; C | 1975 |
Antithrombin and antithromboplastin activity accompanying IgG myeloma. Report of a case with a severe bleeding tendency.
Topics: Antithrombins; Blood Coagulation Tests; Ear Diseases; Factor IX; Factor V; Factor VIII; Hemagglutina | 1975 |
Letter: Treatment of myeloma.
Topics: Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Vincristin | 1975 |
Plasmapheresis in chronic demyelinating polyneuropathy.
Topics: Adult; Female; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Plasmapheres | 1992 |
Primary hyperparathyroidism in an elderly patient with multiple myeloma.
Topics: Aged; Aged, 80 and over; Calcium; Cyclic AMP; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyroi | 1992 |
Myeloma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Multiple Myeloma; Predniso | 1992 |
[Value of C-reactive protein assay for the monitoring of the course of treated multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Female; Humans; Male; Melp | 1992 |
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?
Topics: Cytokines; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melphalan; Middle | 1992 |
Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1992 |
Investigations of the frequency of DNA strand breakage and cross-linking and of sister chromatid exchange frequency in the lymphocytes of patients with multiple myeloma undergoing cytostatic therapy with melphalan and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Linking Reagents; DNA | 1992 |
Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1992 |
[Immunoblastic lymphoma as expression of the final phase of IgA multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; D | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 1992 |
Flow cytometric DNA analysis and clinical correlations in multiple myeloma.
Topics: Adult; Aged; Aneuploidy; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Melph | 1992 |
Bilateral breast involvement in a 71-year-old white man with lambda light chain disease. Regression after a new chemotherapy combination. A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Humans; Immun | 1992 |
[Multiple myeloma in a patient in remission from malignant lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunog | 1992 |
[p170 in multiple myeloma and acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Sub | 1991 |
[Kinetics of circulating hematopoietic stem cells following chemotherapy in patients with hematopoietic malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 1990 |
Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma.
Topics: Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marro | 1991 |
[Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Laryngeal Neoplasms; | 1991 |
Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1991 |
[Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Car | 1991 |
Overall vs. tumor-related survival in multiple myeloma. German Myeloma Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Humans; Melphalan; Meth | 1991 |
Diurnal variations of serum beta 2-microglobulin in multiple myeloma.
Topics: beta 2-Microglobulin; Circadian Rhythm; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Preme | 1991 |
[VCAP combination chemotherapy of multiple myeloma in the aged].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 1991 |
Complete remission in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Interfe | 1990 |
Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged | 1991 |
[A myeloma (IgG-kappa) terminating in acute myelogenous leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunoglobulin G; Immunoglobulin kappa | 1990 |
Adult Fanconi syndrome secondary to kappa-light chain myeloma: improvement of tubular functions after treatment for myeloma.
Topics: Aged; Bence Jones Protein; Fanconi Syndrome; Humans; Immunoglobulin kappa-Chains; Kidney Tubules; Ma | 1990 |
Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carmustine; Cyclophosphamide; Female; | 1990 |
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Topics: Adult; Aged; Bone Marrow Transplantation; Dexamethasone; Dose-Response Relationship, Drug; Doxorubic | 1990 |
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; I | 1990 |
[Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Humans; Life Tabl | 1990 |
Acute leukemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens.
Topics: Acute Disease; Antigens, Neoplasm; Antigens, Surface; Bone Marrow; Chromosome Aberrations; Chromosom | 1990 |
[Erythropoietin in multiple myeloma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphami | 1990 |
[Contribution of anthracyclines in treatment of lymphoproliferative disorders].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubici | 1987 |
[Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
Topics: Adult; Aged; Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Pro | 1987 |
Rapid response to recombinant interferon alpha 2B and high-dose prednisone in multiple drug-resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon alpha-2; Interferon Type I; | 1989 |
[Multiple myeloma].
Topics: Bone Marrow Transplantation; Cytodiagnosis; Diagnosis, Differential; Humans; Interferon Type I; Mult | 1989 |
Spinal cord compression in myelomatosis: response to chemotherapy alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle | 1989 |
[Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
Topics: Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; | 1989 |
[Polychemotherapy of multiple myeloma using pafencil (COPPaf protocol)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; | 1989 |
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubi | 1989 |
Successful treatment of hemorrhagic syndrome due to an acquired, combined deficiency of factors VII and X in a patient with multiple myeloma and amyloidosis.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Factor VII Deficiency | 1989 |
Impaired chemiluminescence response by neutrophils in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Luminescent Measurements; | 1986 |
Successful treatment of peripheral neuropathy with chemotherapy in osteosclerotic myeloma.
Topics: Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neural Conduction | 1987 |
Management of myeloma kidney: an anti-light-chain approach.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cycl | 1987 |
Diagnosis of polymyalgia rheumatica and giant cell arteritis: a note of caution.
Topics: Aged; Diagnosis, Differential; Female; Giant Cell Arteritis; Humans; Lymphoma; Male; Middle Aged; Mu | 1987 |
IgD multiple myeloma: a cure at 21 years.
Topics: Carcinoma, Bronchogenic; Follow-Up Studies; Humans; Immunoglobulin D; Lung Neoplasms; Male; Melphala | 1988 |
The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Half-Life | 1988 |
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Evaluation; D | 1988 |
Early plasma cell recruitment in multiple myeloma following chemotherapy.
Topics: Aged; Bone Marrow; Cell Division; DNA; Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Multi | 1988 |
[Monoclonal gammapathy of indeterminate origin and myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1988 |
M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine | 1988 |
Dose intensity analysis of melphalan and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Humans; Immunoglobulins; Melphalan; | 1988 |
Multiple myeloma of the serosa coat.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; | 1988 |
Multiple myeloma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Male; Melphalan; Multiple Myeloma; Ne | 1987 |
[Multiple myeloma. Clinical experience of 15 years in the 10th region].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Melph | 1987 |
Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Melphalan; Multiple Myelo | 1987 |
[Multiple myeloma: therapeutic response to 2 modalities of chemotherapy].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1986 |
Path model of multidimensional compliance with cancer therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combin | 1987 |
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
[Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fe | 1986 |
Are the current criteria for response useful in the management of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Humans; Melphalan; Multiple Mye | 1987 |
Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance; Humans; Melphalan | 1987 |
Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma.
Topics: Administration, Oral; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Injectio | 1987 |
[VCAP therapy of multiple myeloma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1987 |
Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 1986 |
High-dose glucocorticoid treatment of resistant myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Dexamethasone; Doxorubici | 1986 |
Prognostic factors for multiple myeloma in the dog.
Topics: Animals; Calcium; Cyclophosphamide; Dog Diseases; Dogs; Kidney; Melphalan; Multiple Myeloma; Prednis | 1986 |
Orbital plasmacytoma in established myeloma--a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Melphalan; Mid | 1986 |
Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Carmustine; Cyclophosphamide; | 1986 |
[Results with the use of the M-2 protocol in plasmacytoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Eval | 1986 |
Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA, Recombinant; Drug Evaluation; Hema | 1986 |
Long unmaintained remission in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1986 |
Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubi | 1986 |
Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Admi | 1985 |
[Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; | 1985 |
[Cytostatic polychemotherapy in the aged].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dac | 1985 |
Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Carmustine; Cyclop | 1985 |
[Decrease of paraprotein secretion despite progressive tumor cell proliferation by cytostatic drug therapy of plasmacytoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Cyclophosphamide; Humans; Immunoglob | 1985 |
Osteosclerotic myeloma complicated by diffuse arteritis, vascular calcification and extensive cutaneous necrosis.
Topics: Adult; Aluminum Hydroxide; Arteritis; Bone Neoplasms; Calcinosis; Cyclophosphamide; Etidronic Acid; | 1985 |
Monitoring myeloma: light chain isotype suppression. A new parameter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Immunoelectrophoresis; | 1985 |
Vindesine in refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; | 1986 |
Multiple myeloma masquerading as metastatic breast cancer.
Topics: Agammaglobulinemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasm | 1986 |
Controversies in the treatment of plasma cell myeloma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Drug Resistance; Human | 1985 |
Follicular hyperkeratosis and cryocrystalglobulinemia syndrome. Occurrence in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Darier Disease; Humans; Mal | 1985 |
Obstructive jaundice from hepatic amyloidosis in a patient with multiple myeloma.
Topics: Amyloidosis; Cholestasis; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1985 |
[Multiple myeloma in stage I. Evaluation of the initial therapy].
Topics: Aged; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; | 1985 |
Salvage treatment for patient with multiple myeloma refractory to alkylating agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Female; Follow-Up Studi | 1985 |
Vindesine in plasma cell tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Resistance; Femal | 1985 |
Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Resistance; Femal | 1985 |
Lymphoid interstitial pneumonia with dysproteinemia. Report of two cases with plasma cell predominance.
Topics: Alpha-Globulins; Autopsy; Beta-Globulins; Blood Protein Disorders; Diagnosis, Differential; Female; | 1970 |
Sideroblastic anemia in multiple myeloma: a preleukemic change.
Topics: Anemia, Sideroblastic; Bone Marrow Examination; Cytarabine; Female; Humans; Immunodiffusion; Immunoe | 1973 |
[Cytomorphological, immunochemical and therapeutic aspects of multiple myeloma].
Topics: Adult; Aged; Blood Transfusion; Cyclophosphamide; Epitopes; Female; Humans; Immunoelectrophoresis; I | 1973 |
[Gamma-D-paraproteinemia. Clinical case contribution based on 2 studies].
Topics: Aged; Anemia, Pernicious; Bence Jones Protein; Diagnosis, Differential; Electrophoresis; Female; gam | 1967 |
Spontaneous rupture of the spleen on plasma cell leukemia.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Diagnosis, Differential | 1969 |
A human IgA-myeloma protein with anti-streptococcal hyaluronidase (ASH) activity.
Topics: Antibodies, Bacterial; Binding Sites, Antibody; Bone Marrow; Bone Marrow Cells; Female; Humans; Hyal | 1973 |
Immunoglobulin synthesis and tumor kinetics of multiple myeloma.
Topics: Animals; B-Lymphocytes; Clone Cells; Growth Inhibitors; Humans; Immunoglobulins; Kinetics; Melphalan | 1973 |
[Diagnostic problems raised by tumors of the skull. A propos 2 cases (author's transl)].
Topics: Aged; Biopsy; Cyclophosphamide; Diagnosis, Differential; Frontal Bone; Humans; Immunoelectrophoresis | 1974 |
The cyclic use of multiple alkylating agents in multiple myeloma.
Topics: Aged; Alkylating Agents; Bone Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Multi | 1972 |
[Acute leukemia and myeloma].
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Melphalan; | 1972 |
Treatment of hypercalcemia with furosemide and corticosteroids.
Topics: Female; Furosemide; Humans; Hypercalcemia; Methylprednisolone; Middle Aged; Multiple Myeloma; Predni | 1973 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
A case of acute myelomonocytic leukaemia associated with myelomatosis.
Topics: Aged; Autopsy; Blood Cell Count; Blood Protein Disorders; Blood Protein Electrophoresis; Bone Marrow | 1973 |
Pharmacologic and cytokinetic studies of arabinosyl cytosine.
Topics: Adolescent; Adult; Animals; Antibody Formation; Cell Migration Inhibition; Child; Child, Preschool; | 1973 |
Decreased serum cobalamin in multiple myeloma without signs of vitamin B12 deficiency. A preliminary report.
Topics: Cyclophosphamide; Depression, Chemical; Erythrocytes; Folic Acid; Humans; Male; Middle Aged; Multipl | 1974 |
Multiple myeloma without initial paraproteins.
Topics: Adult; Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Cyclophosphamide | 1972 |
Bone healing in multiple myeloma with melphalan chemotherapy.
Topics: Adult; Aged; Blood Urea Nitrogen; Bone Regeneration; Female; Humans; Male; Melphalan; Middle Aged; M | 1972 |
Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Bence Jones Protein; Cyclophosphamide; Drug Resistance; Female; H | 1972 |
[Significance of ( 85 Sr) radioisotope bone scanning in the early diagnosis of bone metastases and possibilities of their therapy].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Castration; Cobalt Isotopes; Female; | 1973 |
Cutaneous signs of cryoparaproteinemia: control with burst alkeran and prednisone.
Topics: Adult; Blood Protein Disorders; Blood Protein Electrophoresis; Blood Proteins; Cold Temperature; Fem | 1973 |
[Generalized and solitary plasmacytomas. Analysis of 55 cases].
Topics: Adult; Age Factors; Aged; Bence Jones Protein; Bone Neoplasms; Cyclophosphamide; Female; Humans; Mal | 1973 |
Persistence of deoxyribonucleic acid polymerase I and its 5'--3' exonuclease activity in PolA mutants of Escherichia coli K12.
Topics: Drug Synergism; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone | 1973 |
[Prognosis in myelomatosis treated with prednisone and cytostatics].
Topics: Aged; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle | 1973 |
[Rules of current therapy in multiple myeloma].
Topics: Chlorambucil; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Purpura, Hyperglobu | 1973 |
Prognosis of myelomatosis on treatment with prednisone and cytostatics.
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Electrophoresis, Paper; Female; Humans; Immunoglo | 1973 |
Chemotherapy of multiple myeloma.
Topics: Allopurinol; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Pr | 1973 |
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphala | 1974 |
Testicular involvement in plasma-cell leukemia.
Topics: Allopurinol; Cyclophosphamide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; N | 1974 |
Multiple myeloma with pleural involvement.
Topics: Adult; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Electrophoresis; Humans; Immunoelectroph | 1974 |
Multiple myeloma. II. The value of melphalan.
Topics: Allopurinol; Bence Jones Protein; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; | 1974 |
A urinary cryo-Bence Jones protein gelling at room temperature.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Cellulose; Cold Temperature; Cryoglobulins; Cycl | 1974 |
Acute renal failure in multiple myeloma.
Topics: Acute Kidney Injury; Aged; Allopurinol; Female; Humans; Male; Melphalan; Multiple Myeloma; Peritonea | 1974 |
The use of etiocholanolone for the measurement of marrow granulocyte reserves.
Topics: Acute Kidney Injury; Adolescent; Adult; Agranulocytosis; Blood Urea Nitrogen; Bone Marrow; Bone Marr | 1970 |
Fluoride therapy for pain in malignant bone disease.
Topics: Adult; Aged; Analgesia; Bone Neoplasms; Breast Neoplasms; Estrogens; Fluorides; Fluoxymesterone; Hum | 1968 |
[Ulcero-necrotic purpura revealing Kahler's disease, with macroglobulinemia].
Topics: Female; Humans; Leg Ulcer; Melphalan; Middle Aged; Multiple Myeloma; Necrosis; Prednisone; Purpura; | 1967 |
[Symptomatic thrombopenias. Difficulties of early diagnosis and therapeutic possibilities].
Topics: Adult; Blood Platelets; Hemorrhagic Disorders; Hodgkin Disease; Humans; Hydrazines; Immunoelectropho | 1966 |
[Drug therapy in hemoblastosis].
Topics: Antineoplastic Agents; Hematologic Diseases; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid | 1968 |
Kinetics of tumor growth and regression in IgG multiple myeloma.
Topics: Aged; Computers; Humans; Immunoglobulin G; Kinetics; Melphalan; Middle Aged; Models, Biological; Mul | 1972 |
Cutanous lesions in multiple myeloma.
Topics: Aged; Female; Humans; Melphalan; Multiple Myeloma; Prednisone; Skin Neoplasms | 1972 |
Myeloma of the prostate: a case report.
Topics: Adult; Cobalt Isotopes; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prostatic Neoplasms; | 1971 |
Peritoneal dialysis in the treatment of renal failure in multiple myeloma.
Topics: Coma; Cyclophosphamide; Humans; Immunoglobulin G; Kidney Failure, Chronic; Male; Middle Aged; Multip | 1971 |
Alkeran (Melphalan) in the treatment of myelomatosis.
Topics: Adult; Aged; Blood Platelets; Blood Proteins; Creatine; Female; Humans; Hypercalcemia; In Vitro Tech | 1966 |
Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effect on malignant leukocytes in vitro.
Topics: Blood Cell Count; Cytarabine; DNA; Humans; In Vitro Techniques; Injections, Intravenous; Leukemia; L | 1967 |
[Therapy of malignant hemopathies].
Topics: Female; Hematologic Diseases; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; L | 1966 |
[Guidelines in the therapy of various neoplastic diseases with cytostatic drugs].
Topics: Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Gastrointestinal Ne | 1969 |
[Acute renal insufficiency in myelomatosis].
Topics: Acute Kidney Injury; Aged; Bence Jones Protein; Blood Proteins; Female; Humans; Male; Melphalan; Mid | 1970 |
Melphalan and myeloma. Experience with a low-dose continuous regimen.
Topics: Bone Diseases; Bone Neoplasms; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neuro | 1970 |
Hypercalcemia associated with neoplastic disease.
Topics: Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Dactinomycin; Electrocar | 1970 |
[Plasmacytoma with internittent left bundle-branch block and recurrent zoster].
Topics: Bundle-Branch Block; Cyclophosphamide; Electrocardiography; Female; Herpes Zoster; Humans; Multiple | 1967 |
Hereditary aspects of autoimmune hemolytic anemia; a retrospective analysis.
Topics: Adrenal Cortex Hormones; Aged; Anemia, Hemolytic, Autoimmune; Biopsy; Blood Cell Count; Bone Marrow | 1968 |
Treatment of multiple myeloma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Blood Cell Count; Blood Platelets; Cyclophosphamide; H | 1968 |
Current management of multiple myeloma.
Topics: Adult; Cyclophosphamide; Female; Humans; Melphalan; Multiple Myeloma; Prednisone | 1968 |
Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.
Topics: Adult; Aged; Androgens; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immune Sera; Immunoelec | 1969 |
Alkeran and multiple myeloma.
Topics: Anemia; Cyclophosphamide; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Urethane | 1966 |
Carcinoma of the esophagus simulating multiple myeloma. Report of a case.
Topics: Aged; Diagnosis, Differential; Esophageal Neoplasms; Humans; Male; Melphalan; Multiple Myeloma; Pred | 1966 |